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ABSTRACT
Cardiac and Mitochondrial Dysfunction during Diabetes Mellitus: Examination of
Mitochondrial Import Mechanisms
Danielle Lee Shepherd
Approximately 9% of the United States population is diagnosed with diabetes mellitus
(DM), which is comprised of 2 distinct pathologies: type 1 diabetes mellitus (T1DM) and type 2
diabetes mellitus (T2DM). T1DM, which is caused by insufficient insulin production, affects
approximately 5% of diabetic patients, while T2DM results from insulin resistance and affects
95% of all diabetic patients. Within diabetic patients, cardiac complications, such as diabetic
cardiomyopathy, are the leading cause of morbidity and mortality. The mitochondrion has been
implicated as an underlying factor in the etiology and progression of the cardiac contractile deficits
and cardiac failure that accompany DM. The study of cardiac mitochondria is further complicated
by the presence of two distinct mitochondrial subpopulations residing within the cardiomyocyte.
The pool of mitochondria existing beneath the sarcolemmal membrane are termed the
subsarcolemmal mitochondria (SSM), while the group that exists between the myofibrils is called
the interfibrillar mitochondria (IFM). Assessment of mitochondrial subpopulations has revealed
differential impact to both physiological and pathological stimuli. Specifically, during DM, the
IFM are most impacted during T1DM, with the SSM being most impacted under T2DM
pathological insult. During DM, proteomic analyses by our laboratory and others reveal decreased
abundance of nuclear-encoded mitochondrial proteins essential for processes such as oxidative
phosphorylation, fatty acid oxidation and tricarboxylic acid cycle in the subpopulation
predominantly impacted by the DM type. Further, our laboratory has previously shown import
efficiency to be down in the T1DM IFM, which could play a role in the proteomic dysregulation.
Approximately 99% of the mitochondrial proteome is composed of nuclear-encoded proteins
imported into the mitochondrion via a complicated mechanism of translocation that coordinates
both the outer and inner mitochondrial membranes, thus highlighting the importance of studying
the nuclear-encoded mitochondrial protein import process during pathological states. To date,
evaluation of the diabetic heart using a highly sensitive echocardiographic analysis software in
order to assess subtle changes in left ventricular function prior to overt contractile dysfunction
during DM has not been completed. Additionally, the differential proteomic alterations in
mitochondrial subpopulations resulting from distinct DM pathologies and the evaluation of
inefficient nuclear-encoded mitochondrial protein import due to decrements in a key import
constituent in the mitochondrial subpopulation predominantly affected, mitochondrial heat shock
protein 70 (mtHsp70), have not been completed. Further, the mechanisms involved in miRNA
import into the mitochondrion during DM remains limited. Therefore, the goal of the following
studies was to examine subpopulation-specific mitochondrial proteome disruption stemming from
inefficient nuclear-encoded mitochondrial protein import and/or increased miRNA influx into the
mitochondrion, thus leading to increased contractile dysfunction during DM. T1DM was induced
in 6-week-old mice with multiple low-dose (50mg/kg) streptozotocin (STZ) injections for 5
consecutive days. Hyperglycemia was confirmed and echocardiography performed at weeks 1, 3
and 6 post-diabetic onset. Conventional analyses revealed cardiac contractile deficits relative to
control at 6-weeks post-T1DM onset. In contrast, short- and long-axis analyses using the speckletracking based strain analysis software demonstrated changes in the LV myocardium as early as

1-week post-diabetic onset. These findings show that analysis of myocardial function using
speckle-tracking based strain analyses could provide a more precise method for evaluating cardiac
contractile dysfunction during the progression of different pathological states. Our laboratory has
previously shown that proteomic alterations specific to the T2DM SSM and T1DM IFM occur,
potentially due to a decrement in nuclear-encoded mitochondrial protein import. Because
mtHsp70, an essential component in the import of nuclear-encoded proteins into the mitochondrion
is consistently down during DM, we generated a novel transgenic line with a cardiac-specific
overexpression of mtHsp70. We subjected this line to STZ to generate a T1DM mouse model with
mtHsp70 overexpression. Further, we utilized the db/db mouse model for T2DM and with a novel
ovarian transplantation procedure, we were able to generate an increased abundance of mtHsp70
db/db and control animals, which were approximately 20-weeks-old before hearts were excised
and mitochondrial subpopulations isolated. When assessing nuclear-encoded mitochondrial
protein import efficiency in the mitochondrial subpopulations during both types of DM, we found
decrements to this process in the SSM of T2DM mice and IFM of T1DM mice, which was
subsequently restored with mtHsp70 overexpression. Further, alterations to the most impacted
mitochondrial subpopulations proteome were noted, with mtHsp70 affording protection.
Additionally, we also found mtHsp70 protein content to be down in the T1DM and T2DM human
heart. These findings support the rationale for the use of mtHsp70 as a mitochondrial-targeted
therapeutic capable of protecting the mitochondrial subpopulation most impacted during the
different types of DM. Interestingly, the mitochondrial proteome could also be affected by
redistribution of microRNAs (miRNAs) during a pathological setting. MiRNAs are able to regulate
protein expression via transcriptional and translational repression and are suggested to be located
within the mitochondrion. Our laboratory has previously shown detrimental impact to the IFM due
to redistribution of miR-141 and miR-378 during T1DM. This emphasizes the importance of
studying how miRNA are able to translocate into the mitochondrion, a mechanism that currently
remains unknown. Therefore, we assessed the involvement of polynucleotide phosphorylase
(PNPase), a protein located in the mitochondrial intermembrane space, in the import of miRNA
into the mitochondrion. We found PNPase to be associated with argonaute 2 (Ago2), a component
of the RNA-induced silencing complex (RISC). PNPase was found to have an increased expression
in the SSM during T2DM, along with an increased association with Ago2. PNPase protein
expression is also significantly increased in mitochondria from T2DM human patients. Further, an
increased presence of miR-378 within the mitochondrion was noted, which corresponded to a
decrease in ATP6 protein content and ATP synthase function. Overexpression of PNPase in the
HL-1 cardiomyocyte cell line revealed similar results. These findings show for the first time a
potential component involved in the mechanism of miRNA import into the mitochondrion.
Overall, the studies highlighted above indicate that speckle-tracking based strain analyses provide
a mechanism to detect subtle changes in LV myocardial function during the progression of DM.
Further, through manipulating mtHsp70, the driving force behind nuclear-encoded mitochondrial
protein import, we highlight the novel therapeutic paradigm in which multiple dysfunctional
processes are corrected through a single protein target capable of restoring mitochondrial and
cardiac contractile function independent of DM type. We have shown for the first time a potential
constituent involved in the complicated import process of miRNA into the mitochondrion. In
conclusion, targeted therapeutics generated to correct disrupted mitochondrial mechanisms during
DM, may provide cardiac benefit via reduced mitochondrial dysfunction and preservation of the
mitochondrial proteome, ultimately leading to restored cardiac function and a better quality of life
for diabetic patients.
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SPECIFIC AIMS
Approximately 9% of the United States population is diagnosed with diabetes mellitus
(DM) and diabetic cardiomyopathy is the leading cause of heart failure in diabetic patients (1).
Type 1 diabetes mellitus (T1DM), caused by insufficient insulin production, affects approximately
5% of diabetic patients, while type 2 diabetes mellitus (T2DM) results from insulin resistance and
affects 95% of all diabetic patients (2). The mitochondrion has been identified as a central
contributor to contractile dysfunction during DM, with echocardiographic speckle-tracking based
strain analyses allowing for an early detection of subtle myocardial changes (7, 8, 13). Examination
of mitochondrial dysfunction during DM is further complicated by the presence of two distinct
mitochondrial subpopulations residing within the cardiomyocyte (11). A pool of mitochondria
exists beneath the sarcolemmal membrane, the subsarcolemmal mitochondria (SSM), while
another group exists between the myofibrils, the interfibrillar mitochondria (IFM). Approximately
99% of the mitochondrial proteome is composed of nuclear-encoded proteins, which are imported
into the mitochondrion via a complicated mechanism coordinating both the outer and inner
mitochondrial membranes (3, 12, 14). Proteomic analyses by our laboratory and others reveal
decreased abundance of nuclear-encoded mitochondrial proteins, essential for processes such as
oxidative phosphorylation, fatty acid oxidation (FAO) and tricarboxylic acid cycle (TCA), during
DM (4, 5, 9, 15). Further, our laboratory has shown decreased nuclear-encoded mitochondrial
protein import in the T1DM IFM (5). Prior to this dissertation, evaluation of the diabetic heart
using speckle-tracking based strain analyses had not been studied to determine if subtle changes
occur prior to overt cardiac dysfunction. Additionally, it was unknown if a key constituent in
nuclear-encoded mitochondrial protein import would serve as a locus for reversal of the
dysfunction seen during the pathology. Finally, this dissertation also provides insight into a
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potential constituent involved in the mechanism of import of microRNAs (miRNAs) into the
mitochondria.
Our long-term goal was to identify mechanisms to alleviate adverse cardiac and
mitochondrial effects associated with DM with the intent of providing a mechanism for therapeutic
interventions to be designed. The objectives of this dissertation were to determine if during DM:
(1) echocardiographic speckle-tracking based strain imaging analyses would lead to a greater
ability to detect earlier changes in myocardial dysfunction; (2) mitochondrial heat shock protein
70 (mtHsp70) would provide mitochondrial and cardiac contractile protection through increased
mitochondrial proteome stability and nuclear-encoded mitochondrial protein import efficiency; (3)
increased polynucleotide phosphorylase (PNPase) expression led to an increase in miRNA import
into the mitochondrion via an association with the RNA-induced silencing complex (RISC).
The central hypothesis of this dissertation was that strain analyses would offer the
capability to detect early decrements in left ventricular (LV) myocardial strain resulting from
mitochondrial dysfunction associated with a disrupted mitochondrial proteome potentially due to
inefficient mitochondrial protein import or increased miRNA within the mitochondrion. Further,
we hypothesized that mtHsp70 would rectify inefficiencies in nuclear-encoded mitochondrial
protein import, thus restoring the mitochondrial proteome and cardiac contractile function.
Notably, these effects would be most pronounced in the IFM during a T1DM insult and the SSM
during a T2DM insult. The central hypothesis was based upon preliminary data produced in our
laboratory indicating that cardiac contractile dysfunction occurs during DM and that the
mitochondrial proteome is disrupted due to inefficient nuclear-encoded mitochondrial protein
import or miRNA redistribution during the pathological setting (5, 6, 9, 10). Our rationale for the
proposed research was based upon the notion that a greater understanding of the mechanisms
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involved in mitochondrial dysfunction during DM, along with a non-invasive mechanism to
evaluate and detect early myocardial contractile deficiencies, could potentially allow for the
identification of key contributors to alleviate mitochondrial dysfunction, aiding in the development
of a therapeutic paradigm to help combat cardiac complications in diabetic patients. We tested our
central hypothesis by pursuing the following Specific Aims:

Specific Aim I: Determine the therapeutic advantage for using speckle-tracking based strain
imaging analyses versus conventional echocardiographic measurements in a small animal
model of T1DM.
To address Specific Aim I, we utilized the streptozotocin (STZ) T1DM mouse model and
performed a time-course study to evaluate our working hypothesis. Our working hypothesis was
that subtle changes in myocardial strain could be detected earlier using the speckle-tracking based
strain imaging analyses prior to the onset of cardiac contractile dysfunction delineated by
conventional echocardiographic measurements.

Specific Aim II: Assess the cardioprotective efficacy of mtHsp70 overexpression on nuclearencoded mitochondrial protein import and mitochondrial proteome stabilization to alleviate
cardiac mitochondrial and contractile dysfunction in the diabetic heart.
MtHsp70 is a vital component to the mitochondrial protein import machinery. Located
within the mitochondrial matrix, mtHsp70 provides the active motor for import of proteins into
the mitochondrial matrix (3). Previous work from our laboratory demonstrated that this essential
component of the protein import machinery is reduced during DM, potentially causing decreased
efficiency in nuclear-encoded mitochondrial protein import leading to a deranged mitochondrial
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proteome (5, 9). Overexpression of mtHsp70 was employed to assess its effect on proteome
restoration and nuclear-encoded protein import efficiency during DM. Our working hypothesis
was that overexpression of a cardiac-specific mtHsp70 during DM would restore nuclear-encoded
mitochondrial protein import deficiencies, reverse proteome instability and alleviate cardiac
contractile dysfunction. Further, these effects would be shown to occur in the IFM during T1DM
and the SSM during T2DM.

Specific Aim III: Elucidate the role of PNPase in the mechanism of miRNA import into the
mitochondrion via RNA-induced silencing complex (RISC) association in the diabetic heart.
To address Specific Aim III, we used the db/db mouse model for T2DM and evaluated
PNPase protein expression levels, along with miR-378 levels within the mitochondrion. Further,
we overexpressed PNPase in the HL1 cardiomyocyte cell line to examine the impact on miR-378
translocation into the mitochondrion. Our working hypothesis was that the increased association
of PNPase with the RISC would allow for increased miRNA transport into the mitochondrion
during T2DM. Further, increased expression of miRNA, such as miR-378, could affect the
mitochondrial genome and processes such as ATP production via ATP synthase.
The research generated from this dissertation was innovative because it uses advanced
imaging analysis techniques to detect early changes in the myocardium, allowing for early
intervention strategies to be employed for DM patients with cardiac contractile abnormalities.
Further, this dissertation expanded upon previous work of the laboratory utilizing a novel cardiacspecific transgenic mouse line, which alleviated dysfunctional processes during DM. At the
completion of these studies, we were able to utilize a non-invasive approach to detect subtle
myocardial changes during T1DM in a small animal model. This type of analyses will allow
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researchers to approach treatment of adverse cardiac function in different pathological states in
small animal models at the earliest onset of myocardial abnormalities and evaluate the protection
afforded by different therapeutic paradigms. Further, by manipulating mtHsp70, the driving force
behind nuclear-encoded mitochondrial protein import, we highlighted the novel therapeutic
paradigm in which multiple dysfunctional processes are corrected through a single protein target
capable of restoring mitochondrial function independent of diabetic type. Finally, the outcomes on
our research for PNPase during T2DM, enhanced our understanding of a potential player in the
mechanism of miRNA import into the mitochondrion. Altogether, this dissertation research led to
the increased understanding of mitochondrial dysfunction during DM and provided insight into
potential therapeutic interventions that could be applied to the treatment of DM patients in order
to increase their quality of life.
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Chapter 1:
Literature Review
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BACKGROUND AND SIGNIFICANCE

1.1 Diabetes Mellitus
Diabetes mellitus (DM) is a complex pathological condition characterized into two general
types. The predominant form of DM is type 2 diabetes mellitus (T2DM), which encompasses
approximately 95% of diabetic patients, while type 1 diabetes mellitus (T1DM) accounts for 5%
of diabetic cases (353). Chronic hyperglycemia is a characteristic hallmark of DM and oftentimes
leads to damage and failure of organs including the heart, eyes, kidneys and blood vessels (2).
When left untreated, complications resulting from DM can result in death. Other lesser-known
types of DM exist, such as gestational diabetes, which occurs during pregnancy along with DM
arising from genetic conditions, surgeries, medications and other pancreatic diseases. A diagnosis
for DM is generally associated with a fasting blood glucose level above 126 mg/dL and for type 1
diabetics, insulin levels under 0.50 ng/mL (389).

1.1a. Type 1 diabetes mellitus
Affecting approximately 5% of diabetic patients, T1DM is characterized by a lack of
insulin production due to the autoimmune destruction of the pancreatic β-cells, leading to insulin
deficiency within the body (185). The presence of autoantigens within pancreatic islet cells, such
as islet cell antigen, insulin, pro insulin, glutamic acid decarboxylase and protein tyrosine
phosphatase, can promote the destruction of the β-cells (284). Factors such as genetic
predisposition can lead to T1DM, but environmental factors including viral infections, parental
age, and low birth weight have also been associated with its development (6). T1DM is also
referred to as juvenile-onset diabetes, with the majority of T1DM cases occurring in children,
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adolescents and young adults (35). Treatment of T1DM includes monitoring the blood glucose
levels of patients and injection with insulin prior to the consumption of food, which allows the
body to properly transport cellular glucose and utilize it efficiently. During T1DM, severe insulin
deficiency leads to increased ketone body production in the liver, which causes a lowering of the
pH of the blood, ultimately resulting in diabetic ketoacidosis (72, 435). Multiple organ and systems
are affected during T1DM, including complications with the eyes, liver, kidneys, nervous system,
skeletal muscle and heart (2). Diseases and issues such as retinal detachment, diabetic nephropathy
leading to renal failure, amputations of limbs, periodontal and heart disease are some of the
ailments seen coinciding with uncontrolled T1DM (2). The hyperglycemic environment produced
during T1DM produces these catastrophic ailments associated with the disease and no known
prevention of T1DM exists to date.

1.1b. Type 2 diabetes mellitus
T2DM is the more prevalent form of DM, affecting approximately 95% of diabetic patients.
Nine out of 10 individuals with prediabetes, do not know that they are at risk of developing DM,
and of that, 15-30% of people with prediabetes will develop T2DM within 5 years (4). T2DM is
known as non-insulin dependent diabetes because it is characterized by insulin resistance, reduced
insulin sensitivity and occasionally a defect in insulin secretion from the β-cells, ultimately
producing the hallmark hyperglycemic environment of DM (353). Obesity oftentimes
accompanies T2DM; however, it is not a prerequisite for the disease. With that being said, most
T2DM patients display an increased body fat percentage in their abdominal region and unlike
T1DM, T2DM patients do not suffer from ketoacidosis (12). Interestingly, T2DM patients may
present with normal insulin levels; however, their insulin levels rarely compensate for the elevation
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in blood glucose levels, resulting in a deficiency of insulin secretion. Dyslipidemia and an altered
lipoprotein pattern including increased triglyceride levels, low levels of high-density lipoprotein
cholesterol and small, dense low-density lipoprotein particles, are characteristic during the early
stages of T2DM (368). Treatment of T2DM includes monitoring the blood glucose levels of
patients and adherence to a strict regimen of diet and exercise in hopes of reducing the body weight
of T2DM patients suffering from obesity and increasing the body’s ability to properly handle
glucose (368, 424). Treatment with insulin or other medications, such as Metformin, which work
to increase insulin sensitivity or reduce glucose production are also commonly used in T2DM
patients (319).

1.1c. Significance
The leading causes of morbidity and mortality among diabetic patients in the United States
are cardiac failure and heart disease (142). DM is the seventh leading cause of death in the United
States and the incidence of DM has doubled its rates over the past two decades (3, 4). Current
reports suggest that DM affects a staggering 9% of the population worldwide, with 29 million
adults in the United States being diagnosed with DM and another 86 million diagnosed with
prediabetes (2-4, 12). Both T1DM and T2DM are characterized by hyperglycemia resulting either
from deficits in insulin production or resistance, respectively. This chronic hyperglycemic
environment can lead to the damage of many organ systems including the kidneys, eyes, nerves,
blood vessels and the heart (2, 431). Due to the increasing incidence of DM in the United States
and the world, the disease is quickly becoming an epidemic and the evaluation of mechanisms that
underlie the cardiac deficits seen during DM need to be studied in order to develop and implement
therapeutic strategies to increase the quality of life in diabetic patients.
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1.2 Diabetic Cardiomyopathy
DM-associated

cardiac

dysfunction,

termed

diabetic

cardiomyopathy,

occurs

independently of vascular dysfunction, such as atherosclerosis, coronary artery disease (CAD) and
hypertension and serves as the leading cause of heart failure (HF) in diabetic patients (30, 52).
Literature suggests that while CAD and hypertension often occur as comorbidities to diabetic heart
disease, diabetic cardiomyopathy has also been shown to be independent of these pathologies in
both the clinical and experimental settings (8, 38, 97, 159, 270, 326, 337). Rubler et al. first showed
diabetic cardiomyopathy in congestive HF patients with DM; however, it was noted that these
patients also lacked the presence of coronary atherosclerosis and hypertension (337). Following
this study, Regan et al. showed that diabetic patients without CAD had alterations in left ventricular
(LV) end diastolic pressure (EDP), LV compliance and ejection fraction (EF) (326). Experimental
models of DM have revealed decreased contractile efficiency while also being resistant to
atherosclerosis, indicating the presence of diabetic cardiomyopathy (187, 397). This evidence
suggests that diabetic cardiomyopathy leads to LV dysfunction in the absence of vascular
disturbance and further has been associated with decreased mitochondrial function and adenosine
triphosphate (ATP) production (97, 130, 154, 236, 326, 353, 373, 390).

1.2a. Cardiac contractile dysfunction
Cardiac contractile dysfunction is a common hallmark of DM, leading to HF in diabetic
patients due to the effects of the chronic hyperglycemic environment. Diastolic dysfunction occurs
during the beginning stages of DM and is characterized by deficits in LV relaxation time and
compliance (30, 118, 249, 353, 441). By utilizing tissue Doppler analyses and assessing the flow
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of blood across the mitral valve, patients with T1DM revealed decreases in early peak mitral
velocity (E wave) and increased late peak mitral velocity (A wave) leading to a decreased E/A
ratio, along with a prolonged deceleration time (56, 320, 321, 344). Patients with T2DM also show
abnormal LV relaxation and restrictive filling deficiencies (43, 83, 136, 258, 293). Diastolic
dysfunction is also evident in experimental animal models of both T1DM and T2DM (43, 141,
303, 352). Dabkowski et al. showed cardiac dysfunction in T1DM mice through decreased rates
of contraction, relaxation and developed pressure via Langendorff perfusion (85). Prolonged
relaxation time and slowing of relaxation velocity indicated the presence of diastolic deficits in the
diabetic rat myocardium (45). Another study in perfused diabetic rat hearts confirmed diastolic
dysfunction by an increased isovolumetric relaxation time along with increases in inflow velocity
across the mitral valve and LV EDP during T2DM (192). Similar diastolic dysfunction was seen
in animal models of T2DM with decreased rates of relaxation and increased LV wall stiffness (83,
84, 258)
Dysfunction of the heart during systole is also present in diabetic patients and experimental
T1DM and T2DM animal models. Patients with T2DM show decreased fractional shortening (FS)
and changes in LV mass and geometry; however, these data are complicated by the presence of
other comorbidities in the patient populations and the medications of these patients (109, 173,
308). T1DM patients also show dimensional alterations to the myocardium (56, 190). While
diastolic dysfunction is observed during DM, depending on the population studied, systolic
dysfunction varies (133, 265, 320). Animal models of both types of DM show decreased heart rate,
systolic blood pressure, EF, FS, along with dimensional and volumetric changes (22, 84, 91, 161,
171, 192, 431).

6

1.2b. Fibrosis
Structural changes of the heart have been reported in both animal experimental models and
humans with DM (181, 221, 282, 378, 384). Fibrosis accounts for the majority of changes in the
structure of the heart, consisting of two types, interstitial and perivascular (92, 145, 294, 326, 402).
Postmortem evaluation of diabetic patients showed enhanced collagen deposition in the
perivascular loci and between myofibers (326). Further, Regan et al. also found enhanced
triglyceride and cholesterol concentrations in the diabetic patients as compared to controls in the
LV and septum (326). In a different study, myocardial biopsies revealed higher type III collagen,
which is specific to cardiac tissue, while type I collagen is more predominant in the myocardium
and was unchanged between diabetic and non-diabetic patients (357). During the evaluation of the
right ventricle (RV), Nunoda et al. found that the average diameter of the RV myocardial cells was
increased and the percentage of fibrosis was significantly higher in mild diabetic patients without
hypertension or CAD as compared to controls (294). While fibrosis is present during DM, the
mechanisms behind it are not well understood. Widyantoro et al. reported an increase in
endothelin-1 (ET-1) in the plasma, which has been associated with increased fibroblast
accumulation, providing a potential mechanism for the development of fibrosis (426). Other
factors reported to play a role in the development of fibrosis are protein kinase C beta-1 and
transforming growth factor beta-1 receptor II, which were enhanced in the diabetic myocardium
of streptozotocin (STZ) diabetic mice (14, 420, 425). In the obese diabetic mice with leptin
deficiency, the ob/ob mouse model of T2DM showed no LV myocardial fibrosis; however in the
db/db model, cardiac fibrosis was evident (151, 208, 398). It is important to gleam from the current
research in both experimental animal models of DM and diabetic patients that fibrosis is a critical
player in cardiac dysfunction in the diabetic heart (39).
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1.2c. Oxidative stress
One of the major contributing factors in the development of diabetic cardiomyopathy is the
hyperglycemic environment, leading to an increase in the formation of reactive oxygen species
(ROS) and a decrease in antioxidant levels (332). Oxidative stress is classically defined as the
imbalance between ROS generation and the antioxidant defense mechanisms. Common examples
of ROS include oxygen-derived free radicals such as superoxide and hydroxyl radicals, as well as
non-radical derivatives such as hydrogen peroxide (H2O2). Literature suggests that the
overproduction of superoxide increases the activity of polyl pathway flux, advanced glycation end
product formation, hexosamine pathway flux and activation of protein kinase C leading to
oxidative stress (46, 99, 291). The mitochondria are the main source of ROS generation within the
cardiomyocyte through the leakage of electrons from the electron transport chain (ETC) in the
inner mitochondrial membrane (IMM). In the db/db mouse model, Boudina et al. found increased
H2O2 production, along with increased oxidative damage to lipids (41). Our laboratory found
increased ROS production from cardiac mitochondria in the STZ T1DM mouse model (85).
Further, oxidative stress has been show to create alterations in myocyte morphology, function,
protein content and ion action, ultimately leading to diabetic cardiomyopathy (46). With the
overexpression of mitochondrial phospholipid hydroperoxide glutathione peroxidase (mPHGPx),
an antioxidant capable of reducing lipid hydroperoxides to alcohols and free H2O2, our laboratory
found that lipid peroxidation was decreased and mitochondrial function, along with proteome
stabilization was maintained during T1DM and following ischemia/reperfusion (I/R) injury (22,
85, 86, 253, 396).
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1.3 Cardiac Function Using Echocardiography
Cardiac function is monitored routinely by the use of non-invasive, ultrasound imaging
called echocardiography. There are three basic modes to image the heart: two-dimensional (2D)
imaging, motion mode (M-mode) imaging, and Doppler imaging (11). Standard 2D
echocardiography can be captured in both the long- and short-axes and allows for the viewing of
motion in real time in a cross-section of the heart (11). The long-axis of the heart cuts the heart
from top to bottom opening it up into left and right sides, while the short-axis cuts the heart into
top and bottom halves. Doppler flow allows for the assessment of blood flow across valves within
the heart. These measurements provide an efficient, cost-effective and highly accurate way to
complete cardiac functional analyses in order to diagnose and manage patients suffering from heart
disease. Assessment of cardiac function can also be performed in animal models and is oftentimes
used as a measure to determine how a therapeutic treatment is affecting the heart. In both patients
and animal models, systolic and diastolic parameters can be assessed through echocardiography
and involves the use of all three modes of echocardiography to acquire a thorough evaluation of
decrements in cardiac contractile function.

1.3a. Conventional echocardiography
M-mode is one of the earliest forms of cardiac ultrasound and is widely used in the clinical
setting, allowing for the assessment of cardiac function via volumetric and diametric changes
across multiple cardiac cycles. Using the parasternal short-axis view of the LV, a gate is placed
through the 2D image and the motion of the ventricular walls can be measured across onedimension (1D), increasing the temporal and spatial resolutions (11). Measurements obtained from
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LV M-mode images include end-systolic and end-diastolic volumes and diameters, EF, FS, stroke
volume (SV) and cardiac output (CO). M-mode has been found to be a reliable assessment of overt
cardiac dysfunction; however, some clinicians consider it to be obsolete because of the
development of more sensitive indices of cardiac functional assessment, such a speckle-tracking
base strain echocardiography (124).

1.3b. Speckle-tracking based strain echocardiography
Another approach for imaging cardiac function is by using highly sensitive speckletracking based strain echocardiography. During recent years, speckle-tracking based strain has
gained popularity in the clinical setting to allow for the assessment of velocity, displacement and
deformation of the myocardium over the course of multiple cardiac cycles. Speckle-tracking based
strain echocardiography provides a more comprehensive and reliable echocardiographic
assessment through its ability to detect subtle alterations in cardiac motion. 2D echocardiographic
cine loops are used in both the parasternal long- and short-axes to fully evaluate the movement of
the myocardium throughout the cardiac cycle. Speckle-tracking based strain analyses are
completed offline and the algorithms use speckle artefacts in the echo image (33). These speckles
are generated at random from refractions, reflections and the scattering of the echo beams and help
to assess wall motion and deformation throughout the cardiac cycle (33, 146). Some of the
advantages of using speckle-tracking based stain include that it is angle independent because the
speckles move in the direction of the wall and not along the ultrasound beam, it does not require
as high of frame rates as other techniques and allows for strain measurements in three different
dimensions (33, 312).
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Speckle-tracking based strain and its relation to conventional echocardiography is not as
straightforward as simple cardiac functional parameters. For instance, speckle-tracking based
strain uses the parameters of wall motion velocity and displacement, along with the assessment of
strain and strain rate from the deformation of the LV during the cardiac cycles (33, 81, 146, 322).
Displacement is the distance that the speckle travels between two consecutive frames, while the
velocity is the displacement of the speckle per unit time (322). Strain is a dimensionless quantity
of myocardial deformation and measures the magnitude of myocardial fiber contraction and
relaxation, otherwise known as the thickening and thinning of the myocardial wall in the radial
dimension and elongation and shortening of the myocardium in the longitudinal and
circumferential dimensions (33, 81, 146). For example, as the heart goes through the cardiac cycle
and reaches systole, or contraction, the space inside of the heart gets smaller and the myocardial
wall thickens. This allows for the assessment of the radial dimension, which can be evaluated in
both the long- and short-axes. During systole, strain in the radial (R) dimension is represented as
positive because of the thickening of the wall; however, in diastole, radial strain is a negative
number because of the thinning of the wall (Figure 1.1). Longitudinal (L) shortening and
circumferential (C) shortening occur during the contraction of the heart leading to negative values
resented during systole, while lengthening happens during diastole and is represented by positive
values (Figure 1.1).

Figure 1.1 Speckle-Tracking Based Strain Echocardiographic Axes
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Another important measurement obtained from speckle-tracking based strain analyses is
strain rate. Strain rate is the time it takes to reach the peak of deformation or strain during the
cardiac cycle (33, 322). Together, speckle-tracking based strain analyses provide adequate
measurements for a more thorough evaluation of wall motion during the cardiac cycle.
Strain and strain rate analyses have been performed in the clinical setting in patients
suffering from CAD, myocardial infarction (MI), ischemic cardiomyopathy, diastolic HF, Chagas’
disease, DM and patients undergoing cardiac resynchronization therapy (13, 17, 34, 62, 96, 112,
160, 243, 410). Speckle-tracking based strain analyses have also been employed in small animal
models of disease. Using speckle-tracking based strain analyses, Bauer et al. found that these
analyses are capable of detecting subtle changes in myocardial wall function providing highthroughput and sensitive cardiac phenotyping (26). In their study, animals underwent a permanent
left anterior descending coronary artery ligation and a portion of the animals received treatment
with an angiotensin-converting enzyme inhibitor (ACEi) (26). Bauer et al. found that speckletracking based strain analyses were able to detect changes at an earlier time point following MI
and the results also predicted the later development of adverse remodeling of the LV (26). Their
results also revealed that speckle-tracking based strain analyses were capable of detecting subtle
improvement in LV function when MI animals were treated with ACEi (26). Additionally, in the
db/db mouse model of T2DM, Li et al. found global radial and circumferential strain values were
decreased as compared to controls (241). Speckle-tracking based strain analyses provide an
approach to looking at subtle changes in cardiac function in both a clinical and experimental
setting.

12

1.3b.i. Global and regional assessment
When using speckle-tracking based strain analyses, measurements of both global and
segmental analyses can be acquired. Global measurements refer to the overall or average data
acquired in the LV over multiple cardiac cycles, while segmental analyses are the LV myocardium
subdivided into 6 standard anatomic segments (57). For our studies, these measurements are
acquired from curvilinear data obtained from the Visual Sonics Vevo2100 speckle-tracking based
strain software (Figure 1.2). Using the Vevo2100 speckle-tracking based strain software,
segmental analyses can be performed on short-axis images with the LV subdivisions of the
following regions: anterior free (AF), lateral (L), posterior (P), inferior free (IF), posterior septum
(PS) and anterior septum (AS) (Figure 1.2 Top Panel). The long-axis images subdivide the LV
into the anterior base (AB), anterior mid (AM), anterior apex (AA), posterior apex (PA), posterior
mid (PM) and posterior base (PB) (Figure 1.2 Bottom Panel).

Figure 1.2 Speckle-Tracking Based Strain Global and Regional Assessment
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Segmental analyses allow an investigator to find a particular locale within the LV where
dysfunction may be occurring. It is imperative in a clinical setting for subtle changes in cardiac
function to be detected to allow for intervention before a sudden onset of a cardiac insult. Further,
to be able to pinpoint this location of dysfunction via segmental analyses is a powerful tool for
therapeutic treatment. Clinical studies have currently shown that speckle-tracking based strain was
able to detect subtle changes in LV function and were predictive of future development of
cardiovascular disease (77, 112, 113, 117, 119, 239, 276, 283). While conventional measurements
are easier to perform in a clinical setting, strain and strain rate imaging have been shown to increase
the ability to detect cardiomyopathies in diabetic patients (42, 119, 280). Within the past 5 years,
the ability to assess cardiac performance in small animal models was limited; however, speckletracking based strain analyses have provided a platform to gain further insight on subtle changes
in cardiac function in small animal models. Studies have shown that early global changes in LV
function are detected by speckle-tracking based strain analysis prior to changes in conventional
measurements in different animal models with cardiac pathologies (26, 27, 211, 432). Further,
analyses of particular regions within the LV provide a more accurate picture to pinpoint where the
cardiac dysfunction is occurring (26, 33, 167, 322). The ability to obtain a complete picture by
using both a global and segmental functional analysis of the LV during a disease state provides the
opportunity to evaluate and understand disease progression, as well as potentially develop a
therapeutic paradigm to treat a particular locale within the heart.

1.3c. Doppler flow echocardiography
Doppler flow echocardiography is capable of estimating blood flow velocity through the
heart and can be measured by using the comparison of the frequency change between the sound
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waves that are transmitted and the sound waves that are reflected back (11). The use of Doppler in
cardiac ultrasound can be done in three distinct ways: continuous-wave Doppler, pulsed-wave
Doppler, and color-flow mapping (11, 325). Continuous-wave Doppler, while sensitive and able
to detect high velocities, comes with limitations because the velocity of blood flow is measured
along the constant ultrasound beam and not at a specific depth (11). This means that the method is
unable to localize the velocity measurements of blood flow (11, 325). Pulsed-wave Doppler was
developed because of the limitations in continuous-wave Doppler and overcomes these restrictions
by using short bursts of ultrasound with range gating (325). Localized velocity measurements of
blood flow can be measured using pulsed-wave Doppler imaging because this technique measures
blood flow velocity within a small area at a specific depth (11). Thus, pulsed-wave velocity
measurements can be employed to measure blood flow through the valves in the heart; however,
because of the intermittent ultrasound bursts, recording high-velocity signals is more difficult
(325). Taken together, continuous-wave and pulsed-wave Doppler are complementary and can
supply the needed information that is missing from the other mode. Finally, color-flow mapping
allows for the superimposition of blood flow imaging on top of “real-time” 2D echocardiographic
imaging of blood (11, 164). Color-flow mapping is a pulsed-wave Doppler technique and comes
with both the advantages and disadvantages of pulsed-wave Doppler (325). Flow toward the
transducer appears as red, while flow away is indicated by blue (11, 325). Shading of these colors
also lends information on velocity while these images are being acquired (11). Altogether, Doppler
flow echocardiography is a useful non-invasive tool to measure blood flow within the heart.
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1.4 Mouse Models of Diabetes Mellitus
Studying both T1DM and T2DM and its associated cardiac abnormalities has been made
easier by the development of rodent models, since the mechanisms behind DM and human diabetic
cardiomyopathy are only partly understood (49). Using rodent models to study diabetic
cardiomyopathy and the mechanisms behind its development is unique in that rodents do not
develop atherosclerosis, allowing for the uninhibited study of the diabetic cardiomyopathy without
interference from atherosclerotic mechanisms. Many rat and mouse models of T1DM and T2DM
exist and specific advantages and disadvantages arise depending on which is used. Common
models of T1DM include the STZ, OVE26, and Akita mouse models, while the T2DM models are
the ob/ob and db/db mouse models and the Zucker diabetic fatty rat.

1.4a. Streptozotocin mouse model of type 1 diabetes mellitus
The STZ mouse is the most frequently used model of T1DM and is the model that we have
chosen to employ in our studies. STZ, a glucosamine-nitrosourea antibiotic with a similar structure
to glucose, was first used to destroy cancerous pancreatic β-cells, but now is successfully used to
generate a T1DM rodent model (7, 49). Preferentially taken up by the glucose transporter 2
(GLUT2) in the pancreatic β-cells, intraperitoneal injection of STZ results in toxicity and necrosis
eventually leading to insulin deficiency (37, 348). Mechanistically, STZ is capable of causing
DNA damage through alkylation and with this, activation of poly adenosine disphoasphate (ADP)ribosylation leads to the depletion of cellular NAD+ and ATP (348). STZ also causes the
generation of superoxides and an increase in xanthine oxidase activity through the
dephosphorylation of ATP (348). With the increase in ROS within the pancreas, necrosis of the βcells and decreased insulin production ensue (348). Our laboratory uses the multiple low-dose
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intraperitoneal injections (50mg/kg body weight) of STZ in FVB mice for five consecutive days,
as suggested by the Animal Models of Diabetic Complications Consortium (AMDCC). Generally,
the mice develop hyperglycemia, which our laboratory characterizes as a blood glucose level
greater than 250 mg/dL and low levels of insulin at approximately 0.5 ng/mL, within 7 to 14 days
after the first STZ injection (49). Mice treated with STZ have been found to have increased serum
fatty acid, along with increased triglyceride and cholesterol levels (49). Further, cardiac
dysfunction has been found in mice treated with STZ (22, 85, 289, 376, 386, 391). Using a
Langendorff setup, we found significantly decreased rates of relaxation and contraction, along with
increased developed pressure in STZ-treated mice (85). Further, using the Vevo2100 ultrasound
imaging system, we have reported decreased EF, FS, SV and CO in T1DM animals as compared
to littermate controls (22, 386). It is important to note that STZ-induced diabetic cardiomyopathy
can be reversed through regular treatment with insulin, lending evidence that insulin deficiency
and glucose utilization are the cause of cardiac abnormalities in this model (409). Other models of
T1DM are the OVE26 and Akita mouse; however, they differ from the STZ model because they
are genetically engineered and are T1DM from birth (49). This leads to an important advantage of
the STZ model in that DM can be induced at any age and transgenic animals can be made diabetic
to evaluate different mechanisms involved in diabetic cardiomyopathy.

1.4b. db/db mouse model of type 2 diabetes mellitus
The db/db mouse model is a model of T2DM, which develops because of a point mutation
causing dysfunctional leptin receptors. The normal, long form of the leptin receptor gene is
responsible for the action of leptin in the hypothalamus, which regulates appetite and body weight
(73). The genetic manipulation by an insertion of a premature stop codon within the db transcript
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leads to a short-form isoform of the leptin receptor. Therefore, without the functional form of this
leptin receptor, obesity occurs (73). As early as 4 weeks of age, db/db mice begin to show signs of
obesity and severe T2DM is developed by 8 weeks (47). Cardiac contractile abnormalities are
present in the db/db model, along with hyperinsulinemia, enhanced fatty acid production and
increased triglycerides (47). When assessed by echocardiography, db/db mice showed a
development of cardiac hypertrophy, decreased FS and velocity of circumferential shortening
(352). CO, LV-developed pressure and cardiac power were all decreased in isolated, working
db/db hearts (49). Our laboratory and others revealed that in isolated perfused hearts, rates of
contraction, relaxation, peak systolic pressure, rate pressure product and developed pressure were
significantly decreased in the db/db animals versus controls (29, 84). Diastolic dysfunction also
occurs in db/db mice and has been shown through both echocardiography and MRI analyses (375).
Further, db/db mice have increased superoxide formation and oxidative damage by-products,
which have been linked to cardiac mitochondrial dysfunction (41).
Another model of T2DM is the ob/ob mouse model, which develops DM when the mouse
is homozygous for the obese spontaneous mutation (Lepob), leading to a decrease in leptin and the
inability to suppress appetite (134). These mice exhibit obesity, hyperphagia, and diabetes-like
syndrome of hyperglycemia, glucose intolerance and elevated plasma insulin levels and are
considered T2DM at 15 weeks of age (47). Interestingly, even after the development of T2DM,
ob/ob mice develop cardiac hypertrophy, but do not have impaired systolic function (49).
Therefore, our laboratory chose to use the db/db mouse model because of our vested interest in
cardiac abnormalities and restoration of cardiac pump function during T2DM.
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1.5 Mitochondrial Subpopulations
Advanced imaging techniques have allowed for insight into cellular and organellar
structure within the cardiomyocyte, leading to the recognition of mitochondria residing within
specific locales of the cardiomyocyte. Mitochondrial subpopulations have been found in a number
of different mammalian species including mouse, rat, muskrat, guinea pig, hamster, rabbit, dog,
pig, monkey, cow and human (86, 137, 166, 237, 267, 272, 356, 358, 370, 392). Two spatially and
biochemically distinct mitochondrial subpopulations exist within the cardiomyocyte (306). With
the pioneering development of mitochondrial isolation techniques by Palmer et al., distinct
mitochondrial subpopulations can be isolated by utilizing both mechanical and enzymatic
procedures (306). Evaluation of other non-cardiac cells, such as neurons, revealed that functional
heterogeneity between the dendritic, somatic, axonal, and presynaptic segments result from
variations in energy demands and calcium (Ca2+) signaling dynamics (199). These differences
were associated with structural and biochemical attributes of the mitochondria depending upon
their location and demands within a specific neuronal region, leading to particular responses during
pathophysiological stress (199). Literature suggests that mitochondrial spatial locale within the
myocyte may also be associated with particular responses to physiological and pathological stimuli
(157, 193, 217, 266, 384). Within the cardiomyocyte, two spatially distinct mitochondrial
subpopulations have been identified through ultrastructure analyses. Further, these mitochondrial
subpopulations have also been found to have their own biochemical profile (306). The population
of mitochondria that reside beneath the sarcolemmal membrane are termed subsarcolemmal
mitochondria (SSM), while those located between the myofibrils are called interfibrillar
mitochondria (IFM) (Figure 1.3) (176). Another population of mitochondria, which are isolated
with the IFM, reside in the perinuclear region of the cell (176).
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Figure 1.3 Cardiac Mitochondrial Subpopulation Schematic and Electron Micrograph

1.5a. Structural differences
Mitochondria located in distinct subcellular locales have been shown to have different
structural appearances. Scanning electron microscopy and transmission electron microscopy
revealed distinct mitochondrial populations including perinuclear mitochondria, SSM and IFM in
thin sections from the LV tissue of Japanese Monkeys (Macaca fuscata) (356). As their name
describes, perinuclear mitochondria were clustered at the nuclear poles. These mitochondria
maintained a mostly spherical shape, ranging in lengths from 0.8 to 1.4 µm, and contained welldeveloped, curved cristae with minimal matrix area. Between the myofibrils were situated another
pool of mitochondria termed the IFM. These mitochondria occupy the space between the Z-lines
of the myofibrils and form longitudinal rows, which are bookended by the junctional sarcoplasmic
reticulum (122, 254) (Figure 1.3). IFM typically exist as one mitochondrion per sarcomere, are
elongated in shape, and range from 1.5-2.0 µm in length. The cristae structure of the IFM are more
complex with curved configurations. Finally, the mitochondrial pool located beneath the
sarcolemmal membrane are termed the SSM and are considerably more variable in length ranging
from 0.4-3.0 µm. The cristae are typically tightly packed in the SSM. Generally, perinuclear
mitochondria are smaller than IFM and possess a rounder shape, while the SSM vary in size and
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shape with oval, spherical, polygonal, and horseshoe profiles (254, 356). Similar ultrastructural
patterns have been reported in HL-1 cells, a cardiac muscle cell line, using confocal imaging to
look at mitochondria clustered around the nucleus (220). Human papillary muscle subjected to en
bloc staining revealed differential staining patterns between mitochondrial subpopulations leading
to the thought that the SSM, IFM and perinuclear mitochondria may possess differences in
chemical makeup and metabolic activities (90). Additionally, flow cytometry analyses using
membrane-dependent dyes (MitoTracker Deep Red 633) coupled with size calibration
microspheres to determine absolute mitochondrial size and internal complexity in SSM and IFM,
indicated differences between mitochondrial subpopulations (80, 84-86, 287, 386, 428).
Mitochondrial subcellular distribution has also been studied using probability density analyses via
a 3D modeling approach utilized with MitoTracker Deep Red staining (32). This revealed that the
IFM maintained a highly organized crystal-like pattern for cristae and were arranged in
longitudinal rows between the myofibrils (32). Similar results were found using MitoTracker Deep
Red 633 in adult mouse cardiomyocytes (176). Interestingly, cardiomyocytes from rainbow trout
(Oncorhynchus mykiss) revealed no order of mitochondria when situated beneath the single
cylinder-shaped layer of myofibrils underneath the sarcolemma (32). With this finding, it is
important to note that differences in mitochondrial spatial patterns may be species specific.
Structural differences in cristae morphology were examined using high resolution
scanning election microscopy in rat LV tissue (331). Lamelliform cristae, which are broad and flat,
were the predominant pattern in the SSM, while the cristae morphology in the IFM was variable
with some mitochondria possessing only tubular cristae or only lamelliform cristae and others
possessing a mix of the two cristae forms (331). Riva et al. speculated from this data that individual
cristae morphological patterns potentially contribute to functional differences in subpopulations of

21

mitochondria, including a reduction in the intracristal space of tubular cristae (331). This reduction
in intracristal space potentially leads to a higher proton concentration within the structure,
enhancing ATP synthase activity, which is consistent with function findings in the IFM compared
to SSM (331). Biochemical composition of the cristae morphologies may also be different in lipid
or protein content, leading to differences in structural makeup of mitochondrial subpopulations
(331). Indeed, Monette et al. found that sphingolipid pools in cardiac SSM and IFM had different
ceramide contents, which was shown to be higher in the SSM (277). Altogether, differences in
mitochondrial subpopulation structure could be due to their subcellular locale requiring a different
biochemical makeup.

1.5b. Communication between mitochondrial subpopulations
It is interesting to note that subpopulations of mitochondria may interact in vivo; however,
the mechanism by which this occurs is still unclear. Skulachev proposed that intermitochondrial
junctions connect the SSM to each other and that the innermost layer of the SSM are connected to
the IFM via mitochondrial filaments (363). Using electron microscopy, others have found that the
SSM and IFM may be continues in mouse skeletal muscle and network modeling of cardiac
mitochondria revealed a communication system across the cell (314). This hypothesis suggests
that the interaction between the SSM and IFM allows for the consumption of oxygen by the SSM
combined with active respiration to transmit protons by the mitochondrial filaments to the IFM,
enabling ATP generation, which can ultimately be used by the contractile apparatus (363). If the
proposed hypothesis were true, it would support the IFMs ability to generate ATP despite its locale
within the core of the cell with a lower oxygen content (363). With the capability of the IFM to
function in a lower oxygen content, ROS may be limited to the periphery of the cell allowing for
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the preservation of the cell core from damage (363). With this hypothesis, the SSM may serve as
a protective barrier to the cell (220, 363). It is interesting to note that cross talk between the SSM
and IFM may occur, which provides a dynamic network across the cell for energy generation and
transmission of intracellular signals. Additionally, this hypothesis supports the notion that ATP
production from each cardiac mitochondrial subpopulation is likely critical for efficient cardiac
contractile function, indicating that both may play a role in preserving cardiac function during
pathological states. Further, this interconnected mitochondrial network through the mitochondrial
reticulum could provide a pathway for this energy distribution within the cardiomyocyte (149,
364), thus allowing for the restoration of cardiac contractile function if one subpopulation is
detrimentally affected during a pathological state, while the other is unaltered such as what is
observed in DM.

1.5c. Functional differences
Distinct functional differences between mitochondrial subpopulations have been reported
and could be due to their different subcellular locations. While this explanation of differences in
function associated with location is not definitive, it aligns with the concept that spatial location
reflects the processes in which the particular subpopulation of mitochondria supplies ATP.
Perinuclear mitochondria are thought to generate ATP to drive mitochondrial metabolism close to
the nucleus, while it is hypothesized that IFM provide the energy needed for contraction and the
SSM provide ATP for the active transport of metabolites across the sarcolemmal membrane (279,
306, 334, 356). Biochemical differences between mitochondrial subpopulations support the
distinct metabolic roles of the subpopulation within its particular locale of the cell (306). The IFM
typically have higher respiratory rates, succinate dehydrogenase and citrate synthase activities, and
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higher complex oxidation rates in complexes I, II, III and V when compared to the SSM (24, 79,
85, 305). Similarities between the mitochondrial subpopulations also exist, such as the levels of
carnitine palmitoyltransferase and α-glycerophosphate (306). A potential mediator of
mitochondrial metabolic and pathological processes is mitochondrial Ca2+, with the Ca2+ dynamics
being a function of the mitochondria’s proximity to constituents of the Ca2+-handling apparatus
(176). IFM are located near the junctional sarcoplasmic reticulum, the Ca2+ release sites, leading
to their central involvement in the process of mitochondrial Ca2+ cycling (254). SSM and IFM
also possess differences in their ability to accumulate Ca2+ and withstand the damage caused by
Ca2+ overload (307). Further, Kasumov et al. suggest a slower protein synthesis rate in the IFM as
compared to the SSM, which potentially contributes to functional differences between the two
subpopulations (201). Due to the functional differences within mitochondrial subpopulations
based on their subcellular locale, it supports the literature suggesting that mitochondrial
subpopulations differentially respond to pathological stimuli.
Table 1.1 Mitochondrial Subpopulations Characteristics (176)
Parameter
SSM
Beneath Sarcolemma
Location
Random
Organization
Oval, spherical, polygonal,
Shape
horse-shoe
0.4-3.0 µm
Length
Predominantly Lamelliform
Cristae Structure
Active Sarcolemma Transport
ATP Generated For
SDH Activity
CS Activity
Oxidative Metabolism
Lipid Substrates
Non Lipid Substrates
Oxidative Phosphorylation
ETC I-V
Posttranslational Modification
Resistance to Ca2+ Overload

Carbonylation
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IFM
Between Myofibrils
Longitudinal Rows
Elongated
1.5-2.0 µm
Predominantly Tubular
Muscle Contraction
Higher
Higher
Higher
Higher
Higher
Nitration
Higher

1.6 Mitochondrial Protein Import
With approximately 1500 proteins residing in the human mitochondrion and only 13 of
those being transcribed and translated within the organelle itself, nuclear-encoded mitochondrial
protein import is critical to maintain a functioning and stable organelle (9, 21, 54, 313).
Approximately 99% of proteins that reside within the mitochondrion are imported through a
complex mechanism to traverse the two mitochondrial membranes (21, 58). Proteins destined to
enter the mitochondria are termed preproteins and are equipped with targeting signals, typically
N-terminal presequences that direct the protein to a specific compartment of the mitochondrion
(21, 131, 301). For instance, if a protein is targeted to the matrix of the mitochondria, there is a
direct interaction between the protein itself, the outer mitochondrial membrane (OMM), the inner
mitochondrial membrane (IMM) and the presequence translocase-associated motor (PAM) (21,
60). These interactions make up a “supercomplex” for mitochondrial protein import and provide a
pathway for the protein to translocate from the cytosol of the cell, through the mitochondrial
membranes and into the mitochondrial matrix (21, 60).

1.6a. Outer membrane protein import
Cytosolic chaperones aid in the transport of preproteins to the OMM. Heat shock cognate
70, heat shock protein 90 and mitochondrial import stimulation factor carry the nuclear-encoded
preprotein to the translocase of the outer membrane (TOM) complex, which contains receptors for
the recognition of the presequences (110, 440). The TOM complex serves as the gatekeeper to gain
entrance into the mitochondrion and once the presequence is recognized, is able to guide the
preprotein through the OMM. Tom20 serves as the main receptor and recognizer for the N-terminal
presequences on proteins destined for the mitochondrion because of its binding groove that
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attaches to the hydrophobic face of the polypeptide presequence, which subsequently allows the
protein to bind the cytosolic face of the OMM (21, 434). Another protein, Tom22, possesses a
negative charge, which is attracted to the positively charged presequence, and exerts its effects
with Tom20 in order to maintain an unfolded state for the translocating protein (21, 434). Finally,
Tom40, a large β-barrel protein, along with 3 smaller subunits (Tom5, Tom6 and Tom7) forms the
import pore (21, 168). Through this pore, proteins destined to enter the mitochondrion are
translocated across the OMM and guided into the intermembrane space (IMS) (Figure 1.4).

1.6b. Inner membrane protein import
After the preprotein successfully translocates across the OMM and into the IMS of the
mitochondria, preproteins bind to the IMS domain of Tom22 and translocases of the inner
membrane (TIM), Tim50 and Tim21 (59, 286). The binding of the preprotein to Tim50 and Tim21
guides it to the TIM23 complex, which serves as the main mitochondrial import pore, allowing
entrance into and through the IMM (59, 286). Tim23 plays a critical role in the translocation of a
preprotein to the IMS, IMM and matrix of the mitochondria (59). Membrane potential (ΔΨm) is
often required for preproteins to translocate through the TIM23 complex, as well as soliciting help
from the PAM complex (21). Mitochondrial heat shock protein 70 (mtHsp70) is an essential
protein subunit of the PAM complex and through its anchoring to Tim44 within the mitochondrial
matrix, which allows it to still associate with the IMM, the protein is able to “trap” and “pull” a
translocating preprotein through the IMM in an ATP-dependent manner (411). Matrix processing
peptidases (MPP) then cleave the N-terminal presequence upon entrance of the preprotein into the
mitochondrial matrix (218). Because the preprotein is translocated in an unfolded state in order to
pass through the membranes, the protein has to be refolded into its native confirmation with the
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help of co-chaperones hsp60 and hsp10 (156, 361). MtHsp70 is a critical player in the matrixtarget nuclear-encoded mitochondrial protein import because it confers unidirectional
translocation of the protein and then assists in the refolding once the protein is translocated (261)
(Figure 1.4).

1.6c. Pre-sequence translocase-associated motor complex
The essential members of the PAM complex that regulate mtHsp70-driven protein import
are Tim44, Pam16 (Tim14), Pam18 (Tim16), GrpE (Mge1) and the non-essential protein Tim17
(21). Tim44 serves as the anchor for mtHsp70 through its attachment to the IMM on the matrix
side and has been shown to have multiple functions such as recruitment and coordination of PAM
complex constituents increasing the efficiency of protein translocation (347, 395). Interestingly,
when Tim44 and mtHsp70 do not interact, protein translocation is decreased significantly. In one
study, a mutation to the binding domain of Tim44 where mtHsp70 attaches reduced the
mitochondrial translocation activity, while a mutation to the J-related segment of Tim44 in
Saccharomyces cerevisiae decreased mitochondrial protein import viability (245, 268). Pam16 and
Pam18 are a j-like protein and j-protein, respectively, which also regulate mtHsp70 and in turn
regulate protein import activity (82, 132). Pam18 stimulates the ATPase activity of mtHsp70
through its j-domain and Pam16 acts as a negative regulator of Pam18 by affecting the formation
of the Tim44-mtHsp70 complex (82, 132). In a study that destabilized the Pam16-Pam18 complex,
there was decreased mitochondrial protein import, along with decreased yeast cell viability (82,
273). The interactions between Pam17 and other import constituents are influential to the protein
import process. For instance, Pam17 and Tim44 interact in a complementary manner to assist in
protein import and Pam17 is required for proper Pam16-Pam18 complexing (186, 346, 399).
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Interestingly, import and PAM complex formation were only impaired, not abolished, in the
absence of Pam17 (399). GrpE is a nucleotide exchange factor in the mitochondrial matrix that
promotes the release of ADP from mtHsp70 (95). This is a critical step in the process of protein
import because when the ADP is released, the preprotein is subsequently released and allows for
ATP to bind to mtHsp70 driving further mitochondrial protein translocation (95). When the
eukaryotic homolog to GrpE (Mge1) was mutated, binding efficiency of mtHsp70 to translocating
preproteins was decreased, but binding of fully imported preproteins was increased lending insight
into the importance of GrpE on the regulation of ADP-ATP binding to mtHsp70 (223). With a
complicated network for translocation via mtHsp70 into the matrix of the mitochondria, many
proteins are critical to the import process being carried out efficiently. (Figure 1.4).

Figure 1.4 Nuclear-encoded Mitochondrial Protein Import Mechanism (21)
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1.6d. Brownian ratchet versus power stroke model
While mtHsp70 is known to be critical in the translocation of proteins into the
mitochondrial matrix, it remains unclear as to how it exerts its effect upon these proteins. MtHsp70
serves as the ATP-dependent, primary motor subunit for the PAM complex, aiding in the
unfolding, transport and refolding of proteins targeted to the mitochondrial matrix, but also playing
a role in the import of proteins to the IMM and IMS (21). Examples of proteins using the mtHsp70
import mechanism, but not residing in the matrix are oxidase assembly 1, which is imported into
the matrix and then reinserted back into the IMM and cytochrome b2, which is partially pulled into
the matrix, subsequently cleaved, leaving the functional portion of the protein located in the IMS
(36, 144).
Two modes of thinking exist for how mtHsp70 exerts effects on translocating proteins: the
Brownian ratchet model and the power stroke model (285). In the Brownian ratchet model, the
ΔΨm serves as the initial pulling force for the preprotein to get into the matrix (251, 297). Upon
entrance into the matrix, the preprotein binds to mtHsp70, ATP hydrolysis occurs causing the
release of mtHsp70 from Tim44 and mtHsp70 traps the translocating protein to not allow
retrograde movement back into the IMM (251, 297). The binding of additional mtHps70-Tim44
complexes to incoming segments of the polypeptide helps to move the protein into the matrix,
where GrpE catalyzes the release of ADP from mtHsp70 allowing for its dissociation from the
translocated protein (251, 297).
While the power stroke model begins similarly, the key difference is that mtHsp70 does
not dissociate from Tim44. In this model, instead of dissociation, mtHsp70 undergoes a
conformational change, actively propelling the protein through the IMM and into the matrix (144).
GrpE serves the same function as the nucleotide exchange factor in the matrix, facilitating the
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release of mtHsp70 from the translocated protein (297). Because of how this model is set-up, it
indicates that multiple molecules of mtHsp70 would be essential for the movement of the protein
into the mitochondrial matrix (144). Figure 1.5 depicts the two models side by side in order to
visually appreciate their distinct differences.

Figure 1.5 Models of Mitochondrial Protein Import (21)
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Even though there are two proposed models for mtHsp70-dependent mitochondrial protein
import, there may not be a singular method for import, but rather a combined mechanism where
both are employed depending on the protein being imported (214). MtHsp70 likely serves as the
driving force for the linearization of proteins, since unfolded proteins do not exist at the OMM
(411). If the presequence happens to be long enough to span both the OMM and IMM, the
unfolding of proteins happens more quickly and likely uses the power stroke model (263, 427).
This might occur in the case of a tightly folded protein, which requires a lot of force in order to
linearize the protein and maintain its linearization for translocation (263, 427). The contrary occurs
with proteins that are not tightly folded and the Brownian ratchet model would be the most efficient
mechanism for protein import in this instance (427). In summary, the mechanism by which a
protein is transported into the mitochondrial matrix via the mtHsp70-dependent mechanism may
depend upon the tightness in the folding of the domain for that particular protein.

1.7 Mitochondrial Heat Shock Protein 70
MtHsp70 is known by many names such as mortalin, peptide binding protein 74 (PBP71)
and glucose regulated protein 75 (Grp75). This protein serves as a member of the Hsp70 chaperone
family and interestingly, mtHsp70 appears not to be inducible under conditions of heat stress like
many members of this family (203). The subcellular localization of mtHsp70 has been studied
using microscopy, protein tagging with specific antibodies, cell fractionation and organellespecific markers revealing a number of locations for the protein including the endoplasmic
reticulum (ER), cytoplasmic vesicles, cytosol and the mitochondrion (87, 362, 369); however, the
mitochondrion serves as the principle locale of the protein. Because of its many locations within
the cell, a multitude of cellular and mitochondrial functions are impacted by this protein. There
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are three key regions on mtHsp70: the ATPase domain, the peptide binding domain and the
carboxy-terminal segment (216). Each of these segments has been shown to be essential for proper
nuclear-encoded mitochondrial protein import because a mutation to a segment has been shown to
have detrimental effects on the import process (216).
In response to cellular stress, mtHsp70 has been reported to be responsive during thyroid
hormone treatment, glucose deprivation and myocardial I/R (158, 209, 252, 430). Williamson et
al. showed that cardiomyocytes from neonatal rats infected with an adenoviral vector expressing
mtHsp70 were protected from I/R injury (430). These cardiomyocytes had increased import of
nuclear-encoded antioxidant defense proteins, such as manganese superoxide dismutase (MnSOD)
(430). When the yeast equivalent to mtHsp70 (Ssc1) was inactivated by a temperature-sensitive
mutation, it caused an arrest to the unfolding, translocation and refolding of imported proteins
(139, 198). Further, deletion of Ssc1 caused death of the cell lending to the importance of this
protein for the import of proteins into the mitochondria, but also for cellular viability (78).

1.7a. Mitochondrial functions
Central to the vitality of the mitochondrion, mtHsp70 provides the active motor for protein
import and upon the proteins translocation into the matrix, this protein plays an integral role in the
refolding of imported proteins (158, 209, 252). MtHsp70 is fundamental to the mitochondrial
protein import process, particularly for the import of matrix, IMS and IMM proteins as described
above. During nuclear-encoded mitochondrial protein import, mtHsp70 serves an essential role as
the main subunit and motor for the PAM complex. In the mitochondrial matrix, mtHsp70 anchors
to Tim44 to trap and pull the preprotein through the IMM in an ATP-dependent manner (411).
When mtHsp70 is altered, mitochondrial function is compromised with decrements in nuclear-
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encoded mitochondrial protein import, decreased antioxidant defenses, increased misfolding and
degradation of proteins, along with increased cellular apoptosis (21). Additionally to protein
import, mtHsp70 plays a critical role in protein folding and protein degradation within the
mitochondrion. Once the protein is translocated into the mitochondrial matrix, it must be refolded
into its active confirmation in order to perform its specific function. Kang et al. used dihydrofolate
reductase and a temperature-sensitive mtHsp70 mutant in yeast (Ssc1) to display irreversible
binding of mtHsp70 and the translocated preprotein, which resulted in improper protein folding
and enhanced degradation mediated by proteinase K (198). MtHsp70 does not act alone in
refolding of translocated preproteins, but acts in concert with hsp60, hsp10, GrpE and Mdj1 (259).
The current speculation is that mtHsp70, GrpE and Mdj1 form a complex to keep the translocated
preprotein in a loosely folded conformation (259). When GrpE-mediated ATP hydrolysis occurs
releasing the preprotein from mtHsp70, the preprotein is then transferred to the hsp60-hsp10
complex where it is folded into its native conformation (259). Interestingly, mtHsp70 and Mdj1
also have been shown play a role in mitochondrial protein degradation (342). MtHsp70 has been
shown to allow for the stabilization of misfolded or damaged polypeptides into an unfolded
conformation so that the protein will be degraded by mitochondrial proteases like m-AAA and
PIM1p (343, 414). The process of degradation is critical in the mitochondria because it maintains
genome integrity and allows for proper excision of introns in mitochondrially-encoded ETC
proteins (400). While mtHsp70 predominantly resides within the mitochondrial matrix, the protein
has also been shown to have other processes within the cell.
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1.7b. Extra-mitochondrial functions
Though central to mitochondrial viability, mtHsp70 has also been shown to have extramitochondrial functions in the cytosol, centrosomes, cellular membranes and the ER (21).
MtHsp70 is capable of binding a multitude of proteins leading to a diverse functionality for this
multifaceted protein. MtHsp70 has been shown to be important in cellular proliferation, calcium
regulation, play a role in the apoptotic cascade pathway, participate in the process of aging, and
act as a constituent of the immune system (21). The tumor suppressor protein p53, plays a direct
role in DNA repair, cell cycle arrest and cellular apoptotic initiation and mtHsp70 has been shown
to bind to this protein in multiple locales such as the cytoplasm, centrosomes and the
mitochondrion (224, 257, 260, 274, 275, 412). MtHsp70 binds to p53 and sequesters it from the
nucleus to the cytoplasm of the cell, which is important because when bound, this decreases p53
mediated apoptosis (275). MtHsp70 is also known to play a critical role in regulated cell cycle
division through its interaction with the centrosomes in late G1, S and G2 phases of the cell cycle
(257). Further, literature has revealed that mtHsp70 is able to bind with the receptor for hyaluronan
mediated motility during interphase, potentially allowing the protein to play a role in the
stabilization of microtubules (219). In addition to all of these capabilities, through its interaction
with fibroblast growth factor-1 (FGF-1), mtHsp70 may be involved in the regulation of FGF-1
binding to its receptor, regulating the growth factor’s function (269).
As it relates to cellular immunity, the membrane attack complex (MAC) is comprised of C
subunits (C5b, C6, C7, C8 and C9) which assemble on the surface of the cell creating a pore,
leading to the death of a targeted cell (316). Cancer cells show an increased resistance to
complement-dependent cytotoxicity because of the inability for the MAC to form (316). MtHsp70
has been shown to bind to subunits C8 and C9 of the MAC, which Pilzer et al. found to be released
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from the cells in membrane vesicles, resulting in decreased MAC formation and increased cellular
survival in a cancer cell line (315). Additionally, mtHsp70 has been shown to bind Interleukin-1
(IL-1) receptor, which may play a role in the internalization of the receptor, leading to a regulatory
function of mtHsp70 on IL-1 (338).
The ER and mitochondria form a dynamic network among which many processes are
controlled such as metabolic flow, protein transport, intracellular Ca2+ signaling and cell death (44,
127, 380, 381). MtHsp70 has been shown to link the voltage dependent anion channel (VDAC1)
on the OMM of the mitochondrion to the ER Ca2+-release channel inositol 1, 4, 5-triphosphate
receptor (IP(3)R) (380). In support of this, when mtHsp70 was knocked down, Ca2+ concentration
within the mitochondria was shown to be decreased. Finally, the interaction of mtHsp70 with
mevalonate pyrophosphate decarboxylase (MPD) indirectly controls proliferation through MPD
simulated prenylation of Ras, which inhibits cell growth (413). Altogether, the literature suggests
that mtHsp70 is a protein with diverse functional roles both within and outside of the
mitochondrion.

1.7c. Pathological influence
Due to the diverse nature of mtHsp70, the protein itself has been shown to be impacted in
many different pathological settings leading to its role in both disease initiation and progression.
When assessing proteomic alterations, mtHsp70 was affected in cancer, neurological diseases,
cardiovascular diseases, aging and DM (21). In a neuroblastoma cell line, the authors found an
upregulation of mtHsp70 subsequent to differentiation, which is associated with a high probability
of regression, indicating that mtHsp70 is a good prognostic indicator for this disease (182).
Conversely, mtHsp70 is thought to be detrimental during different types of cancer and correlated
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with increased incidence, progression and poor outcomes for this pathological state. In chronic
myeloid leukemia patients, mtHsp70 was increased as compared to controls, demonstrating that
mtHsp70 may play a role in mediating the antiapoptotic effects of cancer cells (317). Further,
studies of colorectal adenocarcinoma patients, hepatocellular carcinoma-associated hepatitis C
virus and human osteosarcoma cell lines all showed increased mtHsp70, suggesting mtHsp70 may
be a good predictor of cancer progression and prognosis (107, 290, 382).
In neurological disorders such as Parkinson’s disease and Alzheimer’s disease, mtHsp70
expression is influenced. MtHsp70 content was found to be decreased in Parkinson’s patients as
compared to controls in the substantia nigra pars compacta, which could potentially impact
nuclear-encoded mitochondrial protein import in the neurons (191). In Alzheimer’s disease, Osorio
et al. found post-translational modifications, such as phosphorylation and oxidation, of mtHsp70,
which could potentially result in diminished binding efficiency and translocation properties for the
protein (300). These studies indicate that alterations to mtHsp70 may play a role in the progression
of neurological diseases and that this protein could serve as a predictor of neurological disease
progression.
During cardiovascular disease, mtHsp70 has been shown to be adversely affected. In the
aged heart, mtHsp70 is shown to be decreased through proteomic analyses (89). Additionally,
neonatal rat cardiomyocytes treated with ET-1 to stimulate cardiac hypertrophy displayed a
decrease in mtHsp70 content, suggesting that mitochondrial impairment may occur during the
early development of hypertrophy (5). During MI, mtHsp70 content was shown to be decreased in
tissue close to the infarcted area; however, after 5-7 days of recovery, the concentration was higher
than other HSP70 family members and returned to normally expressed levels 14-21 days postinfarction (209). Williamson et al. showed that overexpression of mtHsp70 in neonatal rat
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cardiomyocytes after hypoxia/reoxygenation insult, preserved both cell viability and
mitochondrial function (430). These studies suggest that a therapeutic approach to cardiovascular
disease may be through the enhancement of mtHsp70 content.
MtHsp70 is also affected in the heart during both T1DM and T2DM. Interestingly, in rats
subjected to STZ, Hamblin et al. studied the proteomic profile, which revealed an increase in
mtHsp70, while Turko et al., showed significantly decreased mtHsp70 content, indicating that the
protein is affected during T1DM, but literature is unclear as to how the protein is being altered
during this pathological insult (158, 393). Our laboratory found that in mice treated with STZ,
mtHsp70 is significantly decreased in the mitochondrial proteome of the IFM, potentially leading
to the disruption in protein loss coming from nuclear-encoded sources in this particular
subpopulation. Since greater than 99% of proteins residing within the mitochondrion are nuclearencoded and imported from the cytosol to a locale within the organelle, alterations to mtHsp70, a
key player in nuclear-encoded mitochondrial protein import, could lead to a deranged
mitochondrial proteomic profile for the IFM during T1DM (23). Interestingly, in the db/db mouse
model for T2DM, Dabkowski et al. showed decreased mtHsp70 in the SSM subpopulation of
mitochondria, with no alterations in the IFM (84). Interestingly, these studies provide evidence
that mitochondrial proteomes are differentially affected during the distinct types of DM, leading
to mitochondrial dysfunction of a specific mitochondrial subpopulation depending on the type of
DM. Overall, these studies suggest that DM detrimentally impacts mtHsp70 in the diabetic heart.
Further, studying the alterations to mtHsp70 during pathological settings could lead to the
discovery of different therapeutic approaches and interventions within the clinical setting to
increase the quality of life for diabetic patients.
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1.8 Pathological Influence on Mitochondrial Subpopulations
Cardiovascular disease is associated with a plethora of effects on the mitochondrion,
making research efforts regarding pathological influence on mitochondrial subpopulations critical
for the treatment of the morbidity and mortality associated with particular disease states. As the
mitochondrion continues to be elucidated as a key player in cardiovascular disease, a greater
understanding of how to protect this critical organelle during pathology becomes imperative.
Pathological insult to the mitochondrion differentially occurs based on its subcellular location
(176). During ischemia, the SSM subpopulation is predominantly affected, with significant
structural alterations and a decrease in membrane fluidity (358). Further, a study using rabbits
subjected to global ischemia showed decreased OXPHOS, along with decreased contents of
cytochrome c and cardiolipin in the IMM of the SSM (66, 237, 238). Chen et al. showed increased
H2O2 production from complexes I and III in the SSM, which was associated with ETC damage
when global ischemia was induced in rat hearts (66). Oftentimes, an ischemic event is followed by
reperfusion of the blood. Studies show that I/R injury influences both mitochondrial
subpopulations. In rat hearts, I/R injury decreased OXPHOS rates and ADP/ATP translocase
activity in both the SSM and IFM (101, 423). Our laboratory has shown that overexpressing
mPHGPx during a global I/R insult affords protection to both mitochondrial subpopulations
through preservation of ETC complexes (86). Ischemic preconditioning is a therapeutic approach
to protect the heart against damage due to a subsequent ischemic insult (202). Treatments such as
phosphatidylcholine, isoflurane, amobarbital and rotenone have shown improved function of the
SSM during an ischemic event (63, 64, 67, 104, 229, 318). Preconditioning studies indicate that
the SSM is primarily affected, which may be a function of greater sensitivity to the overload of
Ca2+ during the initial ischemic condition and suggests that this type of approach may be beneficial
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in pathologies imparting deleterious effects on the SSM subpopulation. In contrast to
preconditioning, cardiac postconditioning can also be used for cardioprotection. Paillard et al.
suggest that postconditioning reduces oxidative stress and inhibits mitochondrial permeability
transition pore (mPTP) opening (304). Further, studies have shown that postconditioning treatment
may also be best considered for pathologies that predominantly affect the SSM (68, 69).
Hypoxia has been shown affect mitochondrial respiration in the cardiomyocyte, leading to
cellular dysfunction (175). Heather et al. showed decreases in state 3 respiration rates using fatty
acid and pyruvate as substrates in both the SSM and IFM when rats were subjected to chronic
hypoxia of 11% oxygen exposure for 14 days (163). When an area of the heart loses the perfusion
of blood, that region becomes ischemic, causing irreversible damage to the myocardium. A
common model for this MI is coronary artery ligation, which allows for the creation of an ischemic
myocardial region (202). Rats subjected to a coronary artery ligation displayed decreased
respiration rates, ETC complex III protein contents and activities, decreased mitochondrial
cytochrome c levels and an increase in H2O2 production in both SSM and IFM (162). Further,
another study found that coronary artery ligation in rats, along with a high fat feeding protocol led
to an increase in fatty acid availability, state 3 respiration rates and ETC complex II and IV
activities in SSM and IFM, which improved overall mitochondrial and cardiac contractile function
(327-329). During HF, mechanical dysfunction of the myocardium leads to insufficient
oxygenated blood delivery to the body in order to meet its metabolic requirements (202, 335).
Multiple studies have shown that mitochondrial biogenesis and ETC enzymes are impacted during
HF (143, 196, 351). A rodent model of dilated cardiomyopathy that exhibits decreased
mitochondrial oxidative capacity, but is responsive to nutritional and metabolic therapies, showed
distinct effects to the IFM subpopulation including decreased mitochondrial yield and Ca2+-
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induced mPTP opening (137, 138). Hoppel et al. found that cardiomyopathic hamsters have
defective OXPHOS in the IFM and suggests that the dysfunction may be due to alterations in IMM
transport properties with the ATP synthase (180). Pressure overload using aortic banding revealed
a reduced capacity for free radical scavenging in the SSM of mice deficient in apoptosis-inducing
factor, while rats undergoing transverse aortic constriction displayed a decrease in state 3 and state
4 respiration rates in the IFM (350, 401). Volume overload, as completed by aortocaval fistula,
revealed diminished SSM function through decreased levels of ETC complexes I-V and decreased
state 3 respiration rates (148, 394). It is thought that IFM dysfunction may not occur during volume
overload due to its ability to lower state 4 respiration thus increasing mitochondrial efficiency and
responding to the increased myocardial demand (264, 422). Overall, literature suggests that
mitochondrial subpopulations are differentially impacted during HF dependent on the model used.
The IFM appear to be predominantly affected during HF and pressure overload, with the exception
of volume overload in which the SSM appear to be primarily affected.
Due to its role in the generation of ROS, the mitochondrion has been considered a central
player in the development of the aged heart (88). Fannin et al. demonstrated age-related alterations
in mitochondrial function in the IFM subpopulation (120). Decreased OXPHOS rates, cytochrome
oxidase enzyme activities, enhanced oxidant production, decrease complex IV enzyme activities,
increased oxidative stress and antioxidant enzyme activities, along with decreased ETC complex
III activities and increased propensity for mPTP opening were shown in the IFM of the aged heart
in different species (120, 150, 194, 232, 271, 377). Further, structural changes, such as size and
internal complexity, of the IFM were noted by Coleman et al. in an aged mouse model (74).
Ultimately, mitochondrial dysfunction associated with aging predominantly affects the IFM. The
aged heart is more susceptible to additional cardiac events including I/R and while the IFM are
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predominantly affected in the aged heart, both cardiac mitochondrial subpopulation are affected
when the aged heart undergoes injury from I/R (69, 231, 233-235).
Exercise has been linked to the prevention of cardiovascular disease and increased
mitochondrial biogenesis (169, 177, 311, 387). While exercise has been shown to increase
mitochondrial enzyme proteins and activities, it is relatively unexplored what exercise training
does to cardiac mitochondrial subpopulations (372, 379). Coleman et al. showed increased IFM
hypertrophy and loss of structural internal complexity in aged C57BL/6J mice that underwent a
training exercise protocol on the treadmill (74). In contrast, Fischer 344 rats undergoing long-term
wheel running showed a reduction in H2O2 and lower MnSOD in both cardiac mitochondrial
subpopulations (195). Kavazis et al. found that endurance exercise promoted biochemical
alterations that helped to resist apoptotic stimuli in both mitochondrial subpopulations and in
another study by the same group found that proteomic alterations occurred in both subpopulations
as well (205, 206). Rats subjected to an I/R protocol showed increased H2O2 production in both
subpopulations; however, this increase was prevented by exercise training solely in the SSM (227).
This group also found that I/R-induced decrements in state 3 respiration rates were subsequently
reversed in the SSM subpopulation when using complex I driven substrates, suggesting that
exercise training followed by I/R injury allows for the protection of the SSM subpopulation (227).
Another interesting topic is the effects of pharmacological drugs on cardiac mitochondrial
subpopulations. A study using verapamil showed that rat cardiac mitochondrial subpopulations
reversed OXPHOS depression in the SSM after the damage was caused by treatment with
phosphate (103). Another group indicated that increased H2O2 and 8-isoprostane production,
leading to increased propensity for mPTP opening in SSM caused by aldosterone/salt treatment,
was prevented by cotreatment with Carvedilol and Nebivolol (61). The majority of studies testing
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the effects of drugs on cardiac mitochondrial subpopulations found that the SSM were primarily
affected. This is potentially due to their location below the sarcolemmal membrane and their closer
proximity to the drug, while the IFM is more protected within the cell. Ultimately, literature
suggests that mitochondrial subpopulations can be differentially impacted by pathological stimuli,
potentially due to their location and particular function within the cell. Table 1.2 provides an
overview of the differences in SSM and IFM responses to different cardiac pathologies
Table 1.2 Cardiac Mitochondrial Subpopulation Response to Pathological Stimuli (176)
Stimuli/Factor

Species

Primary
Subpopulation
Affected
SSM

Both

(65, 66, 230, 237, 238,
358, 374, 421)
(102, 163)
(162, 296, 327-329, 333,
335)
(86, 106, 230, 423)

SSM

(63, 64, 67, 104, 229, 318)

SSM
SSM

(68-70, 304)
(137, 138, 180, 383, 385)

Pressure Overload
Volume Overload
Aging

Rat, Rabbit
Rat,
Hamster
Mouse, Rat
Rat
Rat, Canine

IFM
SSM
IFM

Aging and I/R
Exercise
Exercise and I/R
Pharmacological
Interventions
Type I Diabetes Mellitus
Type II Diabetes Mellitus
Hypermetabolism

Rat
Mouse, Rat
Rat
Rat,
Hamster
Mouse
Mouse
Rat

IFM
Both
Both
SSM

(264, 350, 370, 401)
(148, 264, 394, 422)
(10, 74, 120, 135, 150,
170, 179, 194, 228, 232,
271, 272, 331, 377)
(69, 231, 233-235)
(74, 195, 204, 206)
(227)
(61, 103, 105, 178, 359,
407, 408)
(22-24, 79, 85, 116, 429)
(84)
(360)

Ischemia
Hypoxia
Myocardial Infarction
Ischemia Reperfusion
(I/R)
Preconditioning
Postconditioning
Heart Failure

Rat, Rabbit,
Canine
Rat
Rat, Dog

References

SSM
Both

Mouse, Rat,
Rabbit,
Canine
Rat, Rabbit

IFM
SSM
IFM
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1.8a. Type 1 diabetes mellitus
DM can be characterized by a lack of insulin production during T1DM or a resistance to
insulin during T2DM. Cardiovascular complications, such as diabetic cardiomyopathy, are the
leading cause of morbidity and mortality among diabetic patients (142). Mitochondrial dysfunction
has been shown to be central to the etiology of cardiac dysfunction associated with DM and
dependent upon the type of DM, cardiac mitochondrial subpopulations can differentially
influenced.
Swiss-Webster mice that underwent multiple low-dose injections of STZ showed that the
IFM subpopulation displayed a decrease in size, internal complexity and ETC complexes I and III
function (85). Further, superoxide production and oxidative damage were increased in the T1DM
IFM (85). In STZ treated mice, cardiolipin content was shown to be decreased, along with
decrements in cardiolipin synthase in the IFM during T1DM (79). Our laboratory has also shown
enhanced apoptotic propensity in the IFM during T1DM via increased caspase-3 and -9 activities,
mPTP opening, Bax and cyclophilin D protein contents, along with decreases in mitochondrial
cytochrome c content and Bcl-2 levels (428). The proteomic makeup of the IFM is also disturbed
as seen by isobaric tags for relative and absolute quantitation (iTRAQ) and 2D differential in-gel
electrophoresis (2D-DIGE) (23). These analyses revealed decreased abundance of fatty acid
oxidation (FAO) and ETC proteins in the IFM during T1DM (23). Additionally, nuclear-encoded
mitochondrial protein import is compromised in T1DM IFM, which could a mechanism by which
proteomic dysregulation is occurring (23). Using a novel transgenic animal overexpressing
mPHGPx, our laboratory found that the IFM had restored ETC complex function, as well as the
attenuation of H2O2 production during T1DM. Furthermore, nuclear-encoded mitochondrial
protein import was restored, lessening the proteomic dysregulation observed in the T1DM IFM
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(22, 86). Solute carrier family 25 member 3 (Slc25a3), an IMM protein transporter involved in
providing the mitochondrial matrix with inorganic phosphate, is decreased in the IFM during
T1DM. Further, this decrease in Slc25a3 is associated with decreased ATP synthase activity and
ATP production in the T1DM IFM (24). ATP-dependent potassium (K+) channels have a decrease
in Kir6.1, a pore-forming subunit, in both cardiac mitochondrial subpopulations during T1DM;
however, SUR1, a diazoxide-sensitive sulphonylurea receptor, was only found to be decreased in
the IFM (116). Studies on cardiac mitochondrial subpopulations during T1DM indicate that the
IFM is predominantly affected during this type of pathological insult. It is unclear as to why this
phenomenon occurs, but it may result from differences in mitochondrial subpopulation function
such as higher respiration rates, ΔΨm and protein import rates or the subcellular locale of the IFM
subpopulation.

1.8b. Type 2 diabetes mellitus
Interestingly, the evaluation of T2DM cardiac mitochondrial subpopulations reveals
substantially different results than T1DM, with the SSM subpopulation being predominantly
affected. Our laboratory found the SSM to be detrimentally impacted in the db/db mouse model
with deficits in mitochondrial size and internal complexity, along with decreased state 3 respiration
rates, ETC complex activities, ATP synthase function and ΔΨm (84). Further, there was also
increased oxidative damage and a greater loss of SSM proteins shown by proteomic analyses as a
result of T2DM (84). It is unclear as to why different cardiac mitochondrial subpopulations are
affected during T1DM and T2DM; however, the deleterious effects on the mitochondrion are
similar with the only difference being the subpopulation in which they are occurring. One
explanation is that the milieu surrounding the distinct mitochondrial subpopulations are somewhat
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different, potentially causing the IFM to be affected during T1DM and the SSM to be affected
during T2DM. The milieu during T2DM has an enhanced free fatty acid content, which was shown
in T2DM patients’ vastus lateralis muscles by a 3-fold increase in the lipid volume of the SSM
locale without affecting the lipids in the IFM region (288). With the increased lipid content in the
SSM region, Nielsen et al. suggests that the lipids may actually interfere with key processes
involved in metabolic signaling in the SSM, while the IFM remain unaffected (288). Notably, these
authors were working on skeletal muscle, not cardiac tissue in these patients.

1.8c. Commonalities between T1DM and T2DM on the mitochondrion
While striking differences do exist between the impact of T1DM versus T2DM on cardiac
mitochondrial subpopulations, with the IFM being predominantly affected during T1DM and the
SSM being primarily affected by T2DM, commonalities also exist. For example, loss of proper
mitochondrial function correlates with the dysregulation of the proteome, which is observed in the
specific mitochondrial subpopulation impacted by that type of DM. Specifically, T1DM IFM show
structural damage and functional deficits, which coincide with proteomic dysregulation (22-24,
79, 386). The opposite occurs during T2DM, with the SSM revealing structural damage and
decreases in mitochondrial function, which correlate with proteome dysregulation (80, 84).
Disturbances to the IMM, which contains proteins involved in OXPHOS and protein import
machinery, are shown to be impacted in the IFM during T1DM and the SSM during T2DM,
suggestive of the IMM locale being prone to proteomic alterations due to the diabetic insult (174).
Nuclear-encoded mitochondrial protein import and protein contents of essential constituents in the
import process are impacted in the IFM of T1DM and the SSM of T2DM (22, 23). It is interesting
to note that commonalities exist in the mirroring of dysfunction in key processes seen in a specific
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subpopulation depending on the type of diabetic insult, allowing each pathology to provide
complementary information in order to develop a therapeutic intervention to treat both diabetic
phenotypes.

1.9 Mitochondrial Dysfunction during DM
Mitochondria are crucial to the maintenance of homeostasis of many cell types because of
their energy producing capacity, along with its oxidative and apoptotic potential. The literature
provides evidence that mitochondrial dysfunction plays a role in the etiology of cardiac
dysfunction during DM (152, 390, 436). Increased oxidative stress, alterations in mitochondrial
Ca2+ handling and mitochondrial bioenergetics, inefficient nuclear-encoded mitochondrial protein
import and proteomic remodeling all contribute to the mitochondrial dysfunction seen in the
diabetic heart.

1.9a. Oxidative stress
The development of cardiovascular disease has been linked to an increase in oxidative
stress in cardiomyocytes. The mitochondrion is susceptible to oxidative stress because of the IMM,
which serves as the primary source of ROS products via the leakage of electrons from the ETC,
particularly from complexes I and III (48, 299). When ROS are generated in excess and the
antioxidant defense systems cannot keep up, oxidative stress occurs. Forms of ROS include
superoxide radicals, hydroxyl radicals, H2O2, nitric oxide and peroxynitrite (48, 431). ROS plays
a detrimental role to the mitochondrion and other cellular components through oxidation of DNA
and proteins, lipid peroxidations and protein nitrations (48, 416). During DM, cardiac
mitochondria have been shown to be detrimentally impacted in animal models of both pathologies,
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suggesting that the increased glucose and free fatty acid levels drives the formation of ROS (48,
99, 100, 292, 355, 433). Our laboratory observed increased protein and lipid damage in T1DM
IFM; however, overexpression of mPHGPx, an antioxidant located in the IMS of the
mitochondrion, provided protection against oxidative damage (22, 85). Shen et al. showed that
overexpression of MnSOD during T1DM also afforded protection to mitochondria, while Ye et al.
showed catalase to have protective benefits (354, 436). Further, overexpression of metallothionein
in STZ-treated mice produced a reduction in nitrosative damage and in OVE26 mice restored levels
of oxidized glutathione (52, 437). In T2DM animal models, reduced cardiac efficiency was seen
due to enhanced ROS generation and lipid peroxidation by-products, leading to increased oxygen
consumption without a subsequent increase in ATP production (41). Yamagishi et al. found
increased mitochondrial H2O2 production and ROS in conjunction with increased electron delivery
from augmented FAO (433). Thus, the development of cardiovascular issues during different
pathological states could result from an increased oxidative stress from the mitochondrion.

1.9b. Calcium handling
Mitochondria are intricate sources of ATP for cardiomyocyte contraction, but the
mitochondrion is also crucial in its interactions with Ca2+ in order to regulate the excitationcontraction coupling and energy metabolism within the heart (188). When high levels of Ca2+
occur in the matrix, generation of ROS is increased, which causes the opening of the mPTP
disrupting the function of the ETC in the IMM (155). With the opening of the mPTP, ionic
homeostasis is disrupted and uncoupling of OXPHOS occurs, triggering an increase in cell death
(345). In T1DM, Flarsheim et al. showed decreased mitochondrial Ca2+ uptake, while LagadicGossmann et al. showed decreased mitochondrial Ca2+ content (130, 222). Additionally, during
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T1DM, mitochondria did not retain the Ca2+ because of an increased propensity for mPTP opening
(298). Our laboratory corroborated these results in our findings of increased mPTP opening and
decreased mitochondrial cytochrome c content in the IFM of T1DM mice (428). Abnormalities in
Ca2+ homeostasis may also be a mechanism linking impaired mitochondrial oxidative function to
insulin resistance (281, 309, 330). Altogether, these studies indicate an impairment in Ca2+
handling during DM, leading to decreased contractility and energy metabolism, while increasing
cellular apoptosis via the mitochondria.

1.9c. Mitochondrial energetics
Mitochondrial energetics play a distinct role in the cell and mitochondrial dysfunction has
been linked to a wide range of pathological states including metabolic diseases, cancer and aging.
Gross et al. showed decreased respiration in STZ-treated rats when assessed with substrates for
complexes I and II in skeletal muscle mitochondria, which was corroborated in other rodent studies
looking at mitochondrial respiration in the heart and brain (85, 125, 153, 278). In the Akita mouse
model for T1DM, mitochondria from the heart displayed decreased state 3 respiration when fueled
with complex I substrates along with decreased ATP synthase activity (50). Additionally, cardiac
mitochondria and mitochondria isolated from the gastrocnemius of STZ-treated rats also showed
a decreased state 3 respiration, ADP/O ratio and ATP synthesis rate (165). In a clinical setting,
T1DM patients showed decreased ATP production in skeletal muscle mitochondria as a result of
discontinued insulin treatment (200). Altogether, mitochondrial respiration and ATP production
are impaired in the T1DM setting. Dysfunction in mitochondrial energetics has also been reported
in animal models of T2DM. In the db/db mouse heart, respiration rates were decreased when fueled
with glutamate/malate and palmitoyl-carnitine, along with decreased expression of the F1 α-
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subunit of ATP synthase and increased proton leak induced by fatty acids (41). In another study
using the db/db model, Boudina et al. found impairments in OXPHOS and increased fatty acidinduced mitochondrial uncoupling (40, 41). Further, in a high-fat feeding model of T2DM,
decreases in tricarboxylic acid (TCA) cycle proteins were found in skeletal muscle along with an
inability to switch substrate utilization from fat to glucose, suggestive of an incapability to deal
with increased fatty acid substrates during T2DM (212). When assessing T2DM patients,
decreased NADH oxidoreductase and reduced citrates synthase activity were seen in skeletal
muscle mitochondria (207). Other studies have indicated increased lipid deposition, deficits in
OXPHOS, decreased ATP synthase and creatine kinase B protein expression in T2DM patients
(172, 288, 324). Altogether, these studies indicate decrements in mitochondrial respiration and
ATP production during T2DM. Independent of the type of DM, mitochondrial energetics are
detrimentally altered.

1.9d. Protein import
Proteomic analyses have revealed that the abundance of nuclear-encoded proteins residing
within the mitochondria are decreased during DM, including proteins essential for the
mitochondrial protein import process (23, 84, 393). Results from our laboratory revealed that
nuclear-encoded mitochondrial protein import is decreased in the T1DM IFM, with no impact on
the SSM subpopulation (23). Interestingly, it is thought that the decrease in import efficiency is
due to a diminished protein content of mtHsp70 in the IFM as discussed above (23). The
overexpression of mPHGPx was able to restore mitochondrial protein import efficiency in the IFM
during T1DM (22). While protein content of mtHsp70 has been shown to be downregulated in
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SSM during T2DM, to date, nuclear-encoded mitochondrial protein import has not been reported
in a T2DM mouse model (84).

1.9e. Proteomic remodeling
Attainment of a broad overview of what proteins are changing in the heart during DM has
allowed for an increased understanding of how mitochondria are affected during the disease state.
Recently, broad scale proteomics have become prevalent within different types of DM models (23,
51, 84, 158, 355, 393). 2D polyacrylamide gel electrophoresis (2D-PAGE) along with matrixassisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) was
performed on mitochondria isolated from STZ-induced T1DM rats (393). Alterations in FAO
proteins, OXPHOS complex I subunits, and mitochondrial heat shock proteins were found in the
T1DM animals (393). Another group using the same model found increases in FAO proteins and
decreases in proteins involved with the antioxidant defense system (158). Using iTRAQ proteomic
labeling coupled with multidimensional protein identification technology mass spectrometry
(MudPIT MS/MS), cardiac mitochondria from STZ-treated rats were analyzed four months postdiabetic onset (197). In this study, Jullig et al. found increases in long chain fatty acid proteins and
decreases in catabolic short chain fatty acid enzymes, potentially providing an explanation for the
lipotoxicity seen in the T1DM setting (197). Further, results from another study found that the
Akita mouse model of T1DM had increased FAO proteins, decreased TCA proteins and alterations
in OXPHOS proteins in mitochondria isolated from the kidney, liver, brain and heart (51).
Proteomic evaluations of mitochondrial subpopulations has been performed by our laboratory in
the STZ-induced T1DM mouse model using two separate approaches: 2D-difference gel
electrophoresis (DIGE) and iTRAQ coupled with MALDI-TOF-MS (23). While similar findings
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were found as far as changes in proteomic evaluations, the two mitochondrial subpopulations were
differentially affected during T1DM, with the IFM showing the predominant changes during this
pathological insult (23). FAO, OXPHOS subunits, TCA cycle intermediates, mitochondrial
structural proteins and mitochondrial protein import constituents were significantly decreased in
the T1DM IFM (23). Further, MudPIT was used in order to assess the posttranslational
modifications of the proteins, which revealed higher oxidation and deamidations to proteins in the
T1DM IFM (23). Our laboratory also assessed proteomic alterations and posttranslational
modifications in the mitochondrial subpopulations of the db/db T2DM mouse model (84).
Dysregulation of proteins in the SSM was more prevalent than that in the IFM of db/db mice when
compared to controls with changes in FAO, respiratory chain components, TCA cycle proteins,
the antioxidant defense protein peroxiredoxin V and mitochondrial protein import constituents
(84). Posttranslational modifications were found on proteins of the SSM and IFM during the
T2DM pathology, with proteins of the ETC being affected with alterations such as acetylations,
deamidations and oxidations (84). Interestingly, the majority of proteins that were altered were
located in the IMM, suggesting that the pathogenesis of the mitochondrial dysfunction may result
from alterations to this sub-compartment during T2DM (84). Altogether, this data reveals that the
mitochondrial proteome is detrimentally impacted during DM.

1.10 MicroRNA
With their original discovery in C. elegans, microRNAs (miRNAs) are regulators of gene
expression that are abundant in many species (415). These miRNAs work by targeting mRNAs
of protein-coding genes for posttranscriptional regulation and translational repression. miRNAs
play a regulatory role in cell physiology and development; however, they have also been
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implicated in pathological disease states such as autoimmune diseases, viral infections, cancer and
DM (24, 184, 189, 213, 302, 310, 438).
MiRNAs are transcribed by RNA Polymerase II, which produces a pri-miRNA transcript
containing a hairpin loop, capped 5’ end and a polyadenylated (poly(A)) tail. Drosha, an RNase
III enzyme located in the nucleus, serves to cut the pri-miRNA into an intermediate form known
as the pre-miRNA (225, 226, 442). This pre-miRNA contains the hairpin loop, but its size is
significantly smaller and once trimmed, the pre-miRNA is then actively transported to the
cytoplasm from the nucleus by exportin-5 and ran-guanosine triphosphate (256, 439). Dicer, a
cytoplasmic protein and RNase III enzyme, cuts the pre-miRNA resulting in the mature, doublestranded miRNA, which now ranges in size from 20-25 base pairs (255). Finally, formation of the
RNA-Induced Silencing Complex (RISC) occurs. First, dicer, along with assistance from cofactors
transactivating response RNA binding protein and protein activator of interferon induced protein
kinase, unravels the miRNA from its complementary sequence, leaving a single-stranded
functional miRNA. Then, dicer helps to bring the miRNA to a member of the argonaute family
(AGO1-4), completing the formation of the RISC (323). Importantly, AGO family proteins
function in miRNA repression through the inhibition of protein synthesis when bound to the
mRNA 3’ untranslated region (UTR) (129). miRNAs then target the RISC via AGO to a specific
mRNA and the seeding region, a particular 2-7 base pair region of the miRNA, can bind directly
to the target mRNA. Once bound, translational repression, deadenylation or endonucleolytic
cleavage causing mRNA degradation to occur in the RISC (246) (Figure 1.6).
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Figure 1.6 miRNA Biogenesis and Function (403)

1.10a. In physiology
miRNAs have been shown to be involved in physiological developmental processes such
as regulation of cellular functions including growth, proliferation, differentiation and apoptosis
(20). Since miRNAs play a role in differentiation, the expression profiles for miRNA can be used
to identify specific cell types, thus leading to the identification of certain tissues (443). Further,
miRNAs have been investigated for their role in stem cells, specifically controlling the fate of the
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stem cell through differentiation and behavior of the cell (55). When looking at embryonic cell
differentiation regulation by miRNA-296 and miRNA-22, miRNA-296 promoted differentiation,
while miRNA-22 inhibited differentiation (140). Additional studies revealed that osteogenic
differentiation of stem cells is regulated by miR-26a and miRNA-138 through the targeting of
transcription factor SMAD1 (114, 140). Interestingly, miRNA networks during development also
interact in important processes for the fate of a cell, conferring robustness to certain biological
processes and reinforcement of transcriptional programs (108). First, miRNAs oftentimes target a
transcriptional regulator and second, with the combination of a feedforward and feedback loop,
cells are able to distinguish between whether they should counteract a transient fluctuation or
incorporate a permanent change (108, 123). Finally, specific cell type miRNA exist and reinforce
the same cell fate decisions for all cells (108, 123). In a study by Cheung et al., the authors found
that the miRNA pathway was essential in the maintenance of quiescence in satellite cells (71).
Specifically, the authors showed that miR-489 regulates satellite cell quiescence through Dek and
helps to promote the proliferation of myogenic progenitors (71). The vast majority of literature
reveals that miRNA play an unprecedented role in proper and controlled physiological
development.

1.10b. In pathologies
Recently, an expanse of research has been performed to elucidate the roles of miRNAs in
pathologies such as cancer, cardiovascular disease, DM and pathologies dealing with the immune
system (76, 98, 121, 295). miR-15a/16-1 are implicated as tumor suppressors, which have been
found to be deleted in chronic lymphocytic leukemia (53). This discovery by Calin et al. set the
stage for the role of miRNA in cancer, where miRNAs have been shown to affect all 6 hallmarks
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of malignant cells (98). Further, miRNAs have important roles in cardiovascular disease such as
MI, hypertrophy and HF (121). In a study of ischemic pre- and post-conditioning, characterization
of the miRNA expression levels showed alterations to 18 miRNAs (405). miR-423-5p was highly
expressed in the blood of HF patients and elevated plasma levels of the same miRNA are linked
with N-terminal prohormone brain natriuretic peptide levels in dilated cardiomyopathy (115, 388).
miRNAs exist in all parts of the body and play a role in cellular processes dealing with both
physiological and pathological development. It is suggested that miRNA can circulate in the blood
during times of stress to target areas within the body, which allows for these circulating miRNAs
to be used as clinical markers for disease states (147).

1.10c. Within the heart
MiRNA are present throughout the body; however, within the heart, certain miRNA have
been shown to be highly expressed and impact cardiomyocyte differentiation, cardiac development
and ventricular hypertrophy (19, 25, 244). Nine miRNAs have been described previously as having
important roles in cardiovascular disease and disease progression: miR-1, miR-133a-2, miR-133b,
miR-208a, miR-208b, miR-214-3p, miR-146a-5p, miR-155-5p and miR-150-5p (126). miR-1 and
miR-133a have been shown to be important in ventricular development, particularly in regulation
of cardiomyocyte growth (250, 371). Interestingly, miR-133a, miR-133b, miR208a and miR-208b
have been shown to be downregulated in chronic Chagas disease cardiomyopathy when compared
to control (126). Further, these authors found that miR-133b, miR-208a and miR-208b were also
reduced in diabetic cardiomyopathy samples when compared with controls (126). In physiological,
exercise-induced LV hypertrophy, the global analysis of miRNAs revealed that miR-26b, miR27a and miR-143 were decreased after 7 days of exercise, while miR-150 was increased after 35
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days of exercise, potentially alluding to these miRNAs playing a role in the regulation of
hypertrophy (262). miR-29 and miR-34a have been suggested to have a role in the development
of cardiac fibrosis, while miR-30d plays a role in diabetic cardiomyopathy (183, 242, 404).
Literature suggests that miRNAs have been abundantly studied in the heart relating to both
physiological and pathophysiological roles, along with their potential use as therapeutic targets
and treatments for cardiac diseases.

1.10d. Within the mitochondria
miRNAs exist throughout the body in many different locales, but recently, research has
focused on determining the role of particular miRNAs within certain organelles. With the
mitochondrion playing a critical role in providing energy for the cell and utilizing proteins
generated from the mitochondrial and nuclear genome in order to properly function, it is critical
for the role of miRNAs within this organelle be elucidated due to their influence on mRNA and
protein expression. Particularly, the study of miRNAs in pathophysiological states is extremely
important to determine their regulatory roles. Studies of liver mitochondria revealed the presence
of miRNA within this organ and suggested that miRNAs have influenced cellular proliferation,
apoptosis and cellular differentiation (31, 215). Further, literature suggests that specific miRNA
subpopulations could potentially exist within the mitochondrion (240). The changing
concentrations of miRNAs within the mitochondria have shown detrimental impacts on OXPHOS,
ATP synthase and FAO during disease states. Interestingly, Bian et al. found that the most highly
expressed miRNAs located in liver mitochondria did not show up in the liver fractions (31). Das
et al. performed a study looking at miRNA-181c translocation into the mitochondria and its
regulation of the mitochondrial genome through the targeting of cytochrome c oxidase subunit 1
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mRNA (93). In the STZ-induced T1DM mouse model, increased levels of miR-494, miR-202-5p,
miR155 and miR-134 were found, while miR-705 and miR122 were decreased in the liver
mitochondria and are suggested to target specific mitochondrial genes (31). Looking at isolated
cardiac mitochondrial subpopulations, our laboratory found that spatially distinct mitochondrial
subpopulations are differentially affected during DM (189). During T1DM, the redistribution of
miR-378 in the IFM led to a decrease in the F0 component of ATP6 in cardiac mitochondria (189).
Another study performed in our laboratory showed an increase in miR-141 expression with a
subsequent decrease in the IMM phosphate transporter, Slc25a3, in the IFM during T1DM (24).
Further investigation of miRNAs within the mitochondria, particularly mitochondrial
subpopulations, could lead to and understanding of how mitochondrial processes are dysfunctional
during pathological settings.

1.10e. Import into the mitochondria
Import of nuclear-encoded proteins into the mitochondrion is a well-studied mechanism,
with the machinery for the process identified; however, the mechanisms behind the import of
miRNAs into the mitochondrion and the constituents involved are unknown. Studies using
different species indicate that nuclear-encoded RNA is likely imported into the mitochondrion via
mechanisms that are ATP-dependent. Schneider showed the import of tRNAs into the
mitochondrion through Tom20, Tom40 and VDAC; however, the mechanisms behind the import
of non-coding RNAs still need to be elucidated (349). Interestingly, studies looking at 5S rRNA
and tRNA targeted to the mitochondrion suggested that the mechanism behind protein import
could potentially be the same machinery used for RNA import (15, 111, 210, 366, 367). In addition
to the pores used by nuclear-encoded protein import, RNA could be imported into the

57

mitochondrion initially through porins, which are voltage-dependent anion channels located on the
OMM (15, 75, 339).
Argonaute 2 (Ago2) could also serve as a mediator in the localization of miRNAs to the
mitochondria and potentially facilitate the miRNAs movement through and into the mitochondrial
matrix, indicating that the RISC potentially plays a role in miRNA import (15). Ago2 has been
shown to associate with mitochondrial transcripts mt-CO3 and mt-CO1, along with miR-181c,
indicating that Ago2 may play a key role in the association of miRNAs being imported into the
mitochondrion (16, 28, 93). Ago2 and its associated miRNA could be delivered to the
mitochondrion through a system of vesicles (15). While miRNAs have been shown to exist in
microvesicles and exosomes, allowing for the transfer of the miRNA between cells, this process
has not been shown to occur on a particular organelle, such as the mitochondrion (128).
Another important protein postulated to be involved in the import of miRNA into the
mitochondrion is polynucleotide phosphorylase (PNPase). Utilizing PNPase for RNA import into
the mitochondrion requires the presence of a specific stem-loop secondary structure in the target
RNA (247, 418). Barrey et al. found that pre-miR-302a and pre-let-7b are predicted to fold into
these stem-loop configurations, leading to the assumption that PNPase could be critical for the
import of these pre-miRNAs into the mitochondrion (18). While potential machinery and
mechanisms of import for miRNA have been postulated, studies still need to be completed in order
to confirm these speculations.

1.10e.i. Polynucleotide Phosphorylase
PNPase is located in the IMS of the mitochondrion, potentially situated on the IMM (418,
419). Functioning as a homotrimeric protein, PNPase aids in the import of RNA into the
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mitochondrion, editing and degradation of RNA, along with controlling cellular senescence and
cell cycle (15, 248, 340, 341, 365, 418). Interestingly, Vedrenne et al. found that a mutation to
PNPT1, the gene encoding for PNPase, impairs RNA import into the mitochondrion and causes
deficiencies in respiratory chain function (406). PNPase also has the capability to form homomultimers, providing the protein with a diverse array of interactions with RNA and other small
molecules, but also complicating the study of the protein (417). PNPase has been shown to induce
degradation of mature miRNA by selectively binding it; however, its role in the import of mature
miRNA has been postulated, but not studied (94). PNPase has been established to play an
important role in the import of nuclear RNA; however, its involvement in the import of miRNAs
needs to be evaluated (336, 349, 418).

1.11 Summary
DM continues to increase in prevalence across the United States and worldwide, with rates
of DM doubling in the past two decades (4). The global prevalence of DM is 8.5%, with a
staggering 9.3% of people within the United States suffering from the disease (1, 2). Annually,
DM costs the United States roughly $245 billion in medical costs and lost productivity (4). Among
the leading causes of morbidity and mortality among diabetic patients are cardiovascular
complications, such as HF (142). We sought to determine if speckle-tracking based strain
echocardiographic analyses were able to detect subtle changes in cardiac function during DM,
prior to detection using conventional measurements, thus allowing for earlier detection and
treatment of cardiac complications during the progression of the disease. Mitochondrial
dysfunction has been suggested as central to the etiology of DM; therefore, it is critical for
scientists to study and elucidate the mechanisms behind mitochondrial dysfunction during DM,
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ultimately leading to better diagnostic and therapeutic treatment options. Alterations to the
mitochondrial proteome during DM could be a leading cause of mitochondrial dysfunction. The
goal of the studies presented was to elucidate whether mitochondrial proteome dysregulation
resulted from dysfunctional nuclear-encoded mitochondrial protein import efficiency in the SSM
during T2DM and the IFM during T1DM. Further, subsequent studies were performed to
determine whether overexpression of mtHsp70, a critical subunit of the PAM complex and motor
for nuclear-encoded mitochondrial protein import, preserves import efficiency, stabilizing the
mitochondrial proteome and ultimately leading to restored mitochondrial and cardiac contractile
function. We also assessed the importance of PNPase for the import of miRNA during T2DM in
order to help elucidate how the miRNAs are translocating into the mitochondria and regulating the
mitochondrial genome with the intent of providing potential targets for therapeutic strategies.
Efficient evaluation of cardiac contractile function via echocardiography and examination of
nuclear-encoded mitochondrial protein import and import of miRNAs into the mitochondrion
during DM could potentially allow for the discovery of therapeutic strategies aimed at helping to
alleviate the mitochondrial dysfunction and cardiac contractile deficiencies seen in patients
suffering from DM.
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Abstract
Enhanced sensitivity in echocardiographic analyses may allow for early detection of
changes in cardiac function beyond the detection limits of conventional echocardiographic
analyses, particularly in a small animal model. The goal of this study was to compare conventional
echocardiographic measurements and speckle-tracking based strain imaging analyses in a small
animal model of type 1 diabetes mellitus. Conventional analyses revealed differences in ejection
fraction, fractional shortening, cardiac output, and stroke volume in diabetic animals relative to
controls at 6-weeks post-diabetic onset. In contrast, when assessing short- and long-axis speckletracking based strain analyses, diabetic mice showed changes in average systolic radial strain,
radial strain rate, radial displacement, and radial velocity, as well as decreased circumferential and
longitudinal strain rate, as early as 1-week post-diabetic onset and persisting throughout the
diabetic study. Further, we performed regional analyses for the left ventricle and found that the
free wall region was affected in both the short- and long-axis when assessing radial dimension
parameters. These changes began 1-week post-diabetic onset and remained throughout the
progression of the disease. These findings demonstrate the use of speckle-tracking based strain as
an approach to elucidate cardiac dysfunction from a global perspective, identifying left ventricular
cardiac regions affected during the progression of type 1 diabetes mellitus earlier than contractile
changes detected by conventional echocardiographic measurements.
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1.1 Introduction
Cardiac complications, such as diabetic cardiomyopathy, are the leading cause of mortality
among diabetic patients [1, 2]. Diabetic cardiomyopathy is characterized by contractile
abnormalities in the absence of coronary disease [1, 2]. The ability to assess cardiac performance
within a clinical setting has been established in patients with coronary artery disease, myocardial
infarction, and ischemic cardiomyopathy by numerous studies providing strain analyses [3-5].
Importantly, however, while this type of imaging and analysis has been utilized in the clinical
setting, it is somewhat limited when considering small animal models of cardiovascular diseases
[6-9]. Multiple methods for imaging cardiac performance noninvasively are available, but highly
sensitive in vivo imaging is imperative for the assessment of cardiovascular dysfunction within
small animal models. Evaluation of potential therapeutic treatments for diseases in small animal
models is difficult without a way to critically assess cardiac function. Some treatments may elicit
subtle beneficial or detrimental changes in cardiac function, undetectable with conventional
echocardiographic assessment such as ejection fraction, emphasizing the importance of methods
capable of detecting minute changes. Sensitive imaging analyses would afford the ability to detect
cardiotoxic side effects of potential therapeutic treatments given for systemic pathological
diseases. It would also allow investigators to assess the ability of pharmacological treatments for
cardiovascular pathological disease states to subtly enhance contractile function. Until recently,
the speckle-tracking based strain approach has been unavailable in small animal models because
of the lack of highly sensitive imaging probes and software limitations preventing rapid assessment
of cardiac performance. Bauer et al. suggested echocardiographic speckle-tracking based strain
analyses as a way to quickly and accurately cardiac phenotype using an experimentally-induced
myocardial infarction model [6]. Compared with conventional echocardiography, these authors
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found that speckle-tracking based strain analyses were capable of detecting subtle changes in
myocardial deformation of the left ventricle (LV) [6]. Our current manuscript focuses on a type 1
diabetic mouse model, previously established to exhibit global cardiac dysfunction, which we
hypothesize will be detected earlier using speckle-tracking based strain analyses compared to
conventional analyses [10, 11]. Moreover, we aim to elucidate whether distinct regions of the LV
develop dysfunction throughout the progression of type 1 diabetes mellitus, as well as decrements
in global LV cardiac strain measurements, prior to the overt LV changes detected by conventional
measurements. We describe the utility of using speckle-tracking based strain analyses to evaluate
the progression of cardiac dysfunction in the type 1 diabetic heart. Comparing speckle-tracking
based strain to conventional echocardiographic analyses, we found that analysis of strain allowed
us to detect subtle changes much earlier during the progression of type 1 diabetes mellitus.
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1.2 Research Design and Methods
1.2.1 Experimental Animals and Diabetes Induction
Animal experiments performed in this study conformed to the National Institutes of Health
Eighth Edition Guidelines for the Care and Use of Laboratory Animals and were approved by the
West Virginia University Care and Use Committee. Male FVB mice were obtained from The
Jackson Laboratory (Bar Harbor, Maine) at 4 weeks of age, placed on a standard diet, and received
free access to water. Animals were housed in the West Virginia University Health Sciences Center
animal facility on a 12-hour light/dark cycle in a temperature-controlled room. Type 1 diabetes
mellitus was induced in 6-week-old mice using multiple low-dose streptozotocin (STZ) (Sigma,
St. Louis, MO) injections. Briefly, mice were injected intraperitoneally after a 6-hour fasting
period for 5 consecutive days with STZ at a dose of 50 mg/kg body weight dissolved in sodium
citrate buffer (pH 4.5) [12, 13]. Hyperglycemia was confirmed one week post-injection by
measuring blood glucose (Contour Blood Glucose test strips; Bayer, Mishawaka, IN), where >250
mg/dL was considered diabetic. One STZ injected animal was removed from the study. Animals
were imaged at baseline prior to STZ injection, as well as at weeks 1, 3, and 6 after confirmation
of type 1 diabetes mellitus.

1.2.2 Echocardiography
For echocardiographic assessment, each mouse was anesthetized in an induction chamber
with inhalant isofluorane at 2.5% in 100% oxygen. When fully anesthetized, the mouse was
transferred to dorsal recumbency, placed on a heated imaging platform, and maintained at 1%
isofluorane for the duration of the experiment [14]. Electrode gel was applied to the limb leads
allowing for an electrocardiogram and the respiration rate to be recorded during ultrasound
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imaging. A rectal probe was used to monitor the temperature of the mouse. Ultrasound images
were acquired using a 32-55 MHz linear array transducer on the Vevo2100 Imaging System
(Visual Sonics, Toronto, Canada). Placing the transducer to the left of the sternum allowed us to
obtain images of the aortic outflow tract, the apex of the heart, and LV along its longest axis (i.e.,
long-axis B-mode images). Once all long-axis B-mode images were attained, the transducer was
rotated 90 degrees to acquire short-axis B-mode images at the mid-papillary muscle level.
Additionally, M-mode images were taken by placing a gate through the center of the short-axis Bmode images to obtain M-mode recordings of internal parameters of the myocardium. All images
were acquired using the highest possible frame rate (233-401 frames/second) depending on the
imaging axis to get the best possible image resolution for speckle-tracking based strain analyses.
One trained individual in the West Virginia University Animal Models and Imaging Facility
acquired all images.

1.2.3 Conventional Echocardiographic M-mode and Doppler Imaging
Conventional echocardiographic assessment was completed on grayscale M-mode
parasternal short-axis images at the mid-papillary level of the LV (Figure 2.1A). Measurements
obtained from LV M-mode images included end-diastolic and end-systolic diameters and volumes,
anterior and posterior wall thickness at both systole and diastole, fractional shortening, ejection
fraction, stroke volume, and cardiac output. LV volumes were automatically calculated by the
Vevo2100 system when using M-mode imaging (Visual Sonics, Toronto, Canada). LV volume in
systole (Volume;systole) was calculated by the program using the equation (7.0 / (2.4 + LVID;s))
x LVID;s3), while LV volume in diastole (Volume;diastole) was calculated using the equation (7.0
/ (2.4 + LVID;d)) x LVID;d3) (Visual Sonics, Toronto, Canada). To calculate stroke volume for
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M-mode images, systolic volume was subtracted from diastolic volume (Visual Sonics, Toronto,
Canada). All M-mode image measurements were calculated over three consecutive cardiac cycles
and then averaged. As a measure of diastolic function, LV filling was assessed using Doppler
echocardiography and measuring the E/A ratio, deceleration time, and Isovolumetric Relaxation
Time (IVRT) over three cardiac cycles. The E/A ratio is a ratio of ventricular filling velocities of
the early (E) peak to the late (A) peak of transmitral blood flow. Deceleration time of the E peak
refers to the deceleration of blood flow through the mitral valve, while IVRT is the time from the
closure of the aortic valve to the onset of mitral flow.
To assess reliability of the conventional measurements, each observer scored the
parameter three times, and the average of the three observations was used for analysis on a
subset of our study population (n=4). To determine intraobserver variability, the average
coefficient of variance ((standard deviation/ mean) x 100) was calculated for the observer for
each measurement. The average coefficient of variance values for ejection fraction and E/A ratio
were 3.4% and 1.3%, respectively. To determine both interobserver and test-retest intraobserver
reliability, intra-class correlation (ICC) coefficients were calculated using a two-way mixed
model with absolute agreement and reported in Table S2.1. Intraobserver test-retest reliability
was calculated using values obtained at two separate time-points by a single rater. All ICC values
for conventional measurements were greater than 0.8, indicating a high degree of both
interobserver and intraobserver test-retest reliability [15]. When performing interobserver
reproducibility measurements, the second observer selected and used the most appropriate image
and frames to complete the strain measurements. All reported analyses in the manuscript used
the Vevo2100 Imaging analysis software and included measurements from all animals for Mmode analyses (Visual Sonics, Toronto, Canada).
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1.2.4 Speckle-tracking-based Strain Imaging Analyses
Based on concepts previously described, strain is defined as the change in the length of a
segment divided by the original length of the segment and the strain rate as the rate at which this
deformation occurs during a cardiac cycle [16-18]. Using the B-mode videos acquired from the
parasternal short- and long-axes (Figure 2.1A), strain and strain rate were calculated for the radial,
longitudinal, and circumferential dimensions with the Visual Sonics VevoStrain software
(Toronto, Canada) using a speckle-tracking algorithm. Velocity and displacement were also
calculated in both the long- and short-axes. Values generated by strain analyses were positive or
negative depending on the assessed measurement. A positive value for strain indicates fiber
lengthening or thickening, such as in the radial dimension, while a negative value illustrates fiber
shortening, in the circumferential or longitudinal dimensions [16, 19]. Briefly, B-mode video loops
were chosen based upon image quality and the ability to visualize both the endocardial and
epicardial wall borders, with limited interference by artifacts such as the sternum or lungs. Borders
of the endocardium and epicardium were traced and checked throughout three cardiac cycles to
ensure tracking was sufficient. Both the endocardial and epicardial borders were tracked through
the image in a frame-by-frame manner by the software for measurements of strain, strain rate,
velocity, and displacement. Strain analyses were performed, giving curvilinear data as output for
both global and segmental values. Average peak global strain values were obtained from six
independent anatomical segments of the LV. Global dyssynchrony for radial velocity, strain and
strain rate were measured by using the standard deviation of time to peak strain, corrected for the
RR interval [20, 21]. Further, segmental analyses were performed on short-axis images with the
LV being split into the following regions: anterior free (AF), lateral (L), posterior (P), inferior free
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(IF), posterior septum (PS), and anterior septum (AS) (Figure 2.1B). Regional analyses were also
performed on long-axis images with the LV divided into the following segments: anterior base
(AB), anterior mid (AM), anterior apex (AA), posterior apex (PA), posterior mid (PM), and
posterior base (PB) (Figure 2.1C). Because type 1 diabetes mellitus presents as a global
dysfunction of LV parameters, segments were grouped into septal (AS and PS for short-axis; AA,
AM, and AB for long-axis) and free wall (AF, L, P, and IF for short-axis; PA, PM, and PB for
long-axis) regions for short- and long-axis in order to assess whether a particular section of the LV
is affected during the progression of the disease. All individual regions were utilized during
analyses and grouped as previously stated.
High intraobserver reproducibility was demonstrated on a subset of animals (n = 4) using
speckle-tracking based strain measurements with a coefficient of variance equal to 6.1%,
respectively. To determine both interobserver and test-retest intraobserver reliability, ICC
coefficients were calculated using a two-way mixed model with absolute agreement and reported
in Table S2.1. Interobserver and test-retest ICC values for strain were greater than 0.8, indicating
a high degree of both interobserver and test-retest intraobserver reliability [15]. When performing
interobserver reproducibility measurements, the second observer selected and used the most
appropriate image and frames to complete the strain measurements. All reported analyses in the
manuscript used the Vevo2100 Imaging analysis software (Visual Sonics, Toronto, Canada). One
control and diabetic short-axis, along with one control long-axis image were excluded from strain
measurements. In the short-axis, only still image pictures were collected and no movie loops;
therefore, strain analyses could not be performed. For the excluded long-axis image, landmarks,
such as the left atria and outflow track were not present; therefore, the movie loop was not used
for strain analysis.
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1.2.5 Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). Comparisons between
control and diabetic animals were made within each given week to see whether changes were noted
between the two groups using different types of echocardiographic analyses. Data were analyzed
using a two-tailed Student’s t test to directly compare the type 1 diabetic animals to the controls at
a given time. P < 0.05 was considered statistically significant. Statistical analyses were performed
using GraphPad Prism version 5.00 (GraphPad Software, San Diego, California).
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1.3 Results
1.3.1 Conventional Echocardiographic Imaging and Analysis
To assess LV functional changes over time during type 1 diabetes, mice were imaged prior
to diabetes induction (baseline) and at weeks 1, 3 and 6 after onset. Table 2.1 represents data
collected from M-mode images at baseline and weeks 1, 3, and 6. M-mode images showed
decreases in anterior and posterior wall thickness at diastole in diabetic animals as compared to
controls 1-week post-diabetic onset (Table 2.1). At 3-weeks post-diabetic onset, decreased anterior
and posterior wall thickness at diastole, as well as a decreased heart rate were noted in type 1
diabetic animals (Table 2.1). Six weeks after diabetes induction, overt LV dysfunction was present
in the type 1 diabetic animals. Global function, assessed by conventional measures of
echocardiography using M-mode images, showed decreased LV function in the type 1 diabetic
animals at 6-weeks as compared to controls. Type 1 diabetes induced decreases in stroke volume,
cardiac output, ejection fraction, and fractional shortening (Table 2.1). Further, type 1 diabetes
caused decreases in diastolic diameter and volume, along with decreases in anterior and posterior
wall thickness, indicative of myocardial remodeling (Table 2.1).
Representative Doppler images from control and type 1 diabetic animals illustrate a
decreased E/A ratio in type 1 diabetic animals as compared to their controls at 6-weeks postdiabetic onset, with no changes occurring before this time point (Figure 2.2A-B). The decreased
E/A ratio is due to the significantly decreased E wave at 6-weeks post-diabetic onset in the type 1
diabetic animals (Figure 2.2C). A decrease in the E wave, or early diastolic filling, could be a
reflection of hemodynamic load, heart rate and/or cardiac output given the known dependence of
the E/A ratio on these factors [22, 23]. The decreased E wave during type 1 diabetes is potentially
due to a decreased ability for LV relaxation, while no changes were seen in the A wave (Figure
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2.2D). E wave deceleration, a measure of how blood flow velocity declines during early diastole,
was unchanged between control and type 1 diabetic animals throughout the course of our study
(Figure 2.2E). IVRT, a measure of the time from the closure of the aortic valve to the onset of
mitral flow, is increased in the type 1 diabetic animals 6-weeks post-diabetic onset (Figure 2.2F).
Together, the echocardiography data indicate deficient systolic and diastolic LV function during
type 1 diabetes mellitus predominantly being observed through conventional measures at 6-weeks
post-diabetic onset.

1.3.2 Measures of Global Myocardial Performance During a Type I Diabetic Insult
Using the VevoStrain software to complete functional analyses for the LV, the complex
pattern of deformation can be examined in the longitudinal, radial, and circumferential dimensions
in both systole and diastole. Speckle-tracking based strain analyses trace the endocardium and
epicardium frame-to-frame during the cine loop, providing assessment of the deformation of the
tissue by using measurements of strain and strain rate in each of these dimensions. Strain refers to
the assessment of myocardial deformation, while strain rate measures the tissue velocity of
deformation [16]. Global LV functional analyses, as well as the evaluation of six anatomic
segments of the LV providing information on regional function, produce curvilinear data for strain
analysis (Figure S2.1). Interestingly, speckle-tracking based strain analyses revealed differences
as early as 1-week post-diabetic onset and persisting throughout the remainder of the study.
Decreases in short-axis average systolic radial strain, strain rate, velocity, and displacement were
noted in the type 1 diabetic animals at week 1 when compared to control animals, along with
significantly decreased circumferential strain (Table 2.2). Three weeks post-diabetic onset,
average systolic circumferential strain rate, radial strain, strain rate, velocity, and displacement
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were all significantly decreased in the diabetic animals as compared to controls (Table 2.2).
Finally, at 6-weeks post-diabetic onset, decrements in average systolic circumferential strain rate,
radial strain, strain rate, and velocity were noted in the type 1 diabetic animals when compared to
controls (Table 2.2). No changes were noted in circumferential rate or displacement (Table 2.2).
When assessing global diastolic strain measurements in the short-axis, radial strain was
significantly decreased in diabetic animals when compared to controls starting at week 1 and
persisting throughout the study (Table 2.2). Further, radial strain rate was decreased at weeks 3
and 6 post-diabetic onset (Table 2.2).
In the long-axis images, diabetic animals had decreased average systolic radial strain, strain
rate, and velocity at weeks 1, 3 and 6 as compared to control within a given week (Table 2.3).
Radial displacement was decreased at 1-week post-diabetic onset; however, this change was not
observed throughout the rest of the study (Table 2.3). Further, longitudinal strain rate was
decreased at weeks 3 and 6 post-diabetic onset; however, other longitudinal parameters such as
strain, velocity, and displacement were unaltered during the progression of type 1 diabetes (Table
2.3). Average diastolic strain parameters were unchanged between control and diabetic animals in
the long-axis (Table 2.3).
Systolic radial velocity, strain, and strain rate parameters, which were globally changing
due to type 1 diabetes mellitus, were also analyzed for dyssynchrony in both the short- and longaxes. Type 1 diabetes mellitus was not associated with significant increases in global dyssynchrony
for radial velocity, strain, and strain rate at any time point throughout the course of the study (Table
S2.2).
Notably, it was discerned that changes in the short-axis, as seen by average myocardial
systolic radial strain, strain rate, velocity, and displacement, as well as changes in circumferential
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strain rate occurred earlier than changes in LV function for conventional echocardiographic
measurements. Further, radial strain and strain rate were also significantly decreased during
diastole as early as 1-week post-diabetic onset. Similarly, decrements in average myocardial
systolic radial measurements in the long-axis, along with longitudinal strain rate, were noted earlier
during the progression of type 1 diabetes mellitus than measurements obtained by conventional
echocardiography. This data provides evidence that global speckle-tracking-based strain analyses
are capable of detecting early, subtle changes in LV function in the type 1 diabetic STZ mouse
model in both systole and diastole.

1.3.3 Measures of Segmental Myocardial Performance During Type I Diabetes
Speckle-tracking based strain allows for the assessment of regional cardiac function by
separating the LV into six distinct segments in both the short- and long-axes (Figure S2.1).
Regional analyses were performed on short-axis images with the LV divided into the free wall
(anterior free, lateral, posterior, and inferior free) and septal wall (posterior septum and anterior
septum) regions (Figure 2.1B). Global strain analyses showed decreases in both short- and longaxis radial dimensions by deficient radial velocity, radial strain, and radial strain rate in the type 1
diabetic animals (Tables 2.2 and 2.3). When assessing these parameters using a regional approach
in the short-axis, we found that radial velocity in the free wall and septal wall regions was
decreased in the type 1 diabetic animals at weeks 1 and 3 (Figure 2.3A-B). Interestingly, only the
free wall region of the LV was affected in the type 1 diabetic animals when looking at radial strain
beginning at week 1 and remaining throughout the progression of type 1 diabetes, with no changes
in the septal wall (Figure 2.3C-D). Finally, radial strain rate was also affected in both the free wall
and septal wall regions of the LV (Figure 2.3E-F). Decreases in radial strain rate in the free wall
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occurred at week 1 and persisted throughout the study, while the septal wall was affected at weeks
3 and 6 post-diabetic onset (Figure 2.3E-F).
We also performed regional assessment on radial velocity, radial strain, and radial strain
rate in the long-axis by separating the LV into free wall (posterior apex, posterior mid, and
posterior base) and septal wall (anterior apex, anterior mid, and anterior base) regions (Figure
2.1C). Type 1 diabetic animals showed a decreased radial velocity in the free wall region of LV
beginning at week 1 and persisting throughout the study, with only week 3 being affected in the
septal wall region (Figure 2.4A-B). Radial strain was decreased in the free wall region of the type
1 diabetic animals at weeks 1, 3, and 6 post-diabetic onset, with no decrements in the septal wall
region (Figure 2.4C-D). Finally, radial strain rate was decreased in the type 1 diabetic animals in
the free wall region of the LV beginning 1-week post-diabetic onset and continuing throughout the
progression of diabetes, while the septal wall region was only affected at week 3 (Figure 2.4E-F).
Overall, regional assessment of the LV in the radial dimension showed that the free wall region in
the short- and long-axis was predominantly affected during the progression of type 1 diabetes
mellitus.
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1.4 Discussion
This is the first application of echocardiographic speckle-tracking based strain analyses for
cardiac phenotyping during the progression of type 1 diabetes in a mouse model. Here we describe
the utility of using noninvasive echocardiographic analyses, such as speckle-tracking based strain,
for early detection of LV dysfunction during the progression of type 1 diabetes mellitus.
The goal of this study was to provide a comparison between conventional
echocardiographic measurements and speckle-tracking based strain analyses to see if changes in
cardiac function would be detected earlier by means of more advanced methods. Further, we aimed
to see if a particular region of the LV was predominantly affected during the progression of type
1 diabetes mellitus. The principal finding of this study was that speckle-tracking based strain
analyses provided a sensitive approach to detect early global changes in LV function, as compared
to changes identified using conventional echocardiography during the development of diabetes
mellitus in a type 1 diabetic mouse model. As early as 1-week post-diabetic onset, decreases in
average systolic radial strain, radial strain rate, radial velocity, and radial displacement, along with
circumferential and longitudinal strain rate at week 3 post-diabetic onset, were observed in shortand long-axis speckle-tracking based strain analyses and persisted throughout the study. Strain and
strain rate were both found to be decreased in the radial axis at 1-week post-diabetic onset,
indicating that myocardial deformation and the velocity at which that tissue deforms is impaired
in this axis during the early stages of type 1 diabetes mellitus. Decreases in these systolic radial
measurements are indicative of LV dysfunction allowing for subtle detection of early dysfunction
occurring during type 1 diabetes mellitus [24]. Further, we found that the free wall region was
predominantly affected in the radial dimension in both the short- and long-axis during type 1
diabetes mellitus. These findings highlight that the LV free wall could potentially be more affected
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than the septal wall during the progression of type 1 diabetes mellitus. These outcomes confirm
other findings indicating that early changes are detected by speckle-tracking-based strain analysis
prior to changes in conventional measurements giving investigators an approach to evaluate
cardiac function in a small animal model with a cardiac pathology [6-9]. Additionally, speckletracking based strain analyses allow the ability to detect particular regions of the LV that may not
be functioning properly. Finally, it provides investigators with the opportunity to assess the
therapeutic benefit or detriment of treatment strategies on cardiac contractile function.
It is imperative in a clinical setting to be able to detect subtle changes in LV function and
global heart function in order to intervene before the onset of a cardiac insult. Currently, clinical
studies have shown that early detection of subtle changes in strain measurements were associated
with the future development of cardiovascular disease, while conventional measures of cardiac
structure and function were unaltered [25-32]. Though ejection fraction is typically the most
prominent clinical measure for systolic dysfunction in the diabetic patient, strain and strain rate
imaging have been shown to increase subclinical diabetic cardiomyopathy detection in patients
[31, 33, 34]. Consequently, it is imperative that researchers using small animal models are able to
detect these subtle and early changes in cardiac function in order to assess different cardiac
therapies used to prevent cardiac dysfunction in the disease state. While strain measures have been
utilized in clinical studies, experimental studies on small animal models were more complicated
to perform due to fast heart rates, imaging equipment, and analysis software. However, advances
such as high frame rates allowing for angle-independent measurements have permitted the
adoption of strain analyses into an experimental setting, advancing the assessment of cardiac
abnormalities and therapeutic approaches in small animal models of cardiovascular disease [27,
35, 36].

136

Because previous studies indicate that myocardial ischemia is associated with a
dyssynchronous profile that undermines appropriate contractile function [9, 20, 21, 37], we
assessed global dyssynchrony in a temporal fashion following type 1 diabetes mellitus induction.
Our data indicated that the progression of the type 1 diabetic pathology through the initial six
weeks was not associated with an increase in dyssynchrony. Our data are in contrast to others who
have shown in models of myocardial infarction, impairments in longitudinal and radial strain and
strain rate parameters along with a concomitant increase in dyssynchrony [9, 20, 21, 37]. It is not
entirely clear why the differences in findings occurred, though it may be a function of the different
pathological models being studied. Specifically, these previous studies examined a focal cardiac
region of tissue damage resulting from infarct, whereas our study in the diabetic heart reflect global
dysfunction at an earlier pathological time point which may not be sufficient to induce an increase
in dyssynchrony. Regardless, our current data suggests that dyssynchrony does not play a
prominent role in cardiac pump function deficits during the initial progression of type 1 diabetes
mellitus.
Speckle-tracking based strain allows for the separation of the LV into six distinct segments,
permitting us to investigate regional cardiac dysfunction during the progression of type 1 diabetes
mellitus. In this study, we found that the region predominantly affected in the radial dimension
was the free wall in the short- and long-axis during the progression of type 1 diabetes mellitus.
These findings highlight that the free wall of the LV could potentially be more affected than the
septal wall during type 1 diabetes mellitus. This finding corroborates the potential use for regional
assessment of the LV in myocardial function during type 1 diabetes, particularly via changes in
the average systolic and diastolic radial measurements.
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Our findings support the current literature stating that speckle-tracking based strain
analysis possesses the potential for the sensitive evaluation of global and regional cardiac function
[6, 16, 38, 39]. Studies of patients with acute heart failure and LV dysfunction concluded that
strain powerfully predicted adverse cardiac events better than other conventional parameters, such
as ejection fraction [40, 41]. In a swine model of heart failure with preserved ejection fraction,
Hiemstra et al. showed decreases in systolic apical rotation rate, changes in strain measurements
from longitudinal, radial, and circumferential axes, as well as strain rate changes all prior to the
onset of increases in LV end diastolic pressure [39]. These results are in agreement with our
findings, as this group found that speckle-tracking was capable of detecting early changes prior to
the onset of overt LV impairment [39]. Bauer et al. found similar results in their assessment of a
small animal model of myocardial infarction with the addition of ACE inhibitors [6]. Their
principal findings concluded that speckle-tracking based strain was more sensitive than
conventional echocardiographic measurements when assessing both the infarct region and the
remote region, while subtle improvements were found in LV function in response to treatment
with ACE inhibitors [6]. Additionally, in a recent study by the same group, they determined
whether speckle-tracking based strain would provide insight regarding early changes in cardiac
performance, prior to LV dysfunction seen by conventional echocardiography, during early stages
of compensatory hypertrophic cardiac remodeling due to pressure overload [7]. These authors
found regional myocardial dysfunction in a mouse model of pressure overload further illustrating
the utility of using speckle-tracking based strain analyses, as well as regional assessment, in the
characterization of early cardiac dysfunction that is not detectable by conventional
echocardiographic measurements [7].
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While standard echocardiographic techniques are useful in the evaluation of cardiac
structure and function, they are often insensitive to subtle changes that occur early during the
progression of cardiovascular disease preceding overt dysfunction. Previously, our laboratory has
reported changes in stroke volume, ejection fraction, fractional shortening and cardiac output due
to type 1 diabetes mellitus; however, this current study offers a unique approach into pointing out
a particular locale of dysfunction within the LV of the type 1 diabetic heart by implementing
speckle-tracking based strain analysis [10, 11]. This study expounds upon current
echocardiographic research providing evidence for using speckle-tracking based strain as an
echocardiographic analysis software in small animal models of cardiovascular diseases [6, 7, 4244]. It has been shown that speckle-tracking based strain analyses are highly sensitive compared
to conventional measurements in small animal models, suggesting that these analyses could be
used for the assessment of different therapeutic treatments for cardiovascular diseases or
predisposing risk factors, including diabetes mellitus.
It is widely accepted that conventional measures of echocardiography are used to assess
both cardiac structure, as well as function. However, the limitation for these types of measurements
lies in the lack of sensitivity, which is overcome by the use of speckle-tracking based strain
analyses. Although, limitations to this study exist even when using speckle-tracking based strain
analyses and should be taken into consideration. The use of isofluorane, or any other anesthetic, is
common in performing echocardiography on animals; however, it should be noted that anesthetics
have the potential to alter the measurements recorded, though multiple studies have shown that
even under anesthesia, echocardiographic measurements are reliable, particularly using speckletracking based strain analyses [45-47]. Although this is a concern because of the risk of causing a
decrease in heart rate during image acquisition, heart rates recorded for the duration of this study
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remained near a physiological level. Literature notes that speckle tracking is heavily dependent
upon 2D image quality, high frame rates, and angle dependency [17, 48]. To prevent variation, a
single trained imaging technician acquired all images at the highest possible frame rate and avoided
artifacts including the lungs and sternum. Other limitations such as out of plane motion and
unknown software algorithms, known as filtering algorithms which calculate strain and strain rate
values, are also important to keep in mind [16]. During a cardiac cycle the heart will move,
sometimes causing speckles to move out of frame, making it difficult to surmise how the accuracy
of speckle-tracking based strain analyses are affected [16]. Further, it is difficult to compare
filtering algorithms between different software vendors and between the analyses, inherently
posing another limitation [16]. Variability in the assessment of strain has also been addressed
within the literature [49, 50]. As in the study performed by Hiemstra et al., we observed variation
between our time points, which could potentially be due to the methodology used, but also because
of animal maturation and normal physiological growth over the duration of the study [39]. Indeed,
we previously reported differences in heart weights, 6 weeks following STZ induction, which may
be a function of animal growth and pathology development that may have occurred similarly in
the current study [10, 51]. With that being said, it is important to note that the goal of the present
study was to determine whether speckle-tracking based strain analyses could identify cardiac
dysfunction at a given time point, earlier than conventional measures, as opposed to across time
points, limiting concern for serial assessment. Further, it is crucial to do a longer period of study
to see if parameters of stress/strain are transient and/or worsen during type 1 diabetes at a longer
duration. As others have previously shown, strain is dependent on a number of factors, such as
complexity of myocardial fiber orientation, which could potentially include the evaluation of
different fiber layers at a diverse number of levels leading to variation in results [6, 39, 52].
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Because of this, we decided that the question of interest was to find out if certain echocardiographic
parameters were capable of detecting changes in LV function earlier during the progression of type
1 diabetes mellitus. Therefore, we chose to not include the serial change, but instead evaluate
different echocardiographic parameters at each time point individually.
One question raised by the current study regards what mechanisms contribute to the
observed changes in cardiac strain parameters? Of note are our findings of decreased radial strain
during diastole which in combination with reduced early diastolic filling (decreased E), decreased
end diastolic volume, and increased IVRT, suggest that impaired filling may be involved in the
decreased stroke volume observed and ultimately, reduced cardiac output following diabetic insult.
Since reduced E and IVRT typically reflect early filling, impaired energetics leading to increased
time to reuptake calcium or trouble breaking cross-bridges during early diastole may be
mechanistic contributors to changes in strain parameters. Because these processes are ATPdependent, any bioenergetic compromise in the mitochondrion’s ability to provide an adequate
supply of ATP could have an effect on strain dynamics. Indeed, we have previously reported
compromised mitochondrial function and ATP-generating capacity during type 1 diabetes mellitus
[10, 51, 53]. Taken together, mitochondrial dysfunction in the face of type 1 diabetes mellitus may
provide a mechanistic link between altered bioenergetic function and changes cardiac strain
dynamics.
During normal LV function the heart deforms to show myocardial thickening and thinning
via the radial axis, as well as shortening and lengthening in the longitudinal and circumferential
axes, depending on whether the heart is in systole or diastole [16]. Alterations in the deformation
of the myocardium, revealed by strain measurements, are the earliest noninvasive indicators for
the development of cardiac dysfunction [54, 55]. We demonstrate the advantage of using speckle-
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tracking based strain analyses to detect changes in LV function earlier than conventional
echocardiographic measurements. While the correlation between contractile complications and
diabetic cardiomyopathy have been well established, the results presented in this study reveal how
early detection via strain measurements has the potential to play a critical role in evaluating
therapeutic treatments for contractile dysfunction in the diabetic heart.
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Figure 2.1
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Figure 2.1. Echocardiography and speckle-tracking-based strain. Representative M-mode and
B-mode control mouse echocardiographic images from which conventional analyses and speckletracking-based strain analyses were performed (A). A schematic of myocardial regions identified
form the parasternal short-axis view (B) and long-axis view (C). SAX indicates short-axis; AF,
anterior free; L, lateral; P, posterior; IF, inferior free (AF, L, P, and IF considered the free wall
region); PS, posterior septum; AS, anterior septum (PS and AS considered the septal wall region).
LAX indicates long-axis; AB, anterior base; AM, anterior mid; AA, anterior apex (AB, AM, and
AA considered the septal wall region); PA, posterior apex; PM, posterior mid; PB, posterior base
(PA, PM, and PB considered the free wall region).
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Figure 2.2
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Figure 2.2. Color Doppler Imaging for Diastolic Function. Comparative color Doppler images
between control (left) and diabetic (right) mice 6-weeks post-diabetic onset (A). E/A ratio data
during type 1 diabetes mellitus progression (B). E wave velocity over time during type 1 diabetes
mellitus (C). A wave velocity over time during type 1 diabetes mellitus (D). Deceleration time (E)
and Isovolumetric Relaxation Time (IVRT) during the progression of type 1 diabetes mellitus (F).
Values are means ± SEM. *P < 0.05 as compared to control at a given time. Open bars = Control
animals, n = 8; Closed bars = Diabetic animals, n = 8.
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Figure 2.3
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Figure 2.3. Regional assessment of systolic radial velocity, radial strain, and radial strain
rate via speckle-tracking based strain analysis in the short-axis. Comparison of control and
type 1 diabetic animals assessing systolic radial velocity, radial strain, and radial strain rate
between free wall and septal wall segments of the LV within a given week (A-F). Values are means
± SEM; *P < 0.05 as compared to control within a given week. Open bars = Control animals, n =
8; Closed bars = Diabetic animals, n = 8. Free wall segments include the anterior free wall, lateral,
posterior, and inferior free wall. Septal wall segments include the anterior septum and posterior
septum.
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Figure 2.4
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Figure 2.4. Regional assessment of systolic radial velocity, radial strain, and radial strain
rate via speckle-tracking-based strain analysis in the long-axis. Comparison of control and type
1 diabetic animals assessing systolic radial velocity, radial strain, and radial strain rate between
free wall and septal wall segments of the LV within a given week (A-F). Values are means ± SEM;
*P < 0.05 as compared to control within a given week. Open bars = Control animals, n = 8; Closed
bars = Diabetic animals, n = 8. Septal wall segments include the anterior base, anterior mid, and
anterior apex. Free wall segments include the posterior base, posterior mid, and posterior apex.
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Figure S2.1
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Figure S2.1 Representative Short- and Long-Axis Speckle-Tracking Based Strain Analyses.
Curvilinear data is generated for the global (average) strain of the heart, as is denoted by the black
line. Strain curves are also generated for each of the 6 anatomical segments of the heart. Speckletracking based strain analyses also give curvilinear data and phase circles to indicate the rate at
which all segments of the heart are moving. Representative images depicting radial strain
measurements in a control animal for the short- (A) and long-axes (B).
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Table 2.1. Conventional Echocardiographic Characteristics
Baseline

Week 1

Week 3

Week 6

Control

Diabetic

Control

Diabetic

Control

Diabetic

Control

Diabetic

418.4 ± 20.9

431.3 ± 14.8

484.0 ± 21.0

457.2 ± 11.9

503.2 ± 11.5

448.4 ± 17.5*

498.5 ± 12.1

494.5 ± 12.1

Stroke Volume (µL)

33.6 ± 2.5

33.0 ± 2.0

30.6 ± 2.4

29.6 ± 1.6

26.7 ± 1.2

25.8 ± 2.5

30.0 ± 1.9

21.0 ± 1.8*

Ejection Fraction (%)

75.3 ± 0.9

74.4 ± 1.4

72.3 ± 1.5

68.6 ± 1.5

71.2 ± 1.3

68.2 ± 3.0

70.9 ± 1.8

65.0 ± 1.7*

Fractional Shortening (%)

42.3 ± 1.0

42.3 ± 1.3

40.5 ± 1.3

37.5 ± 1.1

39.6 ± 1.2

37.4 ± 2.3

39.5 ± 1.7

34.4 ± 1.3*

Cardiac Output (mL/min)

14.0 ± 1.0

13.7 ± 1.3

14.9 ± 1.5

13.4 ± 0.7

13.2 ± 0.6

11.4 ± 1.1

14.9 ± 0.7

10.3 ± 1.0*

Diameter;systole (mm)

1.8 ± 0.1

1.7 ± 0.1

1.9 ± 0.1

2.1 ±0.1

1.8 ± 0.06

1.9 ± 0.2

2.0 ± 0.1

1.9 ± 0.1

Diameter;diastole (mm)

3.3 ± 0.1

3.2 ± 0.1

3.2 ± 0.1

3.3 ± 0.1

3.0 ± 0.05

3.1 ± 0.2

3.2 ± 0.1

2.9 ± 0.1*

Volume;systole (µL)

9.4 ± 0.1

10.6 ± 1.0

12.1 ± 1.2

15.3 ± 1.4

10.4 ± 0.8

13.7 ± 2.9

12.6 ± 1.5

11.5 ± 1.4

Volume;diastole (µL)

43.0 ± 3.4

40.4 ± 2.8

42.7 ± 3.3

44.9 ± 2.7

35.6 ± 1.4

39.5 ± 5.1

42.6 ± 3.2

32.5 ± 3.0*

Anterior Wall Thickness;systole
(mm)

1.7 ± 0.07

1.5 ± 0.09

1.4 ± 0.07

1.4 ± 0.03

1.5 ± 0.05

1.4 ± 0.04

1.5 ± 0.04

1.5 ± 0.03

Anterior Wall Thickness;diastole
(mm)

1.1 ± 0.05

1.1 ± 0.1

1.2 ± 0.04

1.0 ± 0.05*

1.2 ± 0.06

1.0 ± 0.06*

1.0 ± 0.03

0.9 ± 0.03*

Posterior Wall Thickness;systole
(mm)

1.1 ± 0.05

1.1 ± 0.08

1.1 ± 0.04

1.2 ± 0.05

1.3 ± 0.06

1.2 ± 0.05

1.4 ± 0.1

1.3 ± 0.05

1.0 ± 0.04

0.8 ± 0.03*

M-mode
Heart Rate (bpm)

Posterior Wall Thickness;diastole
0.8 ± 0.03
0.9 ± .0.4
1.1 ± 0.06
0.8 ± 0.05*
1.0 ± 0.03
0.8 ± 0.05*
(mm)
Values are shown as means±SEM. *P<0.05 Control versus Diabetic in a given week. 2-tailed Student’s t test. Control n=8, Diabetic n=8.
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Table 2.1. M-Mode Echocardiography Measurements. Values are shown as means±SEM.
*P<0.05 Control versus Diabetic in a given week. 2-tailed Student’s t test. Control n=8, Diabetic
n=8.
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Table 2.2. Average Short-Axis (SAX) Systolic and Diastolic Strain Echocardiographic Characteristics
Baseline
Week 1

Week 3

Week 6

SAX Strain Measurements at Systole
Circumferential Strain (%)
Circumferential SR (1/s)
Circumferential Rotation Rate (deg/s)
Circumferential Displacement (deg)
Radial Strain (%)
Radial SR (1/s)
Radial Velocity (cm/s)
Radial Displacement (mm)

Control
-32.9 ± 1.4
-13.7 ± 1.0
340.3 ± 27.5
4.0 ± 0.5
35.8 ± 2.0
12.8 ± 0.5
1.7 ± 0.07
0.57 ± 0.01

Diabetic
-33.6 ± 1.8
-13.8 ± 1.1
342.7 ± 34.6
3.6 ± 0.7
35.1 ± 2.9
12.8 ± 1.0
1.8 ± 0.1
0.61 ± 0.05

Control
-31.2 ± 1.1
-12.8 ± 0.6
280.4 ± 18.6
3.2 ± 0.4
37.4 ± 0.8
11.8 ± 0.6
1.6 ± 0.06
0.55 ± 0.02

Diabetic
-28.5 ± 0.5*
-11.6 ± 0.9
270.2 ± 15.7
3.3 ± 0.3
34.0 ± 1.3*
10.1 ± 0.4*
1.5 ± 0.05*
0.48 ± 0.02*

Control
-29.0 ± 0.9
-13.3 ± 0.5
320.2 ± 33.5
4.4 ± 0.8
35.5 ± 0.9
11.8 ± 0.3
1.6 ± 0.04
0.53 ± 0.01

Diabetic
-27.8 ± 1.4
-10.9 ± 0.8*
321.9 ± 24.2
4.7 ± 0.5
30.5 ± 2.1*
10.0 ± 0.4*
1.4 ± 0.07*
0.44 ± 0.01*

Control
-29.4 ± 1.5
-12.1 ± 0.4
318.9 ± 37.6
4.1 ± 0.6
33.7 ± 0.8
11.3 ± 0.6
1.6 ± 0.08
0.52 ± 0.02

Diabetic
-26.8 ± 1.8
-11.6 ± 1.5*
347.4 ± 31.0
4.5 ± 0.7
25.7 ± 1.8*
9.8 ± 0.4*
1.4 ± 0.09*
0.48 ± 0.04

SAX Strain Measurements at Diastole
Circumferential Strain (%)
Circumferential SR (1/s)
Circumferential Rotation Rate (deg/s)
Circumferential Displacement (deg)
Radial Strain (%)
Radial SR (1/s)
Radial Velocity (cm/s)
Radial Displacement (mm)

1.5 ± 0.8
24.3 ± 1.6
-391.5 ± 32.0
-3.8 ± 0.7
-2.4 ± 0.4
-15.8 ± 0.9
-2.7 ± 0.2
-0.007 ± 0.002

2.0 ± 0.5
22.9 ± 2.3
-408.3 ± 43.8
-3.8 ± 0.5
-3.9 ± 0.9
-16.6 ± 2.1
-2.4 ± 0.3
-0.008 ± 0.002

1.5 ± 0.2
16.4 ± 0.6
-362.7 ± 20.0
-3.8 ± 0.7
-2.3 ± 0.2
-13.3 ± 0.9
-1.9 ± 0.08
-0.01 ± 0.003

1.4 ± 0.3
17.5 ± 0.8
-382.4 ± 24.7
-2.5 ± 0.3
-1.6 ± 0.3*
-12.5 ± 0.5
-1.9 ± 0.1
-0.02 ± 0.3

2.0 ± 0.4
15.4 ± 0.4
-401.5 ± 26.3
-2.1 ± 0.5
-3.7 ± 0.5
-13.1 ± 0.3
-1.8 ± 0.07
-0.02 ± 0.005

2.1 ± 0.3
16.2 ± 1.1
-421.5 ± 32.6
-2.4 ± 0.4
-2.0 ± 0.4*
-11.2 ± 0.5*
-1.7 ± 0.1
-0.02 ± 0.003

1.9 ± 0.4
17.4 ± 1.2
361.0 ± 33.5
-2.8 ± 0.6
-3.8 ± 0.7
-13.7 ± 0.7
-2.0 ± 0.1
-0.02 ± 0.006

2.2 ± 0.2
17.3 ± 1.2
-395.5 ± 28.9
-3.0 ± 0.4
-2.0 ± 0.5*
-11.1 ± 0.9*
-1.7 ± 0.2
-0.02 ± 0.002

Values are shown as means±SEM. SR=Strain Rate. *P<0.05 Control versus Diabetic in a given week. 2-tailed Student’s t test. Control n=8, Diabetic n=8.
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Table 2.2. Global Short-axis Systolic and Diastolic Strain Measurements. Values are shown
as means±SEM. SR=Strain Rate. *P<0.05 Control versus Diabetic in a given week. 2-tailed
Student’s t test. Control n=8, Diabetic n=8.
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Table 2.3. Average Long-Axis (LAX) Systolic and Diastolic Strain Echocardiographic Characteristics
Baseline
Week 1
Control
Diabetic
Control
Diabetic
LAX Strain Measurements in Systole
Longitudinal Strain (%)
-20.2 ± 0.9
-21.4 ± 2.6
-17.9 ± 0.6
-16.7 ± 0.9
Longitudinal SR (1/s)
-8.3 ± 0.6
-7.5 ± 0.3
-7.1 ± 0.3
-6.7 ± 0.2
Longitudinal Velocity (cm/s)
0.9 ± 0.06
0.9 ± 0.08
0.8 ± 0.04
0.9 ± 0.03
Longitudinal Displacement (mm)
0.2 ± 0.02
0.2 ± 0.03
0.2 ± 0.01
0.2 ± 0.01
Radial Strain (%)
28.8 ± 2.4
26.9 ± 3.0
27.8 ± 1.2
22.0 ± 1.1*
Radial SR (1/s)
8.6 ± 0.8
8.1 ± 0.4
8.1 ± 0.2
6.7 ± 0.2*
Radial Velocity (cm/s)
1.5 ± 0.09
1.5 ± 0.1
1.3 ± 0.04
1.1 ± 0.04*
Radial Displacement (mm)
0.5 ± 0.02
0.5 ± 0.04
0.5 ± 0.01
0.4 ± 0.01*

Week 3
Control
-19.3 ± 1.0
-8.3 ± 0.3
1.0 ± 0.05
0.2 ± 0.02
30.1 ± 2.0
8.6 ± 0.4
1.5 ± 0.08
0.5 ± 0.02

Diabetic
-18.5 ± 0.3
-6.8 ± 0.1*
0.9 ± 0.01
0.2 ± 0.01
24.7 ± 1.0*
6.9 ± 0.3*
1.2 ± 0.05*
0.5 ± 0.01

Week 6
Control
-18.4 ± 1.2
-8.5 ± 0.6
0.9 ± 0.05
0.2 ± 0.02
27.7 ± 2.0
7.6 ± 0.2
1.4 ± 0.01
0.5 ± 0.01

Long-Axis Strain Measurements in Diastole
Longitudinal Strain (%)
2.3 ± 0.4
2.4 ± 1.0
1.3 ± .02
1.3 ± 0.3
1.1 ± 0.2
1.6 ± 0.3
1.1 ± 0.2
Longitudinal SR (1/s)
11.4 ± 0.7
11.5 ± 1.0
7.3 ± 0.2
7.9 ± 0.6
8.9 ± 0.6
9.8 ± 0.6
8.8 ± 0.6
Longitudinal Velocity (cm/s)
-1.0 ± 0.08
-1.1 ± 0.05
-0.9 ± 0.01
-1.0 ± 0.06
-1.0 ± 0.05
-0.9 ± 0.08
-0.9 ± 0.06
Longitudinal Displacement (mm)
-0.03 ± 0.01
-0.04 ± 0.008
-0.03 ± 0.004 -0.04 ± 0.008 -0.02 ± 0.005 -0.04 ± 0.005 -0.02 ± 0.006
Radial Strain (%)
-2.8 ± 0.4
-2.4 ± 0.5
-1.6 ± 0.1
-2.1 ± 0.3
-1.6 ± 0.3
-2.0 ± 0.3
-2.1 ± 0.6
Radial SR (1/s)
-10.9 ± 1.1
-10.5 ± 0.5
-9.9 ± 0.6
-9.1 ± 0.7
-10.2 ± 0.6
-10.2 ± 0.6
-10.0 ± 0.4
Radial Velocity (cm/s)
-2.0 ± 0.1
-2.0 ± 0.1
-1.5 ± 0.04
-1.4 ± 0.08
-1.6 ± 0.1
-1.6 ± 0.1
-1.6 ± 0.05
Radial Displacement (mm)
-0.01 ± 0.002 -0.008 ± 0.002 -0.01 ± 0.001 -0.01 ± 0.002 -0.02 ± 0.003 -0.01 ± 0.003 -0.02 ± 0.004
Values are shown as means±SEM. SR=Strain Rate. *P<0.05 Control versus Diabetic in a given week. 2-tailed Student’s t test. Control n=8, Diabetic n=8.
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Diabetic
-18.7 ± 1.0
-6.8 ± 0.4*
0.9 ± 0.05
0.2 ± 0.03
22.0 ± 0.6*
6.3 ± 0.3*
1.2 ± 0.05*
0.4 ± 0.02

0.9 ± 0.1
10.0 ± 1.0
-1.0 ± 0.05
-0.04 ± 0.008
-1.9 ± 0.4
-10.3 ± 0.5
-1.6 ± 0.09
-0.02 ± 0.003

Table 2.3. Global Long-Axis Systolic and Diastolic Strain Measurements. Values are shown
as means±SEM. SR=Strain Rate. *P<0.05 Control versus Diabetic in a given week. 2-tailed
Student’s t test. Control n=8, Diabetic n=8.
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Table S2.1

ICC
95%
confidence
interval
P value

Strain

EA Ratio

Ejection Fraction

Interobserver

Intraobserver
Test-Retest

Interobserver

Intraobserver
Test-Retest

Interobserver

Intraobserver
Test-Retest

0.88

0.82

0.89

0.99

0.87

0.85

(-0.19-0.99)

(-0.11-0.99)

(0.23-0.99)

(0.97-1.0)

(0.19-0.99)

(0.19-0.99)

.037

.038

0.14

.000

.026

.081
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Table S2.1. Interobserver and Intraobserver Test-Retest Reliability. Reliability tests for
Strain, EA Ratio and Ejection Fraction measurements. ICC = Intra-class Correlation Coefficient.
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Table S2.2. Average Short-Axis (SAX) and Long-Axis (LAX) Systolic Dyssynchrony
Baseline
LAX Dyssynchrony
Dyssynchrony (%) - Radial Velocity
Dyssynchrony (%) - Radial Strain
Dyssynchrony (%) - Radial Strain Rate

Week 1

Week 3

Week 6

Control

Diabetic

Control

Diabetic

Control

Diabetic

Control

Diabetic

0.3 ± 0.03
8.9 ± 1.1
1.6 ± 0.3

0.3 ± 0.03
7.6 ± 1.3
1.0 ± 0.1

0.4 ± 0.04
7.9 ± 0.8
2.0 ± 0.3

0.3 ± 0.02
9.0 ± 0.8
1.2 ± 0.1*

0.4 ± 0.03
8.2 ± 0.9
1.5 ± 0.2

0.3 ± 0.03
7.4 ± 0.8
1.2 ± 0.1

0.4 ± 0.02
8.5 ± 1.3
1.4 ± 0.1

0.3 ± 0.03*
8.6 ± 1.3
1.5 ± 0.2

0.2 ± 0.03
14.2 ± 2.4
3.1 ± 0.5

0.2 ± 0.03
10.9 ± 0.9
2.6 ± 0.3

SAX Dyssynchrony
Dyssynchrony (%) - Radial Velocity
0.2 ± 0.02
0.2 ± 0.03
0.2 ± 0.02
0.2 ± 0.02
0.2 ± 0.01
0.1 ± 0.02
Dyssynchrony (%) - Radial Strain
9.4 ± 1.3
12.3 ± 1.9
11.8 ± 2.4
8.7 ± 0.9
11.9 ± 1.2
12.1 ± 1.05
Dyssynchrony (%) - Radial Strain Rate
2.0 ± 0.2
3.0 ± 0.6
2.8 ± 0.5
1.6 ± 0.2*
2.8 ± 0.2
2.3 ± 0.3
Values are shown as means±SEM. *P<0.05 Control versus Diabetic in a given week. 2-tailed Student’s t test. Control n=8, Diabetic n=8.
Table S2.2. Average Short-Axis (SAX) and Long-Axis (LAX) Systolic Dyssynchrony
Baseline
Week 1
Week 3

Week 6

Control

Diabetic

Control

Diabetic

Control

Diabetic

Control

Diabetic

0.3 ± 0.03
8.9 ± 1.1
1.6 ± 0.3

0.3 ± 0.03
7.6 ± 1.3
1.0 ± 0.1

0.4 ± 0.04
7.9 ± 0.8
2.0 ± 0.3

0.3 ± 0.02
9.0 ± 0.8
1.2 ± 0.1*

0.4 ± 0.03
8.2 ± 0.9
1.5 ± 0.2

0.3 ± 0.03
7.4 ± 0.8
1.2 ± 0.1

0.4 ± 0.02
8.5 ± 1.3
1.4 ± 0.1

0.3 ± 0.03*
8.6 ± 1.3
1.5 ± 0.2

SAX Dyssynchrony
Dyssynchrony (%) - Radial Velocity
0.2 ± 0.02
0.2 ± 0.03
0.2 ± 0.02
0.2 ± 0.02
0.2 ± 0.01
0.1 ± 0.02
Dyssynchrony (%) - Radial Strain
9.4 ± 1.3
12.3 ± 1.9
11.8 ± 2.4
8.7 ± 0.9
11.9 ± 1.2
12.1 ± 1.05
Dyssynchrony (%) - Radial Strain Rate
2.0 ± 0.2
3.0 ± 0.6
2.8 ± 0.5
1.6 ± 0.2*
2.8 ± 0.2
2.3 ± 0.3
Values are shown as means±SEM. *P<0.05 Control versus Diabetic in a given week. 2-tailed Student’s t test. Control n=8, Diabetic n=8.

0.2 ± 0.03
14.2 ± 2.4
3.1 ± 0.5

0.2 ± 0.03
10.9 ± 0.9
2.6 ± 0.3

LAX Dyssynchrony
Dyssynchrony (%) - Radial Velocity
Dyssynchrony (%) - Radial Strain
Dyssynchrony (%) - Radial Strain Rate
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Table S2.2. Global Short-Axis and Long-Axis Systolic Dyssynchrony. Values are shown as
means±SEM. *P<0.05 Control versus Diabetic in a given week. 2-tailed Student’s t test. Control
n=8, Diabetic n=8.
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Abstract
Disruption of mitochondrial proteomic signature following diabetic insult is correlated
with inefficiency in the import of nuclear-encoded mitochondrial proteins that constitute greater
than 99% of the organelle’s proteome. This disruptive dynamic manifests in a spatially-dependent,
subcellular manner such that subsarcolemmal mitochondria display greater dysfunction and
proteome disruption during type 2 diabetes mellitus (T2DM), while interfibrillar mitochondria
display greater dysfunction and proteome disruption during type 1 diabetes mellitus (T1DM). The
goal of this study was to determine whether manipulation of the mitochondrial protein import
process through targeted restoration of a central constituent of its active motor, mitochondrial heat
shock protein 70 (mtHsp70), which displays loss in content that is correlated with the
mitochondrial subpopulation most impacted by a given diabetic phenotype, could rectify proteome
signature. Novel lines of cardiac-specific mtHsp70 transgenic mice were examined in T1DM and
T2DM models. MtHsp70 overexpression restored cardiac function in both diabetic models.
MtHsp70 overexpression restored deficiencies in nuclear-encoded mitochondrial protein import in
a subpopulation-specific manner leading to beneficial impact on proteome signature. Our results
suggest that restoration of a key import constituent of the active motor, mtHsp70, provides
therapeutic benefit to mitochondrial proteome disruption in both T1DM and T2DM leading to
attenuation of contractile dysfunction.
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Introduction
Cardiovascular complications are the leading cause of mortality among diabetic patients,
with the mitochondrion having a central role in the etiology of the dysfunction seen in the diabetic
heart (1-13). Proteomic evaluations have enabled an in-depth survey of potential contributors
involved in mitochondrial dysfunction associated with diabetes mellitus (DM) (1; 2; 8; 14-17).
Our laboratory has observed differential impacts on spatially-distinct mitochondrial
subpopulations during DM with cardiac interfibrillar mitochondria (IFM) being most impacted
during type 1 diabetes mellitus (T1DM) and subsarcolemmal mitochondria (SSM) being more
impacted during type 2 diabetes mellitus (T2DM) (1-5; 9; 10; 18-20).
Approximately 1500 proteins reside in the human mitochondrion, with 13 transcribed from
the mitochondrial genome and the remaining proteins encoded by the nuclear genome, requiring
significant contribution from extramitochondrial sources for the maintenance of a stable organelle
(21-24). Nuclear-encoded mitochondrial proteins require input from a coordinated import process
which includes mitochondrial heat shock protein 70 (mtHsp70) (21). Located in the mitochondrial
matrix, mtHsp70 is a central subunit of the presequence translocase-associated motor (PAM)
complex (21). Anchored to Tim44, mtHsp70 attaches to a translocating preprotein trapping and
pulling it through the inner mitochondrial membrane (IMM) in an ATP-dependent manner (25).
When mtHsp70 is altered, mitochondrial function is compromised with decrements noted in
nuclear-encoded mitochondrial protein import, decreased antioxidant defenses, increased
misfolding and degradation of proteins, along with increased cellular apoptosis (21). Neonatal rat
cardiomyocytes infected with an adenoviral vector expressing mtHsp70 were protected from
ischemia/reperfusion injury, potentially from an increase in nuclear-encoded antioxidant defense
proteins (26). MtHsp70 is dysregulated in the diabetic heart, with proteomic analyses showing
decreased mtHsp70 in the IFM during T1DM and the SSM during T2DM, suggesting that
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proteome disruption may be the result of loss from nuclear-encoded sources (2; 4). These
observations suggests that mtHsp70 loss may represent a central node of dysfunction precipitating
mitochondrial proteome disruption and linking DM-induced mitochondrial dysfunction across
both DM phenotypes. The goal of the current study was to determine whether mtHsp70
overexpression could restore nuclear-encoded mitochondrial protein import efficiency, leading to
preservation of the mitochondrial proteome in the T1DM IFM and T2DM SSM, and alleviate
cardiac contractile dysfunction.
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Research Design and Methods
MtHsp70 Transgenic Mouse Development
Animal experiments in this study conformed to the National Institutes of Health Eighth
Edition Guidelines for the Care and Use of Laboratory Animals and were approved by the West
Virginia University Care and Use committee. Cardiac-specific mtHsp70 transgenic mouse lines
were generated using a chimeric transgene consisting of the human HSPA9 gene (mtHsp70)
inserted into the plasmid pJG/Alpha MHC vector containing an alpha-myosin heavy-chain
(αMHC) promoter (a kind gift from Dr. Jeffrey Robbins) (27) (Figure 3.2A). The HSPA9 gene
consists of a 5’ mitochondrial targeting sequence (ATG) and the human mtHsp70 cDNA, which
was inserted into the Sal1 cloning site of the pJG/Alpha MHC vector via sticky-end and blunt-end
ligation of Xho1 and HindIII, as a fragment of approximately 3001 bp (Figure 3.2A). The
chimeric transgene was cut out of the plasmid by Not1 digestion, purified, and used to generate
transgenic mice by the Mouse Transgenic and Gene Targeting Core at Emory University as
described previously (1; 9; 19). All control and transgenic mice were generated using an FVB
background, and experimental procedures were performed on animals of approximately 12-15weeks-old for T1DM and 20-22-weeks-old for T2DM.

MtHsp70 Transgenic Mouse Screening
To verify the chimeric transgene presence in the genome, DNA from 3-week-old mice was
isolated from tail clips using Allele-In-One Mouse Tail Direct Lysis Buffer (Allele Biotechnology,
San Diego, CA) per manufacturer’s instructions and screened as previously described (1; 9; 19).
Four transgenic mouse lines were generated, with two high expressing transgenic lines (20-22
cycle number) and two low expressing transgenic lines (26-28 cycle number). All experimentation
was performed on line 1 (Figure 3.2B).
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T1DM Induction
Four groups were utilized for the type 1 studies: control, mtHsp70, T1DM, and mtHsp70
T1DM. T1DM was induced in 6-week-old, mixed sex control and mtHsp70 mice using multiple
low-dose streptozotocin (Sigma, St. Louis, MO) injections as previously described (1; 2; 5; 9; 1820; 28). Confirmation of hyperglycemia was performed by measuring blood glucose (Contour
Blood Glucose test strips; Bayer, Mishawaka, IN) one week post-injection, with levels >250
mg/dL considered diabetic. Animals were maintained for 6 weeks in a hyperglycemic state,
echocardiography performed and then euthanized for experimentation.

Ovarian Transplantation Procedure
A db/db, mtHsp70 transgenic mouse line was generated using an ovarian transplantation
procedure developed in our laboratory. Because homozygous db/db mice are unable to breed,
generation of db/db, transgenic mice is cumbersome due to the need for extensive breeding with
unfavorable Mendelian genetics. Briefly, a db/db donor mouse was euthanized by cervical
dislocation, an incision made in the abdominal wall, followed by the exteriorization of the ovarian
fat pad where the ovaries were removed for future implantation into recipient mice.
The recipient mouse was maintained under a surgical plane of anesthesia, an incision made
in the abdominal cavity and the ovarian fat pad exteriorized. The ovarian bursa was incised
cranially at the junction of the bursa and the fat pad to enable access to the ovary. The donor ovary
was placed on top of the ovarian blood vessels and the bursa retracted into its original position.
The fat pad and ovary were returned into the abdominal cavity and the incision in the abdominal
wall closed. Removal of the contralateral ovary was performed after a successful ovarian
transplantation.
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MtHsp70 db/db Transgenic Mouse Screening
The developmental strategy for ovarian transplantation and breeding can be seen in Figure
3.2E. Briefly, ovaries from a homozygous db/db female mouse were excised and then implanted
into an immunohistocompatible recipient mouse. This recipient mouse was bred with a mouse
heterozygous for both the db/db and mtHsp70 genotype, increasing the probability that the
offspring would have the homozygous db/db mutation and the mtHsp70 transgene. MtHsp70
genotyping was completed as described above (Figure 3.2E). To determine whether the offspring
possessed the db/db mutation, DNA was amplified via PCR for the Leprdb locus followed by allelic
discrimination analysis to identify Leprdb/db homozygous (db/db), Leprdb/- heterozygous (db/-) or
control (-/-) offspring (Figure 3.2E). Fluorometric probes designed by our laboratory were used
to detect the db/db point mutation via allelic discrimination. The sequence containing the mutation
was tagged with FAM, while the normal sequence was tagged with HEX enabling assessment of
whether the animals DNA contained 2 HEX tags (-/-), a HEX tag and a FAM tag (db/-), or 2 FAM
tags (db/db) (Figure 3.2E). DNA from known db/db, db/-, and -/- mice obtained from and
validated by Jackson Laboratory (Bar Harbor, ME) were included as internal controls. Once
appropriate genotypes were obtained, animals were aged to 20-22-weeks-old, echocardiography
performed and euthanized for experimentation.

Echocardiography
Echocardiography and speckle-tracking based strain imaging analyses were performed as
previously described using the Vevo 2100 Imaging analysis software (Visual Sonics, Toronto,
Canada) (1; 9; 28; 29).
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Preparation of Individual Mitochondrial Subpopulations
Cardiac mitochondrial subpopulations were isolated as previously described following the
methods of Palmer et al. (30) with minor modifications by our laboratory (1; 2; 4; 5; 9; 18; 19; 29).
Mitochondrial pellets were resuspended in the appropriate buffer depending upon assay. Protein
concentrations were determined by the Bradford method with bovine serum albumin as a standard
(31), while mitochondrial number was determined by flow cytometry.

Determination of Mitochondrial Number by Flow Cytometry
Mitochondrial number was determined using Sphero AccuCount Blank Particles, 2.0 µm
(Spherotech Inc., Lake Forest, IL). An aliquot of mitochondria were diluted in sucrose buffer
(1:2,500) and subsequently stained with Mitotracker Deep Red 633 (Invitrogen, Carlsbad, CA),
resulting in event rates below 1,000 events/s using FACSDiva 8.0 software (BD Biosciences, San
Jose CA) on an LSRFortessa equipped with a FSC PMT (BD Biosciences) in the WVU Flow
Cytometry and Single Cell Core Facility. Events were determined as mitochondria by thresholding
on Mitotracker Deep Red 633 and each sample was run for 1 minute at low speed. Fifty µL of
Sphero AccuCount blank particles were added to 450 µL of sucrose and run on the flow cytometer
for 1 minute to obtain the number of events. Mitochondrial number was calculated per
manufacturer’s instructions.

iTRAQ Labeling and Mass Spectrometry Analyses
Pooled IFM (n = 8) from T1DM and mtHsp70 T1DM mice, as well as pooled SSM (n = 8)
from T2DM and mtHsp70 T2DM mice were prepared as previously described (1; 2; 4). Samples
were labeled with iTRAQ reagents following the manufacturer’s protocol (Applied Biosystems,
Foster City, CA) and combined to create a 400 µg pooled protein digest with equal fractions of
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labeled samples. The fractions were submitted for LC-MALDI TOF/TOF mass spectral analysis
for protein identification, characterization, and differential expression analysis as previously
described (2; 4) with slight modifications. Briefly, a Q Exactive MS (Thermo Scientific, San Jose,
CA) was utilized with Xcalibur 3.0 software. The resulting spectra were analyzed using ABI
ProteinPilot software 4.0 (Applied Biosystems, Foster City, CA).

Ingenuity Pathway Analyses
Proteomic data was integrated into the Ingenuity Pathway Analysis (IPA) software to
establish

associations

between

changing

mitochondrial

protein

constituents

and

upstream/downstream effects on cellular pathways. The “Mitochondrial Dysfunction Metabolic
Pathway” was generated through the use of QIAGEN’s IPA (www.qiagen.com/ingenuity) and
used as the basic model for protein associations. Changes in protein expression are presented for
two separate mitochondrial populations: 1) mtHsp70 T2DM SSM in relation to T2DM SSM and
2) mtHsp70 T1DM IFM in relation to T1DM IFM. All changes are depicted as increasing,
decreasing, or sustained proteomic expression in the mtHsp70 diabetic mice compared to DM.

Mitochondrial Protein Import
The fusion protein pAcGFP1-Mito (Clonetech Laboratories, Mountain View, CA)
containing the precursor subunit VIII of human cytochrome c oxidase and the green fluorescent
protein (GFP) from Aequorea coerulescens (AcGFP1) were cloned into pIVEX2.3d (Roche
Applied Science, Indianapolis, IN) as previously described (1; 2). Using the S30 T7 protein
expression system (Promega, Madison, WI) in vitro transcription/translation of mitoGFP1 was
performed per manufacturer’s instructions (1; 2). The mitoGFP1 lysate was used to assess the
protein import process and mitochondrial protein import performed as described (32) with
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modifications by our laboratory (1; 2). Briefly, mitochondria were counted by flow cytometry,
MitoGFP1 lysate added to the samples and protein import performed and assessed at time intervals
of 30 s, 1 and 2 mins at 25°C (1; 2).

Human Patient Samples
The West Virginia University Institutional Review Board and Institutional Biosafety
Committee approved all protocols. Patient demographics have been described and characterized
as non-diabetic, T1DM or T2DM based on a previous diagnosis of DM (3; 9).

Western Blot Analyses
SDS-PAGE was run on 4-12% gradient gels, as previously described (1; 2; 4; 9; 10; 29;
33). For assessment of protein content overexpression and mitochondrial protein import, 100
million intact mitochondria were loaded as determined by flow cytometry. For assessment of
protein content in human samples and tissue homogenates, equal amounts of protein were loaded
as determined above by the Bradford method (31). Further, assessment of protein loading control
was done by utilizing a COXIV antibody and Ponceau S solution (Sigma, St. Louis, MO). Relative
amounts of mtHsp70 and COXIV were assessed using the following primary antibodies: antimtHsp70 (Stressgen, Ann Arbor, MI) and anti-COXIV (Cell Signaling Technology, Danvers,
MA). The secondary antibodies used in the analyses were goat anti-mouse IgG horseradish
peroxidase (HRP) conjugate (Pierce Biotechnology, Rockford, IL) for mtHsp70 and goat antirabbit IgG HRP conjugate (Cayman Chemical, Ann Arbor, MI) for COXIV. Nuclear-encoded
mitochondrial protein import blots were probed with the primary anti-GFP mouse monoclonal
antibody (Clonetech Laboratories, Mountain View, CA) followed by the secondary antibody anti-
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mouse IgG horseradish peroxidase conjugate (Pierce Biotechnology, Rockford, IL). Densitometry
analyses using Image J software, were performed as previously described (1; 2; 9; 19; 20; 29).

Statistics
All data are presented as mean±standard error of the mean (SEM). Data were analyzed
using a One-Way Analysis of Variance (ANOVA) with the Bonferroni post-hoc test to determine
significant differences between groups (GraphPad Prism 5 Software, La Jolla, CA). When
differences in variability between groups was noted by Bartlett’s test for equal variances, a
Kruskal-Wallis analysis was utilized with the Dunn’s multiple comparison tests to assess
differences between groups. When appropriate, a Student’s t-test was used. In all instances, P≤0.05
was considered significant.
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Results
Evaluation of Human Patient Samples
MtHsp70 was assessed in isolated mitochondrial subpopulations from atrial appendage
tissue from non-diabetic, T1DM and T2DM patients. Our data revealed decreased mtHsp70
protein content in the IFM of T1DM patients as compared to the non-diabetic patients; however,
it did not reach significance (P = 0.1) (Figure 3.1B). No changes in protein expression level were
found in the SSM (Figure 3.1A). Conversely, the T2DM SSM showed decreased mtHsp70, with
no changes noted in the IFM (Figure 3.1C-D).

MtHsp70 Transgenic Mice Characterization
Tissue homogenates were tested for mtHsp70 protein expression. MtHsp70 transgenic
mice possessed higher levels of mtHsp70 protein solely in cardiac tissue, with no changes in any
other tissue type (Figure 3.2C). To determine whether mtHsp70 expression was increased in the
mitochondrion, we assessed mtHsp70 protein levels in cardiac mitochondrial subpopulations and
observed a significant increase in its expression in both the SSM and IFM (Figure 3.2D).

Impact of T1DM and T2DM on mtHsp70
T1DM IFM displayed decreased expression of mtHsp70; however, overexpression of
mtHsp70 restored the protein expression (Figure 3.3B). SSM were not altered as a result of T1DM
(Figure 3.3A). In the T2DM heart, mtHsp70 protein levels were decreased in the SSM, and
mtHsp70 overexpression was able to restore these levels, while the IFM were not impacted (Figure
3.3C-D).
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Cardiac Contractile Function
Ejection fraction (EF), fractional shortening (FS) and cardiac output were significantly
decreased in T1DM mice as compared to controls, but mtHsp70 restored these decrements (Table
3.1). Speckle-tracking based strain echocardiography provided an additional measure of left
ventricular (LV) function, specifically longitudinal strain (LS) and longitudinal strain rate (LSR)
(34; 35). In agreement with our previous study, we found no changes in LS in the T1DM mice as
compared to the controls (Table 3.1) (28). Decrements in the T1DM LSR measurement was
observed and subsequently restored with mtHsp70 overexpression (Table 3.1) (28). Further, in the
LSR measure, we assessed the impact of T1DM on the six segments that make up the LV: Posterior
Apex (PA), Posterior Mid (PM), Posterior Base (PB), Anterior Apex (AA), Anterior Mid (AM)
and Anterior Base (AB). We found a significant decrease in the PA and AA regions of the T1DM
animals as compared to controls, with the PA regional function showing a trending (P=0.06)
restoration with mtHsp70 overexpression (Table 3.1).
Heart rate, EF and FS were significantly decreased in db/db mice versus control; however,
mtHsp70 restored these measures (Table 3.2). Further, diametric and volumetric changes in the
LV during systole were increased during T2DM, which were attenuated with mtHsp70
overexpression (Table 3.2). LS and LSR were significantly decreased in the db/db animals as
compared to their controls and mtHsp70 overexpression led to the restoration of these
measurements in the face of T2DM (Table 3.2). In the LS regional measurements, the PB, PA and
AM regions were detrimentally impacted in the db/db animals, with mtHsp70 overexpression
providing restoration to the PB and PA regions (Table 3.2). LSR regional analyses revealed
decreased function in the PA, PB, AB, AM, and AA regions in the db/db animals, with mtHsp70
overexpression preserving function in the PB, PA, and AM regions (Table 3.2).
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Mitochondrial Protein Import
Analyses of protein import efficiency in the T1DM SSM revealed no differences between
any of the groups at 30s, 1 min and 2 min time points (Figure 3.4A). In contrast, T1DM IFM
displayed a significant decrease in protein import efficiency at 2 mins, which was restored with
mtHsp70 overexpression (Figure 3.4B). Conversely, in the T2DM SSM, protein import efficiency
at 30s, 1 min and 2 min were decreased relative to control (Figure 3.4C). MtHsp70 overexpression
restored protein import efficiency in the T2DM SSM back to that of control levels, while T2DM
IFM displayed no import deficiencies (Figure 3.4C-D).

MtHsp70 T1DM Proteomic Changes in IFM
During T1DM, overexpression of mtHsp70 impacted protein expression of the ETC
differentially. The majority of proteins were increased in complexes I, III, IV and the F0 component
of complex V, while the F1 complex was decreased (Figure 3.5A). Proteins involved in fatty acid
oxidation were decreased in mtHsp70 T1DM animals, while glucose oxidation components were
increased. These data suggest that proteins involved in glucose oxidation may have been increased
in response to the enhanced glycemic milieu present during T1DM, despite an inability to utilize
glucose reliably in this model (Figure 3.5A). Assessment of the percentage of proteomic
alterations within each subcompartment of the mitochondria during T1DM revealed alterations in
IFM proteins residing within the IMM (46%) and the mitochondrial matrix (40%) (Figure 3.5B).
Of the proteins that were increased because of mtHsp70 overexpression, we found approximately
47% located in the IMM and 40% in the mitochondrial matrix (Figure 3.5C).
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MtHsp70 T2DM Proteomic Changes in SSM
During T2DM, proteins involved in the ETC were increased in complexes I, III, IV, and V
(F0 and F1 complexes) with mtHsp70 overexpression (Figure 3.6A). Enzymes involved in the
phosphorylation of glucose and initiation of glucose metabolism pathways were decreased, while
proteins essential in fatty acid metabolism were increased in the SSM of mtHsp70 db/db animals
suggesting utilization of the substrates available in abundance (fatty acids) (Figure 3.6A).
Assessment of the percentage of proteomic alterations within each subcompartment of the
mitochondria during T2DM revealed alterations in SSM proteins residing within the IMM (46%)
and the mitochondrial matrix (45%). Of the proteins that were increased via mtHsp70
overexpression, 53% were located in the IMM, while 47% were in the matrix (Figure 3.6C).
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Discussion
Mitochondrial dysfunction is central to the etiology of cardiovascular complications
observed in diabetic patients (1-13). Our laboratory has reported that mitochondrial subpopulations
are differentially affected based on the type of DM, with the SSM being more negatively impacted
during T2DM and the IFM being more substantially impacted during T1DM (1-5; 9; 10; 18). The
mitochondria are essential for a variety of cellular processes including energy metabolism,
oxidative phosphorylation, and ATP synthesis, all of which depend on nuclear-encoded proteins.
Thus, the process of nuclear-encoded mitochondrial protein import is critical to the overall
function of the mitochondrion. Since the nucleus encodes for the vast majority of proteins in the
mitochondrion (>99%), a complex mechanism of translocation through the mitochondrial
membranes occurs in order for proteins to enter a particular mitochondrial subcompartment and
perform their specific functions, ultimately allowing for a properly functioning mitochondrion
(36). Previous studies from our laboratory revealed a decrease in nuclear-encoded mitochondrial
protein import efficiency in the T1DM IFM (1; 2).
We speculated that decrements in nuclear-encoded mitochondrial protein import was due
to decreased mtHsp70 content, which was found during proteomic analyses (2; 4). As a result, the
current study was designed to test the hypothesis that overexpression of mtHsp70 would increase
the efficiency of nuclear-encoded mitochondrial protein import. MtHsp70 is an essential
component of the PAM complex, anchored to Tim44 within the mitochondrial matrix and serves
to “trap” and “pull” the translocating preprotein through the IMM in an ATP-dependent manner
(25). Our results revealed decrements at the 2 min time point in the T1DM IFM, with no changes
noted at 30s and 1 min; however, the T2DM SSM displayed changes at all time points. These
differences may be a function of the distinct etiology and duration of the pathologies. The db/db
animals become obese and show elevated plasma insulin at approximately 3-weeks-old, with
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hyperglycemia occurring as early as 4-weeks-old (37), thus these animals endure the diabetic
milieu throughout the course of the 16-week study, while T1DM is induced by pancreatic β-cell
destruction and manifested in the animal for 6 weeks. While it has been shown that mitochondrial
subpopulations are differentially impacted by these distinct pathologies, it is unknown how aging
and exposure to the diabetic environment for differing times impacts mitochondrial
subpopulations. In either case, we observed that overexpression of mtHsp70 allowed for the
restoration of the mitochondrial import process in the T1DM IFM and T2DM SSM regardless of
the differences in pathology etiology or disease duration.
An important implication for nuclear-encoded mitochondrial protein import is its impact
on the mitochondrial proteome. During DM, proteomic analyses have revealed alterations in
mitochondrial functional processes such as oxidative phosphorylation and ATP synthesis, which
could result from decrements in nuclear-encoded mitochondrial protein import (1; 2; 8; 14-16).
Interestingly, during DM, mtHsp70 was affected with decreases in the T2DM SSM and T1DM
IFM, which is consistent in both animal and human patient models (2-4). MtHsp70 overexpression
increased proteins involved in ETC complexes, along with the transporter protein Slc25a3,
independent of diabetic type and mitochondrial subpopulation. Proteomic analyses revealed a
differential impact on β-oxidation with mtHsp70 overexpression during T1DM and T2DM, with
fatty acid metabolism being decreased in the mtHsp70 T1DM IFM, while showing increases in
the mtHsp70 T2DM SSM. These findings suggest that during T1DM and T2DM, mtHsp70
overexpression preserves the import of proteins that are required for processing the substrates that
are most abundant despite an inability to do so. Proteomic surveys suggest that approximately 67%
of mitochondrial proteins reside in the mitochondrial matrix, followed by 21% located within the
IMM, and 6% and 4% residing in the IMS and OMM, respectively (38; 39). Independent of
diabetic type and mitochondrial subpopulation, the IMM and matrix were the most predominantly
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affected mitochondrial subcompartments for proteomic alterations, with mtHsp70 overexpression
revealing targeted restoration within the locations. This was particularly relevant for the IMM
which displayed the largest benefit in terms of protein restoration from mtHsp70 overexpression,
which may be a function of the greater number of proteins lost in this region during diabetic insult.
Without properly functioning mitochondria and ample ATP production, cardiac contractile
dysfunction can occur (1; 2; 4; 5; 37). In the current study, we observed decreases in LV pump
function as reflected by changes in EF and FS, along with volume and diametric changes during
systole in both the T1DM and T2DM hearts. Overexpression of mtHsp70 restored these measures
back to that of control. Analyses using the speckle-tracking based strain software to evaluate global
and regional LS and LSR were performed to provide a more complete picture for the deficits noted
in the LV. Literature suggests that LS provides a good correlation to LVEF, a measure that is
decreased during both T1DM and T2DM (4; 28; 35; 40). Decrements in LS and LSR during both
T1DM and T2DM provide complementary evidence of LV systolic dysfunction with subsequent
restoration via mtHsp70 overexpression. Evaluation of regional differences revealed
commonalities between LSR in T1DM and T2DM with decrements in the apex regions, in which
mtHsp70 overexpression was able to restore the PA region independent of DM type. Further,
mtHsp70 overexpression provided more regional benefit during T2DM. This restoration
potentially occurred due to a positive impact on mitochondrial functionality through increased
efficiency of nuclear-encoded mitochondrial proteins, which would be critical for stabilization of
the mitochondrial proteome in the face of pathological insult. It is interesting to note that ATP
production from each subpopulation is likely critical for efficient cardiac contractile function,
indicating that both may play a role in preserving cardiac function during pathological states.
Further, an interconnected mitochondrial network through the mitochondrial reticulum could
provide a pathway for energy distribution within the cardiomyocyte (41; 42), thus allowing for the
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restoration of cardiac contractile function by mtHsp70, despite different mitochondrial
subpopulations being affected.
In conclusion our data reveal for the first time, several key findings: 1) disruption of
mitochondrial proteomic signature in the spatially-distinct subpopulation most impacted by a given
diabetic phenotype is linked to an inability to efficiently import nuclear-encoded mitochondrial
proteins; 2) overexpression of mtHsp70 levels provides restoration of protein import efficiency
and ultimately proteomic signature in the spatially-distinct subpopulation most impacted by a
given diabetic phenotype; 3) overexpression of mtHsp70 provides cardiac contractile benefit in
both T1DM and T2DM. Taken together, these findings suggest that restoration of a key import
constituent of the active protein import motor provides therapeutic benefit to mitochondrial
proteome signature, highlighting the critical role of this mitochondrial process.
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Figure 3.1

203

Figure 3.1. Mitochondrial heat shock protein 70 (mtHsp70) levels in human atrial
appendage. (A) Representative Western blot analysis and quantification of SSM and (B) IFM in
cardiac mitochondria isolated from human atrial appendage in ND and T1DM patients. CoxIV and
Ponceau staining were used as loading controls. (C) Representative Western blot analysis and
quantification of SSM and (D) IFM in cardiac mitochondria isolated from human atrial appendage
in ND and T2DM patients. CoxIV and Ponceau staining were used as loading controls. Values are
expressed as means ± SEM. *P ≤ 0.05 for ND vs DM.
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Figure 3.2
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Figure 3.2. MtHsp70 transgenic mouse construction. (A) Schematic of the generation of
mtHsp70 transgenic mice. (B) Verification of transgene presence using real-time PCR. (C)
Representative Western blot analysis of mtHsp70 protein expression in isolated tissues from
control and mtHsp70 transgenic mice. CoxIV was used a loading control. (D) Representative
Western blot analysis and quantification of cardiac mitochondrial subpopulations from control and
mtHsp70 transgenic mice loaded per mitochondria. (E) Schematic representation of breeding
strategy for mtHsp70 db/db mice, verification of transgene presence using real-time PCR and
allelic discrimination screening. C = control; Tg = transgenic. Values are expressed as means ±
SEM. *P ≤ 0.05 for control vs. transgenic.
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Figure 3.3
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Figure 3.3. MtHsp70 expression during DM. (A) Representative Western blot analysis and
quantification of mtHsp70 protein expression in SSM of control, T1DM, and mtHsp70 T1DM
mice loaded per mitochondria. (B) Representative Western blot analysis and quantification of
mtHsp70 protein expression in IFM of wild-type, T1DM, and mtHsp70 T1DM mice loaded per
mitochondria. (C) Representative Western blot analysis and quantification of mtHsp70 protein
expression in SSM of wild-type, T2DM, and mtHsp70 T2DM mice loaded per mitochondria. (D)
Representative Western blot analysis and quantification of mtHsp70 protein expression in IFM of
wild-type, T2DM, and mtHsp70 T2DM mice loaded per mitochondria. Ctl = control; DM =
diabetes mellitus; Tg = transgenic; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes
mellitus. Values are expressed as means ± SEM. *P ≤ 0.05 for T1DM vs other groups; †P ≤ 0.05
for mtHsp70 T2DM vs other groups.
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Figure 3.4
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Figure 3.4. Mitochondrial protein import during DM. (A) Effect of T1DM and mtHsp70
overexpression on MitoGFP1 import into the SSM and (B) IFM at 30 seconds, 1 minute and 2
minutes. (C) Effect of T2DM and mtHsp70 overexpression on MitoGFP1 import into the SSM and
(D) IFM at 30 seconds, 1 minute and 2 minutes. T1DM = type 1 diabetes mellitus; T2DM = type
2 diabetes mellitus. Values are expressed as means ± SEM. *P ≤ 0.05 for control vs. diabetes
mellitus.
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Figure 3.5
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Figure 3.5. Mitochondrial proteome changes during T1DM with mtHsp70 overexpression.
(A) IFM from mtHsp70 T1DM mice and T1DM mice representative network connections
constructed from the Ingenuity Pathway Analysis (IPA) software database. Arrow heads indicate
proteins acting on/being acted upon within a specific pathway. Coloring is indicative of increasing
or decreasing protein concentration in the mtHsp70 T1DM mouse model compared to the T1DM
mice. Color key: light green = trending increase in expression, dark green = significant increase in
expression, light red = trending decrease in expression, dark red = significant decrease in
expression, gray = protein constituents not changing in the proteomic analysis. (B) Approximate
percentages of protein contents altered and their locales between the T1DM IFM vs. mtHsp70
T1DM IFM. (C) Approximate percentages of proteins restored and their locales with
overexpression of mtHsp70 during T1DM. ETC = electron transport chain; OMM = outer
mitochondrial membrane; IMS = intermembrane space; IMM = inner mitochondrial membrane.
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Figure 3.6

213

Figure 3.6. Mitochondrial proteome changes during T2DM with mtHsp70 overexpression.
(A) SSM from mtHsp70 db/db and db/db mice representative network connections constructed
from the Ingenuity Pathway Analysis (IPA) software database. Arrow heads indicate proteins
acting on/being acted upon within a specific pathway. Coloring is indicative of increasing or
decreasing protein concentration in the mtHsp70 db/db mouse model compared to db/db mice.
Color key: light green = trending increase in expression, dark green = significant increase in
expression, light red = trending decrease in expression, dark red = significant decrease in
expression, gray = protein constituents not changing in the proteomic analysis. (B) Approximate
percentages of protein contents altered and their locales between the db/db SSM vs. mtHsp70
db/db SSM. (C) Approximate percentages of proteins restored and their locales with
overexpression of mtHsp70 during T2DM. TCA = tricarboxylic acid cycle; OMM = outer
mitochondrial membrane; IMM = inner mitochondrial membrane.
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Table 3.1. T1DM Echocardiographic Measurements
Conventional Echocardiographic Assessment
Control

T1DM

mtHsp70

mtHsp70 T1DM

531.2 ± 39.5

465.2 ± 19.5

526.6 ± 18.7

430.6 ± 19.7

Stroke Volume (µL)

34.3 ± 3.9

26.2 ± 1.3

33.4 ± 3.6

35.6 ± 1.8

Ejection Fraction (%)

76.6 ± 2.2

64.5 ± 1.9*

78.2 ± 2.2

76.0 ± 1.7

Fractional Shortening (%)

44.4 ± 1.9

34.4 ± 1.4*

46.5 ± 2.2

44.1 ± 1.7

Cardiac Output (mL/min)

28.6 ± 3.5

13.5 ± 1.0*

20.7 ± 2.9

26.3 ± 3.0

Diameter;systole (mm)

1.8 ± 0.2

2.1 ± 0.1

1.7 ± 0.1

1.9 ± 0.1

Diameter;diastole (mm)

3.2 ± 0.2

3.2 ± 0.1

3.1 ± 0.2

3.4 ± 0.1

Volume;systole (µL)

11.0 ± 1.7

15.4 ± 1.5

9.2 ± 1.4

12.0 ± 1.4

Volume;diastole (µL)

41.9 ± 3.7

42.5 ± 2.7

36.1 ± 3.0

48.2 ± 3.0

-18.26 ± 1.3

-18.24 ± 0.9

-6.98 ± 0.5

-6.50 ± 0.3

-9.9 ± 1.4

-8.3 ± 1.0

-8.1 ± 0.6

-8.5 ± 0.7

Heart Rate (bpm)

†¥

†¥

¥

†

†

#

#

Speckle-tracking Based Strain Echocardiographic Assessment
¥

Longitudinal Strain (%)

-16.4 ± 1.0

-15.43 ± 0.8

Longitudinal Strain Rate (1/s)

-6.0 ± 0.3

-5.12 ± 0.2*

Posterior Base (1/s)

-10.5 ± 1.3

-11.1 ± 0.7

Posterior Mid (1/s)

-7.9 ± 1.0

-8.6 ± 0.7

Posterior Apex (1/s)

-13.8 ± 0.9

-9.38 ± 0.7*

-14.0 ± 1.1

-12.60 ± 1.3

Anterior Base (1/s)

-9.1 ± 1.3

-9.4 ± 1.1

-11.5 ± 1.8

-10.0 ± 1.0

Anterior Mid (1/s)

-10.3 ± 1.6

-9.2 ± 0.6

-8.7 ± 0.7

-8.5 ± 0.6

Anterior Apex (1/s)

-13.3 ± 1.6

-8.8 ± 0.4*

-11.6 ± 0.8

-9.5 ± 0.9

†¥

¥

†

†

†

#

Values are shown as means±SEM. *P<0.05 Control versus T1DM animals; P<0.05 T1DM versus mtHsp70 animals; P<0.05
¥

mtHsp70 T1DM versus mtHsp70 animals; P<0.05 T1DM versus mtHsp70 T1DM animals. 1-way ANOVA with Bonferroni’s
Multiple Comparison Post-hoc Test.
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Table 3.1. Conventional and Speckle-Tracking Based Strain Echocardiographic
Measurements During T1DM. Values are shown as means±SEM. *P<0.05 Control versus
†

#

T1DM animals; P<0.05 T1DM versus mtHsp70 animals; P<0.05 mtHsp70 T1DM versus
¥

mtHsp70 animals; P<0.05 T1DM versus mtHsp70 T1DM animals. 1-way ANOVA with
Bonferroni’s Multiple Comparison Post-hoc Test.
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Table 3.2. T2DM Echocardiographic Measurements
Conventional Echocardiographic Assessment
Control

T2DM

mtHsp70

mtHsp70 T2DM

523.3 ± 16.5

430.3 ± 16.6*

500.3 ± 9.3

459.9 ± 38.8

Stroke Volume (µL)

27.3 ± 3.7

28.3 ± 2.8

27.9 ± 1.8

35.3 ± 4.7

Ejection Fraction (%)

77.6 ± 1.7

65.4 ± 1.7*

†¥

82.7 ± 1.5

82.9 ± 2.3

Fractional Shortening (%)

42.3 ± 1.6

35.0 ± 1.3*

†¥

50.4 ± 1.7

50.9 ± 2.4

Cardiac Output (mL/min)

13.7 ± 1.5

12.0 ± 1.2

13.9 ± 0.8

16.0 ± 2.0

Diameter;systole (mm)

1.6 ± 0.1

2.1 ± 0.1

†

1.5 ± 0.1

1.6 ± 0.2

Diameter;diastole (mm)

3.0 ± 0.2

3.3 ± 0.2

2.9 ± 0.1

3.2 ± 0.2

Volume;systole (µL)

6.7 ± 1.5

15.7 ± 2.3*

5.9 ± 0.7

8.0 ± 2.3

Volume;diastole (µL)

30.8 ± 5.4

44.0 ± 4.9

33.8 ± 2.3

43.3 ± 7.0

-17.69 ± 1.6

-17.68 ± 1.0

Heart Rate (bpm)

†

Speckle-tracking Based Strain Echocardiographic Assessment
¥

Longitudinal Strain (%)

-18.2 ± 0.8

-13.97 ± 1.0*

Posterior Base (%)

-18.4 ± 2.4

-10.5 ± 1.8*

-14.4 ± 3.5

-19.5 ± 3.1

Posterior Mid (%)

-13.8 ± 1.8

-19.0 ± 1.6

-20.0 ± 4.3

-15.8 ± 2.4

Posterior Apex (%)

-33.3 ± 2.5

-22.6 ± 3.0*

-28.4 ± 3.4

-34.4 ± 2.2

Anterior Base (%)

-20.0 ± 2.7

-18.2 ± 3.0

-19.0 ± 2.3

-20.5 ± 4.6

Anterior Mid (%)

-16.6 ± 1.0

-12.3 ± 1.5*

-17.9 ± 2.0

-15.6 ± 2.0

Anterior Apex (%)

-23.0 ± 1.9

-20.1 ± 1.2

-24.8 ± 3.3

-17.8 ± 1.4

Longitudinal Strain Rate (1/s)

-7.2 ± 0.7

-4.77 ± 0.3*

-6.43 ± 0.6

-6.79 ± 0.6

Posterior Base (1/s)

-10.0 ± 1.2

-7.1 ± 0.6*

-10.4 ± 1.5

-11.8 ± 1.1

Posterior Mid (1/s)

-7.1 ± 0.7

-8.3 ± 0.7

-10.0 ± 1.7

-7.7 ± 0.5

Posterior Apex (1/s)

-15.5 ± 2.1

-8.2 ± 0.7*

¥

-12.1 ± 1.9

-14.0 ± 1.7

Anterior Base (1/s)

-13.8 ± 1.9

-7.4 ± 1.0*

†

-12.5 ± 1.6

-9.3 ± 0.7

Anterior Mid (1/s)

-9.3 ± 0.6

-5.4 ± 0.6*

†¥

-9.8 ± 0.9

-8.0 ± 0.7

Anterior Apex (1/s)

-10.8 ± 1.0

-9.3 ± 1.3

-8.5 ± 0.4

¥

¥

†

†¥

†¥

-7.7 ± 0.7*
†

¥

Values are shown as means±SEM. *P<0.05 Control versus T2DM animals; P<0.05 T2DM versus mtHsp70 animals; P<0.05
T2DM versus mtHsp70 T2DM animals. 1-way ANOVA with Bonferroni’s Multiple Comparison Post-hoc Test.
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Table 3.2. Conventional and Speckle-Tracking Based Strain Echocardiographic
Measurements During T2DM. Values are shown as means±SEM. *P<0.05 Control versus
†

¥

T2DM animals; P<0.05 T2DM versus mtHsp70 animals; P<0.05 T2DM versus mtHsp70
T2DM animals. 1-way ANOVA with Bonferroni’s Multiple Comparison Post-hoc Test.
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Abstract
Cardiac complications and heart failure are the leading cause of death in diabetic patients.
The mitochondrion has been implicated in the etiology of the diabetic pathology. Two distinct
mitochondrial subpopulations exist within the cardiomyocyte. The subsarcolemmal mitochondria
(SSM) are located beneath the sarcolemmal membrane and the interfibrillar mitochondria (IFM)
are located between the myofibrils. Proteomic, transcriptomic and epigenomic remodeling occurs
during diabetes mellitus in the attempt to adapt to the pathological insult. MicroRNAs (miRNAs)
play a vital role in the regulation of gene expression though degradation of target messenger RNAs
(mRNAs) or translational repression and have been shown to be present within the mitochondrion;
however, the mechanism by which miRNAs traverse the mitochondrial membranes remains
unknown. The goal of this study was to elucidate whether polynucleotide phosphorylase (PNPase),
an intermembrane space protein potentially anchored to the inner mitochondrial membrane, plays
a role in the complicated mechanism of miRNA translocation during type 2 diabetes mellitus. We
found an increase in PNPase protein expression in the SSM of the type 2 diabetic human atrial
appendage and db/db mouse model. Further, we discovered the novel association of PNPase with
Argonaute 2 (Ago2) in both cardiac mitochondrial subpopulations that was subsequently increased
in the SSM during the type 2 diabetic insult. In the SSM of the db/db mice, we found an increased
level of miR-378, which was associated with a corresponding decrease in ATP6 protein content.
Finally, in the HL-1 cardiomyocyte cell line, overexpression of PNPase led to increased miR-378
levels in the mitochondria and a decrease in ATP synthase activity. Altogether, PNPase may
potentially be a constituent in the import mechanism of miRNAs via association with Ago2 into
cardiac mitochondria.
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Introduction
Type 2 diabetes mellitus (T2DM) currently affects 29 million Americans, with an
inordinate cost to society of $245 billion in medical bills and missed work (1, 33). Further, T2DM
serves as a major risk factor for cardiovascular disease as the heart needs a constant nutrient supply
in order to produce the proper amount of energy, which does not always occur in the diabetic
pathology (33). During T2DM, when cardiac tissue becomes insulin resistant, a proteomic,
transcriptomic and epigenomic remodeling occurs as an adaptive mechanism to the pathological
insult (2, 34, 36). Our laboratory and others have shown that the assault to the transcript can occur
in both the cytosol and mitochondria within the cardiomyocyte (34, 37). Cardiac mitochondrial
subpopluations have been previously shown by our laboratory to be differentially affected during
diabetic insult, with the interfibrillar mitochondria (IFM) being negatively influenced during type
1 diabetes mellitus and the subsarcolemmal mitochondria (SSM) predominantly being affected
during T2DM (7-9, 17-20, 37, 66).
The mechanism of protein import into the mitochondria consists of the unfolded protein in
the cytoplasm being threaded through the translocase of the outer membrane, TOM40, and the
translocase of the inner membrane, TIM23, followed by the action of mitochondrial heat shock
protein 70 (mtHsp70) “pulling” the polypeptide into the mitochondrial matrix via an ATPdependent manner (6, 27). Not only are proteins transported into the mitochondria, which is critical
due to the vast majority of mitochondrial proteins being encoded by the nuclear genome, but
ribosomal RNA (rRNA) and transfer RNA (tRNA) have also been shown to traverse the
mitochondrial membranes (3). Polynucleotide phosphorylase (PNPase) situated in the inner
mitochondrial membrane and extending into the intermembrane space, has been found to facilitate
the transport of rRNA and tRNA based on their hairpin-loop structure (3, 69, 70). This protein also
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functions to edit and degrade RNA, as well as plays a role in controlling cellular senescence and
cell cycle (44, 56, 57, 60). Interestingly, a major determining factor between RNA degradation or
transport by PNPase seems to be the length of the RNA species’ 3’ overhang. Wang et al. showed
that an 8 nucleotide (nt) 3’ overhang of a messenger RNA (mRNA) species resulted in degradation,
while a 0-2 nt 3’ overhang led to transport (43, 64). Various other studies suggested that the
machinery facilitating protein import could contribute to RNA import as well (3, 28, 40, 55, 58,
61, 62).
Emerging research is likely to discover how the mitochondrial genome is being regulated
to influence both disease initiation and progression. MicroRNAs (miRNAs) are a type of
noncoding RNA that have been shown to play a vital role in the regulation of gene expression
though degradation of target mRNAs or translational repression (45). MiRNAs exert their
influence through binding to the 3’-untranslated region of the target mRNAs (45). The association
of miRNA with the RNA-induced silencing complex (RISC) has been shown in the cytoplasm,
with the argonaute (AGO) family proteins functioning to help in miRNA repression through the
inhibition of protein synthesis when bound to the 3’-untranslated region of the mRNA (5, 30). The
miRNA-mediated regulatory potential of the mitochondrial genome is especially precise as the
genome itself is comprised of only 37 genes, 13 of which code for protein subunits involved in
oxidative phosphorylation and the remaining genes coding for 22 tRNAs and 2 rRNAs (46).
Data from a variety of groups, including our own, has elucidated the presence of miRNA
in the mitochondria (3, 4, 11-13, 22, 23, 37, 41, 63-65, 67, 73). Even more exciting has been the
validation of miRNA species targeting mRNA transcripts produced by the mitochondrial genome
in the mitochondria to control mRNA stability and degradation (22, 23, 26). Since fatty acid
oxidation, the citric acid cycle, the electron transport chain and ATP synthase are housed in the
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mitochondrial matrix and inner mitochondrial membrane, the differential expression of miRNA in
the mitochondria targeting any of these components is consequential to the overall functionality
of the organelle. PNPase has been established to play an important role in the import of nuclear
RNA; however, its involvement in the import of miRNAs into the mitochondrion needs to be
evaluated (55, 58, 69). Our current manuscript focuses on a key player in the mechanism of
miRNA import into the mitochondrion. We aim to elucidate whether PNPase in association with
Ago2 plays a role in the complicated mechanism of miRNA translocation, influencing the function
of SSM during the type 2 diabetic insult.
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Research Design and Methods
Human Tissues
The West Virginia University Institutional Review Board and Institutional Biosafety
Committee approved all protocols. Patients undergoing cardiac valve replacement or coronary
artery bypass graft surgery at Ruby Memorial Hospital in Morgantown, West Virginia, allowed
the release of the right atrial appendage tissue to the West Virginia University School of Medicine.
Patients were characterized as non-diabetic or type 2 diabetic based on a previous diagnosis of
diabetes mellitus by a medical doctor. Pericardial fat was trimmed from right atrial appendage
samples and mitochondria isolated as previously described (7, 8, 17-21, 48, 49, 66, 72).

Experimental Animals
The animal experiments performed in this study conform with the National Institutes of
Health Eighth Edition Guidelines for the Care and Use of Laboratory Animals and were approved
by the West Virginia University Care and Use Committee. Mixed gender db/db mice (strain
FVB.BKS(D)-Leprdb/ChuaJ) and wild-type (WT) littermate controls (Jackson Laboratories, Bar
Harbor, ME) were housed and bred in the West Virginia University Health Sciences Centers
animal facility. Microisolator cages were used to maintain animals with ad libitum access to food
and water and housed on a 12 hour light/dark cycle in a temperature-controlled room. All mice
were aged to approximately 20 weeks old and then euthanized for experimentation.

Preparation of Individual Mitochondrial Subpopulations
At approximately 20-22 weeks of age, db/db mice and littermate controls were euthanized,
hearts excised and cardiac mitochondrial subpopulations were isolated for analyses as previously
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described following the methods of Palmer et al. (49) with minor modifications by our laboratory
(7, 8, 17, 19-21, 48, 66). Beneath the sarcolemmal membrane resides a pool of mitochondria
termed subsarcolemmal mitochondria (SSM), while the mitochondria that exist between the
myofibrils are called interfibrillar mitochondria (IFM). Our laboratory has previously reported
SSM dysfunction during the type 2 diabetic pathology, with the IFM being relatively unaffected
(19). After isolation of cardiac mitochondrial subpopulations was completed, SSM and IFM were
further purified by percoll gradient (23%, 15%, 10% and 3% percoll solution) in the case of the
db/db and littermate control animals. The samples were centrifuged in a Beckman Optima MAXXP Ultracentrifuge (Beckman Coulter, Fullerton, CA) at 32,000 x g for 8 minutes. Mitochondrial
subpopulation pellets were resuspended in the appropriate buffer for each assay. Protein
concentrations were determined by using the Bradford method with bovine serum albumin as a
standard (14).

Cell Culture
For cell culture experiments, the mouse cardiomyocyte cell line (HL-1), which maintains
a cardiac-specific phenotype following repeated passages was used as previously described (9, 16,
37). The miR-378 HL-1 overexpressing cell line generated by our laboratory was also used as
previously described (37). Cells were grown up in a humidified atmosphere of 5% CO2/95% air
and maintained at 37°C in Claycomb media (Sigma Aldrich, St. Louis, MO) with 10% fetal bovine
serum and other supplements as previously described (9).
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Overexpression of PNPase
Cells were seeded and transfected at 60% to 70% confluence. RNA importer, PNPase was
transfected into the HL-1 cell line to determine if increased overexpression of PNPase leads to
increased transport of miRNA into the mitochondrion. Briefly, FuGENE 6 Transfection Reagent
(Promega, Madison, WI) was used per manufacturer’s instructions. Forty-eight hours posttransfection, cells were washed with PBS and harvested. Sample number was determined by the
number of independent transfections performed, accounting for variation of plasmid uptake in
cells. Mitochondria were isolated using a mitochondrial isolation kit (Biovision, Milpitas, CA) for
protein, qPCR, and enzymatic analyses.

qPCR Analyses
First, total RNA was isolated from HL-1 and HL-1 378 overexpression cell lines and
converted to cDNA using the miRNA First Strand cDNA synthesis kit (Origene, Rockville, MD)
per the manufacturer’s protocol. The cDNA was used with SYBR Green components in a total
sample volume of 25µL: 12.5µL 2X SYBER Green I qPCR Master Mix (Origene, Rockville, MD),
9.5µL RNAse/Nuclease free H2O, 1µL of primer for the control (U6) or experimental group
(MP300294 – miR-378, Origene, Rockville, MD), and 2µL of cDNA (~500ng/µL). Data is
expressed as fold change relative to the difference in Ct expression of the miR-378 to U6 log
expression. All samples were run in duplicate for both the miR-378 and U6 primers. Standard
deviation values in either primer pair exceeding a Ct value of 0.5 were excluded from the study.
7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) was used for
analysis, with reaction conditions optimized to Origene’s qSTAR miRNA qPCR Detection System
instructions.
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Immunoprecipitation Analyses
Dynabeads® protein G (Life Technologies, Grand Island, NY) were used to determine
protein associations between Ago2 and PNPase per the manufacturer’s instructions. Briefly, 50uL
of Dynabeads® protein G were incubated with either anti-PNPT1 (PNPase; OriGene, Rockville,
MD) or anti-Ago2 (Abcam, Cambridge, MA) primary antibody overnight. The beads were
subsequently washed in NP-40 buffer and 150ug of mitochondrial protein, as determined by the
Bradford method, was resuspended with beads and NP-40 wash/binding buffer and incubated
overnight. Finally, beads were washed and loading dye added to the samples and Western blots
performed on the eluted protein and subsequently probed with the protein of interest to examine
the associations.

Western Blot Analyses
SDS-PAGE was run on 4-12% gradient gels, as previously described (7, 8, 19, 42, 48, 66,
72) with modifications. For assessment of protein content, equal amounts of protein were loaded
as determined by the Bradford method using bovine serum albumin as a standard as previously
described (14). Further, assessment of protein loading control was done by utilizing the COXIV
antibody and Ponceau S solution (Sigma, St. Louis, MO). Relative amounts of PNPase, Ago2,
ATP6, GAPDH, and COXIV were assessed using the following primary antibodies: anti-PNPT1
(PNPase; OriGene, Rockville, MD); anti-Ago2 (Abcam, Cambridge, MA); anti-ATP6 (Abcam,
Cambridge, MA); anti-GAPDH (Abcam, Cambridge, MA); and anti-COXIV (Cell Signaling
Technology, Danvers, MA). The secondary antibodies used in the analyses were goat anti-mouse
IgG horseradish peroxidase (HRP) conjugate (Pierce Biotechnology, Rockford, IL) for Ago2 and
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GAPDH and goat anti-rabbit IgG HRP conjugate (Cayman Chemical, Ann Arbor, MI) for the
PNPase, ATP6 and CoxIV primary antibodies. Pierce Enhanced Chemiluminescence Western
Blotting substrate (Pierce Biotechnology; Rockford, IL) was used to detect signal per
manufacturer’s instructions. A G:Box Bioimaging system (Syngene, Frederick, MD) was used to
detect signals and data were captured using GeneSnap/GeneTools software (Syngene, Frederick,
MD). Densitometry was analyzed using Image J Software (National Institutes of Health, Bethesda,
MD) and expressed as arbitrary optical density units.

Complex Activities
Electron transport chain complexes I, III, and IV were measured in mitochondria isolated
from the cells spectrophotometrically as previously described (19-21, 68). Briefly, by measuring
NADH oxidation at 340 nm, complex I activity was determined. Complex III activity was
measured by assessing the reduction of cytochrome c at 550 nm in the presence of 50 µM of
reduced decylubiquinone, while complex IV activity evaluated cytochrome c oxidation at 550 nm.
Further, ATP synthase activity was measured as oligomycin-sensitive ATPase activity using an
assay coupled with pyruvate kinase, which converts ADP to ATP and produces pyruvate from
phosphoenolpyruvate as described previously (19, 29, 52, 53). Values for complex activities were
expressed as nanomoles substrate converted/min/mg of protein.

Statistics
Means ± SEMs were calculated for all data sets. Data were analyzed with two-tailed
Student’s t-test to compare differences between groups (GraphPad Software, La Jolla, CA) where
a P ≤ 0.05 was considered significant.
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Results
PNPase and Ago2 in Cytosolic Fractions in Non-diabetic and Type 2 Diabetic Settings
PNPase and Ago2 protein expression were assessed in non-diabetic and type 2 diabetic
patients. Cytosolic fractions were isolated from atrial appendage tissue and revealed a faint band
for PNPase in the cytosolic fraction with no significant alterations in Ago2 in the type 2 diabetic
patients (Figure 4.1A). A similar phenomenon was noted in the db/db animal model for type 2
diabetes mellitus with no PNPase showing up in the cytosolic fraction and Ago2 remaining
unchanged during the pathological setting (Figure 4.1B). As a result of our findings, we decided
to assess the protein content of Ago2 and PNPase in mitochondrial subpopulations.

Impact of Type 2 Diabetes Mellitus on PNPase and Ago2 in Cardiac Mitochondrial
Subpopulations
When assessing the Ago2 protein content in human non-diabetic and type 2 diabetic
patients, there was no change noted in either cardiac mitochondrial subpopulations (Figure 4.2AB). Further, in the db/db model, SSM and IFM showed no alterations in Ago2 protein expression
levels (Figure 4.2C-D). Interestingly, in the type 2 diabetic SSM from atrial appendage tissue
from patients, PNPase protein content was increased (Figure 4.3A); however, in the IFM, no
changes were noted in PNPase protein expression levels (Figure 4.3B). A similar story was found
in the db/db model, with significantly increased PNPase protein expression levels in the SSM
(Figure 4.3C), with no changes noted in the IFM subpopulation (Figure 4.3D).
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Ago2 and PNPase Associate within the Cardiac Mitochondria
Due to our results of finding a conventional cytosolic RISC component in the
mitochondrial fraction, we speculate that Ago2 may serve as facilitator for transport of miRNA
from the cytosol into the mitochondria. We immunoprecipitated Ago2 from the mitochondrial
pellet and found that PNPase was co-immunoprecipitated in both

the SSM and IFM

subpopulations (Figure 4.4A-B). Interestingly, the SSM showed an increased association of
immunoprecipitated Ago2 with PNPase (Figure 4.4A), while the IFM revealed no difference in
the association of these proteins (Figure 4.4B). We then performed the reciprocal
immunoprecipitation with PNPase, immunoprecipitating with PNPase and looking to see if Ago2
coimmuniprecipitated with this protein. We again found the association between the 2 proteins
(Figure 4.4C-D). Interestingly, we found a trending increase in association between PNPase and
Ago2 in the SSM of the type 2 diabetic animals as compared to their controls (Figure 4.4C).
Again, we found an association between PNPase and Ago2 in the IFM; however, no differences
exist between the control and type 2 diabetic pathology (Figure 4.4D).

miR-378 in Cardiac Mitochondria
To assess whether micro-RNAs within the mitochondria are affected in the type 2 diabetic
setting, we used qPCR to determine whether miR-378 showed an alteration in expression levels
during the diabetic pathology. We found an increase in miR-378 expression level in SSM isolated
from db/db cardiac tissue (Figure 4.5A), with no changes noted in the IFM (Figure 4.5A). Since
miR-378 is predicted to target ATP6 within the mitochondrion, we assessed ATP6 protein levels
in the SSM and IFM from control and db/db mice (Figure 4.5B). Corroborating our miR-378
increased expression levels in the type 2 diabetic SSM, we found decreased ATP6 protein
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expression levels in the type 2 diabetic SSM (Figure 4.5B). Further, we found no changes in the
IFM subpopulation for ATP6 expression levels (Figure 4.5B).

Impact of PNPase Overexpression in HL-1 Cardiomyocte Cells
Our laboratory has established and previously published on a HL-1 miR-378 stable
overexpression cell line (37). We have elucidated that miR-378 is overexpressed in the
mitochondria isolated from this cell line and found that both ATP6 mRNA and ATP6 protein
expression levels were down with miR-378 overexpression (37). In the HL-1 cardiomyocyte cell
line, we transfected the cells with a plasmid encoding for PNPase and found increased expression
levels of PNPase in mitochondria isolated from these cells (Figure 4.6A). Further, to determine
whether the overexpression of PNPase increased the presence of miR-378 in the mitochondria of
Hl-1 cells, we conducted qPCR. We found that overexpression of PNPase significantly increased
the miR-378 detected in mitochondria isolated from the HL-1 cells (Figure 4.6B). Further, we
found that overexpression of miR-378 decreased the ATP synthase activity in isolated
mitochondria (Figure 4.6C). Interestingly, overexpression of PNPase in the HL-1 cell line also
revealed decreased ATP synthase activity. Taken together, these data provide complementary
evidence that in a model with PNPase overexpression, miR-378 expression is enhanced within the
mitochondria leading to decreased ATP synthase activity, potentially due to an increased
mechanism for miRNA transport into the mitochondrion.
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Discussion
Mitochondrial dysfunction is central to the etiology of cardiovascular complications seen
in diabetic patients (7, 8, 18-20, 31, 54, 59, 66, 72). Within the mitochondria, complex, functional
processes occur, such as oxidative phosphorylation and ATP synthesis, which are critical in an
appropriately functioning organelle. The mechanisms behind nuclear-encoded mitochondrial
protein import and mechanisms of miRNA intercellular transport via exosomes and intracellular
transport into the nucleus have been elucidated; however, the process of miRNA import into the
mitochondria has proven elusive (6, 24, 27, 71). Nuclear translocation of miRNA involves the colocalization of the Ago2/miRNA complex with Importin 8 on the nuclear membrane followed by
transport of the complex into the nucleus (71). Here we have shown a similar co-localization of
Ago2 with PNPase in the cardiac mitochondria and this association was increased in the T2DM
pathological setting as compared to control mice. While this is not suggestive of an absolute
mechanism of miRNA transport into the mitochondrion, with other constituents within the
mitochondrion potentially playing a role in import, this work contributes to the validation of
specific protein components (PNPase and AGO2) involved in the mechanism of miRNA transport.
PNPase upregulation in human T2DM and db/db mice is further complicated by its influence on
the transport or degradation of a multitude of RNA species, along with its regulation of other
functions.
The decreased activity of ATP synthase in HL-1 PNPase overexpressing cells compared to
control HL-1 cells could be a result of a variety of changes downstream of the PNPase protein.
One of these changes that may be occurring because of the increase in PNPase is the transport of
many miRNA sequences into the mitochondrion, resulting in targeting and negatively regulating
transcripts of the electron transport chain or ATP synthase subunits. Further, the decreased activity
of ATP synthase in HL-1 miRNA-378 overexpressing cells compared to controls provides a more
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causal picture, as miRNA-378 has been shown to directly target and repress the ATP6 subunit of
ATP synthase. This corroborates our findings in the T2DM mouse model, where miRNA-378 is
upregulated and ATP6 protein expression is downregulated. These changes coincide with an
increase in PNPase protein levels within the db/db animals, as well as increased association of
PNPase with Ago2. While we have shown that PNPase protein expression level is increased in the
T2DM atrial appendages from patient samples as compared to non-diabetic patients, it would be
of great interest to determine if the patients also have an association of PNPase and Ago2 within
the mitochondrion and further, to see if this association is increased during the diabetic pathology.
MiRNAs localized to the mitochondrion have been found to directly target essential
processes such as energy metabolism and apoptosis (22, 23, 37, 41, 50). For example, Das et al.
found an increase in miRNA-181c in cardiomyocyte mitochondria during heart failure, which
targets and represses mtCOX1, an important component of the respiratory complex IV (22, 23,
25). Further, the role of miR-378 in regulating metabolic processes in multiple organs in the body
has been previously noted, with targets include Med13 and Cret in the liver and IGF-1 and ATP6
in the heart (15, 37, 39). Our laboratory previously found an increase in miR-378 in cardiac
mitochondria during the type 1 diabetic pathology, which resulted in decreased ATP6 protein
content in the IFM and a decreased ATP synthase activity (37). In this study, we have shown an
increase in miR-378 and a decrease in ATP6 protein in the SSM during a type 2 diabetic setting,
demonstrating that mitochondrial subpopulations are differentially impacted depending on the type
of diabetic insult. The systemic pathological environment and accompanying stimuli of the
diabetic state undoubtedly provide the impetus for a multitude of proteomic, transcriptomic, and
epigenomic adaptations or maladaptations. While this is indeed a complex and interconnected
phenomenon of which we have only elucidated a potential component in the process, we present
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that differential miRNA expression in the mitochondria of the diabetic heart, particularly miR378, leads to a decrease in ATP synthase complex activity and potentially contributes to the cardiac
dysfunction implicated in T2DM.
The recent characterization of miRNA localization to various organelles within the cell and
changes in miRNA species and levels during pathological states suggests a role in miRNAmediated pathologic phenotypes (3, 32, 51). Further, the introduction of miRNA mimics to
increase miRNA species levels that have been downregulated or supplementation with antimiRs
to decrease miRNA species levels that have been upregulated, may have the potential to attenuate
or reverse decrements due to the pathological state. This strategy is currently being used in the
clinic to treat hepatitis C virus, with clinical trials of miRNA mimics and antimiRs underway (38).
A variety of miRNA-based therapies to address T2DM and heart disease are in the preclinical trial
stage, providing the need for comprehensive study on miRNA effects on different cellular
organelles. One such biologic is antimiR-208a, which has been shown to increase systemic
metabolism, display a lean phenotype when provided a high-fat diet, and improve overall cardiac
function (10, 35, 47). It will be of interest to determine in subsequent studies whether inhibition of
miRNA-378 using an antimiR during T2DM will provide benefits to cardiac mitochondrial
function and cardiac contractile function. Furthermore, the prospect of elucidating the complicated
mechanism for miRNA import into the mitochondrion during T2DM and modulating PNPase
expression/activity and its potential role in miRNA import, could lead to a therapeutic paradigm
to alleviate mitochondrial and cardiac dysfunction during T2DM.
Our data reveal the following key findings: 1) PNPase protein expression is increased in
the type 2 diabetic SSM in both human patient atrial appendage samples and the db/db mouse
model; 2) PNPase is associated with Ago2 as shown via immunoprecipitation and this association
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is increased in the SSM during T2DM; 3) db/db SSM have an increased level of miR-378,
corresponding to a decrease in ATP6 protein content in the SSM; 4) overexpression of PNPase in
the mouse cardiomyocyte HL-1 cell line significantly increases miR-378 levels, corresponding to
a decrease in ATP synthase activity. These findings suggest that during T2DM, PNPase may be a
potential constituent in the import mechanism of miRNAs into cardiac mitochondria.
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Figure 4.1

250

Figure 4.1. Expression levels of PNPase and Ago2 in cytoplasm. (A) Representative Western
blot analysis of PNPase and Ago2 protein expression levels in the cytoplasm of human atrial
appendage from non-diabetic and type 2 diabetic patients. GAPDH was used as a loading control.
(B) Representative Western blot analysis of PNPase and Ago2 protein expression levels in the
cytoplasm of wild-type and db/db mice. GAPDH was used as a loading control.
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Figure 4.2
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Figure 4.2. Expression levels of Ago2 in cardiac mitochondrial subpopulations. (A)
Representative Western blot analysis and quantification of Ago2 protein expression levels in the
SSM of human atrial appendage from non-diabetic and type 2 diabetic patients. CoxIV and
Ponceau staining were used as loading controls. (B) Representative Western blot analysis and
quantification of Ago2 protein expression levels in the IFM of human atrial appendage from nondiabetic and type 2 diabetic patients. CoxIV and Ponceau staining were used as loading controls.
(C) Representative Western blot analysis and quantification of Ago2 protein expression levels in
the SSM of wild-type and db/db mice. CoxIV was used as loading controls. (D) Representative
Western blot analysis and quantification of Ago2 protein expression levels in the IFM of wild-type
and db/db mice. CoxIV was used as loading controls. Values are expressed as means ± SEM.
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Figure 4.3
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Figure 4.3. Expression levels of PNPase in cardiac mitochondrial subpopulations. (A)
Representative Western blot analysis and quantification of PNPase protein expression levels in the
SSM of human atrial appendage from non-diabetic and type 2 diabetic patients. CoxIV and
Ponceau staining were used as loading controls. (B) Representative Western blot analysis and
quantification of PNPase protein expression levels in the IFM of human atrial appendage from
non-diabetic and type 2 diabetic patients. CoxIV and Ponceau staining were used as loading
controls. (C) Representative Western blot analysis and quantification of Ago2 protein expression
levels in the SSM of wild-type and db/db mice. CoxIV was used as loading controls. (D)
Representative Western blot analysis and quantification of Ago2 protein expression levels in the
IFM of wild-type and db/db mice. CoxIV was used as loading controls. Values are expressed as
means ± SEM. *P ≤ 0.05 for control vs. type 2 diabetic.
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Figure 4.4
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Figure 4.4. Association of Ago2 and PNPase. (A) Representative co-immunopreciptation and
quantification with a pulldown of Ago2 and probed with PNPase in control and db/db SSM. (B)
Representative co-immunopreciptation and quantification with a pulldown of Ago2 and probed
with PNPase in control and db/db IFM. (C) Representative co-immunopreciptation and
quantification with a pulldown of PNPase and probed with Ago2 in control and db/db SSM. (D)
Representative co-immunopreciptation and quantification with a pulldown of PNPase and probed
with Ago2 in control and db/db IFM. Values are expressed as means ± SEM. *P ≤ 0.05 for control
vs. db/db.
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Figure 4.5
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Figure 4.5. MicroRNA-378 Concentration and ATP6 Expression levels. (A) qPCR of mir-378
concentration in control line (n = 3) and db/db (n =3) mice for both the subsarcolemmal
mitochondria (SSM) and interfibrillar mitochondria (IFM).. Replicates were determined as
individual transfections. (B) Representative Western blot analysis and quantification of ATP6
protein expression levels in the SSM (Left) and IFM (Right) of control and db/db mice. CoxIV
was used as a loading control. Values are expressed as means ± SEM. *P ≤ 0.05 for control vs.
db/db.
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Figure 4.6
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Figure 4.6. Overexpression of PNPase in HL-1 Cardiomyocyte Cells. (A) Representative
Western blot analysis of PNPase overexpression in the HL-1 Cell line. (B) qPCR of mir-378
concentration in HL-1 cells (n = 3) compared to HL-1 cells overexpressing PNPase (n =3).
Replicates were determined as individual transfections. (C) ATP synthase activity in HL-1 control
and HL-1 378 overexpression cell lines. (D) ATP synthase activity in HL-1 control and HL-1
PNPase overexpression cell lines. Values are expressed as means ± SEM. *P ≤ 0.05 for control vs.
overexpression cell line.
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GENERAL DISCUSSION
The overall objective of this dissertation was to evaluate a new imaging technique for
myocardial function and to assess the mechanisms leading to mitochondrial proteome
dysregulation and miRNA import into the mitochondrion. Specifically, we wanted to determine if
during DM: (1) echocardiographic speckle-tracking based strain imaging analyses would lead to a
greater ability to detect earlier changes in myocardial dysfunction; (2) mtHsp70 would provide
mitochondrial and cardiac contractile protection via restored nuclear-encoded mitochondrial
protein import and mitochondrial proteome stability; (3) increased PNPase expression would lead
to an increase in miRNA import into the mitochondrion via an association with the RISC. Our
long-term goal was to identify mechanisms to alleviate adverse cardiac and mitochondrial effects
associated with DM with the intent of providing a mechanism for therapeutic interventions to be
designed. The central hypothesis of this dissertation was that strain analyses would offer the
capability to detect early decrements in myocardial strain resulting from mitochondrial proteome
derangement associated with inefficient mitochondrial protein import and mitochondrial
dysfunction, all rectified by manipulation of mtHsp70. Further, the increased expression of
miRNAs inside of the mitochondrion could potentially be due to an increased association of
PNPase with the RISC. Our rationale for the proposed research was based upon the notion that a
greater understanding of the mechanisms involved in mitochondrial dysfunction during DM, along
with a non-invasive mechanism to evaluate and detect early myocardial contractile deficiencies,
could potentially allow for the identification of key contributors to alleviate mitochondrial
dysfunction, aiding in the development of a therapeutic paradigm to help combat cardiac
complications in diabetic patients.
Roughly 9.3% of the United States population is diagnosed with DM and the rate of
incidence is increasing at an alarming frequency (1, 3). T1DM, caused by insufficient insulin
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production, accounts for approximately 5% of diabetic patients, while T2DM results from insulin
resistance and affects 95% of all diabetic patients (3). The cardiovascular complications resulting
from DM are the leading cause of morbidity and mortality among diabetic patients (25). The
mitochondria within the cardiomyocyte have been linked to the cardiac dysfunction seen during
DM with abnormalities associated with altered substrate utilization, increased production of ROS,
enhanced susceptibility for apoptosis, altered mitochondrial structure, increased adverse effects
due to miRNA, decreased nuclear-encoded mitochondrial protein import efficiency and a
dysregulated mitochondrial proteome (11-13, 19-22, 39, 56, 59, 65, 70-72, 81). Further
complicating the study of cardiac mitochondria, is the presence of two spatially and biochemically
distinct mitochondrial subpopulations within the cardiomyocyte, which respond differentially to
physiological stimuli and pathological insults (4, 11-13, 19-22, 40, 41, 45-47, 51, 53-55, 58, 72,
81, 82). A review published by our laboratory highlights the differential impact of distinct
pathological insults on cardiac mitochondrial subpopulations including ischemia, hypoxia,
myocardial infarction, I/R, preconditioning/postconditioning, HF, aging, exercise, DM and
hypermetabolism (33). Previous research from our laboratory demonstrates that T1DM
differentially influences mitochondrial subpopulations, with the IFM being predominantly
disturbed during this pathological insult, while SSM are detrimentally affected during T2DM (2,
11-13, 19-22, 72, 81). Increased ROS production and damage, along with decreased size and
internal complexity were shown in the IFM of the T1DM heart (22). In 18-week-old db/db mice,
our laboratory previously reported oxidative damage via lipid peroxidation byproducts and
nitrotyrosine residues in the SSM isolated from cardiomyocytes (21). Further, db/db animals
revealed decreased mitochondrial size, internal complexity, and ΔΨm in the SSM, with no changes
in the IFM (21). A study in skeletal muscle from T2DM patients revealed decreased mitochondrial
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size and SSM abundance (43). Interestingly, when fueled with glutamate and malate, decrements
in mitochondrial state 3 respiration rates in the SSM subpopulation were observed; however, when
fueled with palmitoylcarnitine, fatty acid-stimulated state 3 and state 4 respiration were
significantly decreased in the SSM, with no alterations to the IFM (21). This is interesting due to
the milieu created during the T2DM setting, with a gross overabundance of lipids present within
the environment. Additionally, mitochondrial function was assessed via ETC complex activities,
which revealed deficits in complexes I, III and IV, as well as the ATP synthase for the SSM
subpopulations, without having an effect on the IFM (21). These studies reveal that cardiac
mitochondrial subpopulations are differentially impacted depending on the type of DM.
It is interesting to note that T1DM and T2DM affect cardiac mitochondrial subpopulations
differentially; however, it is unknown as to why this occurs. Our speculation to the differential
impact on cardiac mitochondrial subpopulations during the distinct types of DM arises from the
differences in the phenotypes elicited by the pathologies. While similar deleterious effects are
noted in the cardiac mitochondrial subpopulations, the milieu resulting from the pathology are
somewhat different. The T1DM condition creates a milieu of starvation and deprivation while the
glucose remains in the bloodstream instead of being utilized by the cells, leading to the cells being
starved of this energy source. Conversely, in the T2DM condition, the cells are still facing
starvation; however, this is in the face of excess. In our particular DM models, the IFM could
potentially be more susceptible to damage from the STZ during T1DM because of their innately
higher respiratory rates and subsequent oxidative environment caused by the pathology. Our
laboratory has previously shown in the db/db model of T2DM that lipid profiles are significantly
increased compared to the T1DM condition (21, 22). Further, db/db mice have higher circulating
fatty acids and triglycerides than STZ mice, which is likely due to the phenotype elicited by the
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pathological insult of T2DM (21, 22). With a greater propensity for lipid accumulation and the
proximity of the SSM to the sarcolemmal membrane, the SSM are likely subjected to an
environment high in lipid content, which was found by Nielson et al. in T2DM skeletal muscle
(52). As the circulating free fatty acids and lipid deposition to the subsarcolemmal region during
T2DM increases, the SSM are likely at a larger susceptibility for damage as they are located at the
cell periphery, than the IFM located between myofibrils (52). This leads to the speculation that as
lipid accumulation occurs in the SSM region, processes involved in metabolic signaling including
insulin signaling, may be more readily affected (52). While the two primary cardiac mitochondrial
subpopulations are differentially impacted during DM, commonalities in the dysfunction exist. For
instance, loss of function and proteomic dysregulation in a specific mitochondrial subpopulation
during DM insult is noted depending on the subpopulation predominantly impacted (12, 21). Key
processes such as nuclear-encoded mitochondrial protein import and ETC function, along with the
loss of mtHsp70 protein expression results in dysfunctional IFM during T1DM and SSM during
T2DM (12, 21), indicating that the most negatively impacted mitochondrial subpopulation incurs
similar deleterious effects to key mitochondrial processes. In Chapter 3, overexpression of
mtHsp70 allowed for restoration of these impacted mitochondrial processes in the mitochondrial
subpopulation most impacted by the type of DM. Within our transgenic model, mtHsp70
overexpression is not specific to a single mitochondrial subpopulation and should be expressed at
equivalent levels within the cardiac mitochondrial subpopulations, thus imparting protection to the
subpopulation detrimentally impacted by the disease state. It is important to note that
overexpression of mtHsp70 in the subpopulation that appears to be unaltered during the type of
DM does not preclude a positive benefit to the mitochondria within that locale and could
potentially allow for the mitochondria to function more efficiently; however, our data indicate that
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an elevated level of mtHsp70 in the unaffected mitochondrial subpopulation during DM does not
necessarily provide an extra positive benefit (Chapter 3). As a result, both pathologies are capable
of providing complementary information in order to delineate potential therapeutic interventions
that could treat cardiac mitochondrial dysfunction in both diabetic phenotypes.
Interestingly, in both the T1DM and T2DM diabetic pathologies, mtHsp70 was shown to
be decreased in the subpopulation predominantly impacted by the disease, revealing the T2DM
SSM and the T1DM IFM to have altered mtHsp70 (12, 21). Since greater than 99% of proteins
within the mitochondria are imported to the organelle, alterations to mtHsp70, a key player in
nuclear-encoded mitochondrial protein import, could lead to a deranged mitochondrial proteomic
profile during DM (12). In addition to mtHsp70 being shown to have an essential role in matrixtargeted mitochondrial protein import, mtHsp70 can also play a role in protein import into the
IMM and IMS (10). When mtHsp70 is altered, mitochondrial function is compromised with
decrements noted in processes including nuclear-encoded mitochondrial protein import, decreased
antioxidant defenses, increased misfolding and degradation of proteins, along with increased
cellular apoptosis (10). In the aged heart, mtHsp70 is shown to be decreased through proteomic
analyses (23). Additionally, neonatal rat cardiomyocytes treated with ET-1 to stimulate cardiac
hypertrophy displayed a decrease in mtHsp70 content, suggesting that mitochondrial impairment
may occur during the early development of hypertrophy (5). Williamson et al. showed that cardiac
myocytes from neonatal rats infected with an adenoviral vector expressing mtHsp70 were
protected from I/R injury (82). These cardiomyocytes had increased import of nuclear-encoded
antioxidant defense proteins, such as MnSOD (82). In the current work, overexpression of
mtHsp70 could lead to a greater efficiency of the nuclear-encoded mitochondrial protein import
process.
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With mtHsp70 being the key player in powering the mitochondrial import process, along
with consistently being altered during both types of DM in our proteomic data, we sought to
understand the role of mtHsp70 overexpression during both T1DM and T2DM in Chapter 3. As
an integral member of the PAM complex, mtHsp70 is anchored to Tim44 within the mitochondrial
matrix and serves as the protein that “traps” and “pulls” the translocating preprotein through the
IMM in an ATP-dependent manner (77). Previously our laboratory has shown that during T1DM
insult, import of mitochondrial matrix import protein (MitoGFP1) is decreased in the IFM
subpopulation, with no changes in the SSM (12). Further, overexpression of mPHGPx, provided
protection to processes in the IMM and proteomic restoration likely due to its antioxidant defense
system and its restoration of mtHsp70 (11). In the current work, we overexpressed mtHsp70 in
order to evaluate its impact on nuclear-encoded mitochondrial protein import during DM. In
agreeance with previous work, we saw decrements in MitoGFP1 protein import efficiency at 2
minutes in the T1DM IFM and as early as 30 seconds in the T2DM SSM (Chapter 3). We found
that overexpression of mtHsp70 allowed for the restoration of nuclear-encoded mitochondrial
protein import in the IFM during T1DM and the SSM during T2DM (Chapter 3).
While decrements in mtHsp70 is one mechanism for nuclear-encoded mitochondrial
protein import deficiencies in the heart, other potential mechanisms may include alterations to
ΔΨm or structural stability of the mitochondria during a pathological state. Interestingly, previous
work from our laboratory shows that during T1DM and T2DM, IFM and SSM have a reduced
ΔΨm, respectively, which could be involved in decrements to protein import processes, as this is
a critical force required for proper protein translocation (12, 21, 35). The currently proposed
methods for nuclear-encoded mitochondrial protein import through mtHsp70 both require an
active ΔΨm, as it is essential for opening the Tim23 channel within the IMM and allowing the pre-
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protein to enter into the matrix (14, 73). The Brownian ratchet model for nuclear-encoded
mitochondrial protein import relies on the ΔΨm electrophoretic force to move the protein across
the IMM, with mtHsp70 trapping the protein and not allowing it to slide backward into the IMS
(10). Further, ΔΨm can also help to promote unfolding of protein domains; however, this
mechanism is still relatively unexplored (34).
Secondly, alterations to other proteins involved in the import process could be occurring.
While our lab has previously assessed major import constituents such as Tom20, Tom40, Tim23
and Tim44 and found no changes during T1DM (12), these protein contents have not been assessed
during T2DM. Differences in the pathological conditions, as well as subcellular locale of the
mitochondrial subpopulations predominantly affected during the disease, could lead to a
differential impact on other import constituents and should be evaluated. Further, while Tim44
may not be decreased in expression level, as was previously shown by our laboratory in the T1DM
IFM (12), if the dissociation of mtHsp70 from Tim44 is impaired in the power stroke model, this
could potentially lead to an inefficient import process. In regards to structure, proteins involved in
mitochondrial protein import, such as mtHsp70, were shown to be associated with mitofilin, an
IMM structural protein known to maintain cristae morphology and structure (72). While this likely
does not represent a direct association between mitofilin and mtHsp70, it will be important to
further investigate the role of maintaining cristae morphology during DM and its effects on
nuclear-encoded mitochondrial protein import efficiency.
Mitofilin may also play a critical role in the import of miRNA into the mitochondrion,
particularly during DM. While mitofilin has been shown to be directly related to mitochondrial
proteins involved in the import of nuclear-encoded proteins, it would be interesting to see if
mitofilin is also associated with PNPase, a potential player for the import of miRNA. PNPase is
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located in the IMS of the mitochondrion; however, it is speculated to be situated on the IMM (79,
80). If an interaction between PNPase and mitofilin existed, this could be one explanation for how
PNPase is tethered to the IMM to allow for the import of miRNA. Our laboratory has previously
reported that mitofilin is decreased in the IFM during T1DM, altering the morphology of the
mitochondrion and disrupting the proteomic makeup (12, 72). Overexpression of mitofilin during
DM could potentially allow for maintained associations between PNPase and unknown miRNA
import constituents to the IMM. Preserving the structural stability of the mitochondrion during
DM could sustain the functionality of the organelle; however, this might also allow the influx of
miRNA into the mitochondrion through PNPase, which could serve a beneficial or detrimental
role during DM. Our data revealed that PNPase is upregulated in the T2DM SSM, with an
increased association between PNPase and Ago 2, an integral member of the RISC (Chapter 4). It
is unknown whether the upregulation of PNPase is detrimental or a compensatory mechanism for
miRNA import during a pathological insult. On the one hand, harmful miRNAs targeting important
proteins involved in the ETC could be imported through the upregulated PNPase during DM, thus
decreasing the ability for the mitochondrion to function properly. Conversely, PNPase expression
could be increased in the diabetic setting to allow the entry of miRNAs targeting ROS, which are
present due to the diabetic environment. The oxidative environment generated by the induction of
the NADPH oxidase (NOX) protein family during different pathological states, could be due to
the downregulation of miRNAs targeting these proteins (57). For example, the loss of NOX2
prevents oxidative stress in a pressure overload model of HF, with miRNA-34 and miRNA-17
showing capability of targeting this protein and miRNA-17 being downregulated during HF (27,
36, 38, 48). It would be interesting to utilize the mPHGPx transgenic animal to decrease oxidative
stress during DM and evaluate the impact this antioxidant overexpression could have on PNPase
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protein expression levels and miRNA import into the mitochondrion. This could potentially allow
for scavenging of ROS, thus increasing the functionality of the mitochondrion and decreasing
PNPase expression levels during DM, thus in turn influencing miRNA influx into the
mitochondrion. Further, while mtHsp70 overexpression has been shown to decrease the
accumulation of intracellular ROS when overexpressed in cells subjected to glucose deprivation
(49), we did not study ROS levels in our novel transgenic line to determine whether this could also
play a role in the association with PNPase and miRNA import into the mitochondrion. MtHsp70
overexpression could potentially serve as a mechanism to protect the mitochondrion from ROS
damage during DM, thus allowing for better functionality of the organelle. Additionally,
overexpression of mtHsp70 may also play a role in decreasing PNPase levels during DM and
influencing the import of miRNA into the mitochondrion. Further research needs to be done to
elucidate the mechanism of and the constituents involved in miRNA import into the
mitochondrion, particularly within the context of a pathological insult. Moreover, it will be
important to determine whether the upregulation of PNPase is due and contributing to the
detrimental impact of the pathological insult or is a compensatory mechanism to counteract this
insult.
While the different diabetic pathologies reveal influences on mitochondrial processes, our
laboratory previously analyzed the impact of DM on the mitochondrial proteome (11, 12, 21).
Proteomic profile analyses revealed differential alterations between the mitochondrial
subpopulations affected depending on type of DM, with the IFM proteome showing more changes
as a result of T1DM, while the SSM proteome showed increased detriment during T2DM (12, 21).
We have previously shown in the T1DM and T2DM pathological conditions, alterations to proteins
of the mitochondrial respiratory chain, TCA cycle, FAO components, along with transport and
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structural proteins (12, 21). Studies from our laboratory indicate that during T1DM, FAO proteins
were significantly decreased in the IFM as compared to control (12). In contrast, proteomic
analyses from other STZ models of T1DM, displayed increased FAO protein concentrations as
compared to controls (31, 74). It is important to note that the protocols for STZ injections, duration
of DM and animal backgrounds were different from our previous study, as well as the analysis on
total mitochondria not individual mitochondrial subpopulations. Interestingly, overexpression of
mtHsp70 during T1DM revealed further decrements in FAO proteins in the IFM when compared
to the T1DM mice, whereas in the T2DM SSM, proteins involved in fatty acid metabolism were
significantly increased (Chapter 3). During T1DM, the manifestation of the pathology does not
possess a gross hyperlipidemia as seen during T2DM, yet our proteomic analyses for the mtHsp70
T1DM mice revealed a down regulation of proteins involved in FAO, indicating that the alternate
fuel source is not in use during T1DM. This is contrary to what would be expected because during
T1DM while the heart does not utilize glucose efficiently, it would be assumed another fuel source,
such as β-oxidation would be increased to allow for proper mitochondrial function. Further, the
overexpression of mtHsp70 could be showing decreases in fatty acid metabolism due to the
decrease in ETFB, an essential protein for the shuttling of protons to initiate the process (Chapter
3). Our study also found GSTK1 to be significantly increased in the mtHsp70 T1DM IFM, which
would allow for a greater insulin sensitivity through adiponectin in these animals, providing
evidence that mtHsp70 is utilizing the fuel source most available during the pathological insult
(Chapter 3). During T2DM insult, enzymes involved in the phosphorylation of glucose and
initiation of glucose metabolism pathways, HK1 and HK2, were decreased in the T2DM SSM,
while FAO proteins were increased, thus in line with the milieu that is present during this
pathological condition (Chapter 3). Overall, our mitochondrial proteomic evaluation reveals that
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in the T1DM IFM and T2DM SSM, mtHsp70 overexpression is responsive to the most abundant
fuel source.
Additionally, our laboratory has previously shown alterations to complexes I, IV and V in
the IFM during a T1DM insult and the SSM during T2DM (12, 21). Overexpression of mtHsp70
during T1DM led to an increase in proteins involved in complexes I, III, IV and the F0 complex of
complex V as compared to the T1DM mice (Chapter 3). Interestingly, decrements in four subunits
of the F1 complex of complex V were further decreased with the overexpression of mtHsp70 in
the T1DM setting (Chapter 3). The F1 complex contains the extramembraneous core responsible
for catalysis, while the F0 complex forms the membrane channel for protons to travel through (37).
As complex V is situated in the IMM and uses the energy of the H+ electrochemical gradient,
which is generated by the movement of electrons through the ETC, the movement of this proton
from the IMS to the matrix is coupled with the generation of ATP (29). While it is puzzling as to
why the F1 complex would show increasing decrements with mtHsp70 overexpression during
T1DM, mtHsp70 utilizes ATP for the process of nuclear-encoded mitochondrial protein import
potentially altering the ATP levels within the mitochondrion. Mechanisms that change the F1
subunit protein expression levels, however, are difficult to elucidate. Previously, our laboratory
has shown decrements in essential proteins in the mitochondrial respiratory chain during T2DM,
particularly in the SSM (21). During T2DM, proteins from complexes III, IV and both the F0 and
F1 of complex V, were increased in the SSM with mtHsp70 overexpression (Chapter 3). Thus, our
proteomic data reveal that constituents in the ETC, as well as those involved with ATP production,
were preserved with mtHsp70 overexpression in the SSM during T2DM (Chapter 3).
The mitochondrial proteome could be altered via mechanisms of miRNA regulation, as
miRNAs play a role in nuclear gene transcription and translation and proteins encoded by the
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nuclear genome are key players in normal mitochondrial function. Gene silencing and regulation
occurs via the 18-24 nucleotide miRNA binding to the target mRNA (9, 18, 24). Interestingly,
miRNAs are capable of getting into the mitochondrion and regulating mitochondrial gene
expression (6-8, 13, 16, 39, 44, 57, 68, 69); however, the mechanism of translocation is currently
unknown. With literature suggesting a key role for miRNAs in pathological disease states, it is
essential to understand their role in cardiovascular diseases, particularly the role within the
mitochondrion. While the underlying mechanism for miRNA import into the mitochondria is
unknown, evidence suggests that Ago2 plays a pivotal role in the transportation of miRNAs into
and out of the mitochondrion (15, 24, 32, 50, 84). While the recent thinking of miRNA transport
into the mitochondrion utilizes import constituents from the protein import process (TOM and
TIM) (67), we suggest that PNPase may also contribute to this complex import mechanism for
miRNA transport across the mitochondrial membranes (Chapter 4). Our research has shown a
unique association between Ago2 and PNPase within the mitochondria, which was increased in
the SSM during T2DM (Chapter 4). It is currently unknown whether other players in the protein
import process play a role in miRNA import; however, it would be important to investigate if
PNPase or Ago2 associate directly with TOM or TIM proteins. It would also be interesting to note
that if TIM proteins, such as Tim44, played a role in miRNA import into the mitochondrion,
whether mtHsp70 would also influence this import process. In addition, it has been postulated that
different sequences within the miRNA are capable of targeting the miRNA into the nucleus (67),
which could potentially be another mechanism that miRNA are translocating into the
mitochondrion. Our laboratory revealed that of the mitomiRs identified in the mitoRISCome by
next generation sequencing and microarray analyses, sequences enriched in the nucleotide motifs
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AGG and UGG were present (39), potentially supporting the hypothesis that a sequence within the
miRNA may target the miRNA to its particular location, such as the mitochondrion.
Another complicating factor in miRNA translocation into the mitochondrion is the
differential impact a pathological state can have on mitochondrial subpopulations. Our laboratory
has previously shown alterations to miR-141 within the IFM during T1DM (13). MiR-141
regulates IMM phosphate transporter, Slc25a3, which provides inorganic phosphate to the
mitochondrial matrix, an essential component for ATP production (13). In addition to miR-141,
our laboratory has found a redistribution of miR-378 in the IFM of the T1DM heart, which
coincided with a decrease in ATP6 protein expression levels and ATP synthase function (39).
Interestingly, alterations to the SSM were uncommon indicating that miRNA can translationally
regulate mitochondrially encoded proteins in spatially distinct mitochondrial subpopulations
during DM (13, 39). In the current work, we found that overexpression of PNPase in the HL-1
cardiomyocyte cell line resulted in the accumulation of miR-378 within the mitochondrion
(Chapter 4). This accumulation corresponded with the decrease in ATP6 protein expression levels
and ATP synthase activity (Chapter 4). Further, in the T2DM db/db mouse model we found
increased expression of PNPase in the SSM, the mitochondrial subpopulation predominantly
affected by T2DM, along with an increase in the association of PNPase with Ago2, providing
evidence that PNPase may play a role in the translocation of miRNAs into the mitochondria
(Chapter 4). Further studies including PNPase knockdown or knockout would help to clarify our
current results and support our claim of PNPases role in miRNA translocation. While we suggest
that PNPase may be a player in mitochondrial miRNA import, other constituents playing a role in
this translocation mechanism still need to be elucidated.
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Within the mitochondrion, proteins are not evenly distributed to the different
subcompartments: OMM, IMS, IMM and matrix. Proteomic surveys suggest that approximately
67% of mitochondrial proteins reside in the mitochondrial matrix, followed by 21% located within
the IMM, and 6% and 4% residing in the IMS and OMM, respectively (26, 63). Independent of
diabetic type and mitochondrial subpopulation, our laboratory has previously shown the IMM and
matrix as the most predominantly affected mitochondrial subcompartments for proteomic
alterations (12, 21). Of the 21% of total proteins residing within the IMM, approximately 50% of
them are altered in the respective subpopulation during DM insult (12, 21). Importantly, the IMM
houses the complexes of the ETC, which are imperative for sufficient ATP production and properly
functioning mitochondria; therefore, we aimed to restore the proper proteomic makeup for the
IMM through overexpression of mtHsp70 during DM. Interestingly, in Chapter 3 we note that
both the T1DM IFM and T2DM SSM revealed proteomic alterations in the IMM and
mitochondrial matrix, with mtHsp70 allowing for restoration in both subcompartments, thus
suggesting that mtHsp70 overexpression allowed for targeted restoration particularly within these
locales. MtHsp70 is known to play a role in matrix-targeted mitochondrial protein import, but
mtHsp70 has also been demonstrated to play a role in proteins targeted to the IMM and IMS (10).
Work by Bohnert et al., revealed that oxidase assembly 1 (oxa1), an IMM translocase, is imported
into the matrix via mtHsp70 and reinserted back into the IMM (17). This provides evidence for
the assumption that overexpression of mtHsp70 could lead to an increase in nuclear-encoded
mitochondrial protein import efficiency into the IMM and help provide stability to the
mitochondrial proteome during DM.
In addition to mtHsp70 helping to restore the mitochondrial proteome via increased
efficiency in nuclear-encoded mitochondrial protein import, mtHsp70 has been shown to play a
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critical role in mitochondrial stability via protein degradation (60). During environmental stress,
such as a pathological insult, proteins are at an increased susceptibility for inactivation through
misfolding or aggregation (28). Literature suggests that mtHsp70 is capable of stabilizing
misfolded or damaged proteins in their unfolded state in order to make them more susceptible to
proteolytic degradation from m-AAA and PIM1, which was decreased when mtHsp70 was inactive
(60, 61, 78). During DM, mtHsp70 expression levels are decreased, thus leading to the assumption
that proteolytic degradation of proteins could be impaired during this pathological insult. With
impaired PIM1 proteolysis activity, mitochondrial genomic integrity and proper intron excision of
mitochondrially-encoded ETC proteins could be disturbed (75, 76), which may be the case during
DM. Further investigation into mtHsp70s role in protein degradation during a pathological
influence is warranted due to the effects this could have on the mitochondrial proteome.
Cardiac complications are the leading cause of morbidity and mortality among diabetic
patients (42, 83). It is imperative for physicians to be able to detect changes in cardiac function
through either conventional measures or using the highly sensitive speckle-tracking based strain
analysis software. In Chapter 2, we discussed the efficiency of using speckle-tracking based strain
analyses in detecting subtle changes of LV function prior to conventional changes during the
progression of T1DM. Conventional measures revealed changes at 6-weeks in the T1DM heart
(Chapter 2). In Chapter 3, we highlight that LV pump function is decreased in the type 1 and type
2 diabetic animals as seen by conventional measures, such as EF and FS. We found that
overexpression of mtHsp70 restored conventional measurements back to that of control level,
likely due to the restored functionality of the mitochondria through increased efficiency of nuclearencoded mitochondrial protein import, leading to a stabilized mitochondrial proteome despite the
pathological influence of DM (Chapter 3). Further, analyses using the speckle-tracking based
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strain software to evaluate global and regional strain were performed to provide a more complete
picture for the deficits noted in the LV. When using speckle-tracking based strain analyses, we
found changes as early as 1-week post-T1DM onset, mainly in the radial dimension (Chapter 2).
Further, assessment of regional changes within the LV were performed during T1DM, with the
detriments predominantly in the free wall region (Chapter 2). This brings into question, why the
free wall region was affected by T1DM, but few decrements were seen in the septal wall region.
We speculate that the IFM, which are predominantly affected during T1DM, are dysfunctional
particularly within the free wall region of the LV. The LV myocardial wall becomes activated in
the septal and anterior free wall regions through the Purkinje system, with this activation traveling
from the apex to the base of the LV (62, 64). Interestingly, the LV activation sequence through
this system is relatively similar between the septal and free wall regions (62, 64), thus it would be
interesting to evaluate each region of the LV and determine if mitochondrial function is decreased
within the particular locale coinciding with the strain and strain rate dysfunction during T1DM.
Further, it would also be interesting to evaluate subpopulations within each LV region to determine
if deficits during T1DM is due to decreased IFM function. Without properly functioning
mitochondria and ample production of ATP, cardiac contractile dysfunction is oftentimes
disrupted (11, 12, 21, 22). In Chapter 3, our studies using speckle-tracking based strain analyses
provide evidence that this technique is capable of detecting subtle changes in myocardial
performance during both types of DM; however, these mice already demonstrated decreased LV
function through conventional measures. Decrements in longitudinal strain and longitudinal strain
rate during both T1DM and T2DM provide complementary evidence of LV systolic dysfunction
with subsequent restoration via mtHsp70 overexpression (Chapter 3). Evaluation of regional
differences revealed commonalities between longitudinal strain rate in T1DM and T2DM with
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decrements in the apex regions, in which mtHsp70 overexpression was able to restore the posterior
apex region independent of DM type. Interestingly, mtHsp70 overexpression appeared to provide
more regional benefit during T2DM than T1DM. It is noteworthy to evaluate why mtHsp70
overexpression appears to provide protection to certain regions and not others of the LV when the
αMHC promotor should allow for even expression throughout the heart. It would be interesting to
evaluate the expression levels of mtHsp70 in each LV region and determine if mtHsp70
overexpression restored mitochondrial function within these particular sub-locales. If mtHsp70 did
not restore contractile function within a particular LV region, it would be interesting to evaluate
the nuclear-encoded mitochondrial protein import mechanism and the activity of mtHsp70. We
speculate that the restoration of cardiac contractile function in Chapter 3 is due to mtHsp70’s
positive impact on mitochondrial functionality through increased efficiency of nuclear-encoded
mitochondrial proteins, which would be critical for stabilization of the mitochondrial proteome in
the face of DM. While the type of DM has differential influences on mitochondrial subpopulations,
it is interesting to note that ATP production from each subpopulation is likely critical for efficient
cardiac contractile function. This indicates that both the SSM and IFM may play a role in
preserving cardiac function during pathological insults. Literature suggests that an interconnected
mitochondrial network through the mitochondrial reticulum could provide a pathway for energy
distribution within the cardiomyocyte (30, 66), thus allowing for the restoration of cardiac
contractile function by mtHsp70, despite different mitochondrial subpopulations being affected.
Further, Glancy et al. suggest that the contiguous matrix and its elements between the different
mitochondrial subpopulations could be a conductive element through this network to allow for the
electrical conduction (30). This type of energy distribution could be disrupted during DM and
potentially restored with the overexpression of mtHsp70; however, this would need to be assessed.

278

In summary, the data presented suggest that deficits in the mitochondrial proteome leads
to inefficient mitochondrial function, presumably due to deficient nuclear-encoded mitochondrial
protein import. In particular, mtHsp70 serves as a central node for restoration of nuclear-encoded
mitochondrial protein import, which is essential for maintenance of proper nuclear-encoded
protein content within the mitochondrion, particularly in the mitochondrial subpopulation most
impacted during the different types of DM. Further, the import of miRNA species into the
mitochondria potentially through a complex mechanism of interaction between the RISC and
PNPase, could contribute to posttranscriptional regulation and translational repression of proteins
encoded by the mitochondrial genome during DM. In conclusion, therapeutic interventions
targeted to maintain the mitochondrial proteome through efficient nuclear-encoded mitochondrial
protein import and regulation of miRNA import into the mitochondrion during DM may provide
protection against cardiac contractile dysfunction in the diabetic heart independent of type of DM.
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